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Anticholinergics show therapeutic utility in the treatment of some types of dystonia 
and in Parkinson’s disease, however, this is accompanied by wide range of unpleasant 
side effects, including dry-mouth. It has been proposed that muscarinic M4 receptors, 
located in the striatum, could be a novel therapeutic target to minimise involuntary 
movements and improve parkinsonian disability without producing unfavourable 
peripheral side effects.  
The effect of muscarinic antagonists with different relative selectivity for receptor 
subtypes, including a novel highly selective muscarinic antagonist for the M4 subtype, 
have been investigated using the pilocarpine-induced purposeless chewing model of 
dystonia in rats and MPTP-treated common marmoset model of PD. The peripheral 
effects of these drugs were assessed on pilocarpine-induced saliva secretion in rats.  
Pilocarpine purposeless chewing was significantly inhibited by centrally but not 
peripherally acting anticholinergics including the novel M4 selective antimuscarinic. 
It was confirmed that M1/M3 selective antimuscarinics are important in the onset of 
dry-mouth, and that this effect was peripherally mediated. Moderate suppression of 
salivation was also observed with M1 and M2 antimuscarinics, but not with the 
selective M4 antagonist.  This suggests that selective blockade of muscarinic M4 
receptors may have a role in dystonia without accompanying peripheral side effects. 
Interestingly, in MPTP-treated marmosets, co-administration of clinically used 
centrally acting anticholinergics alone and in combination with L-DOPA resulted in 
the expected improvement of locomotor activity and motor disability but also 
enhanced expression of L-DOPA-induced dyskinesia. By contrast, selective 
muscarinic M4 antagonist showed no significant improvement in locomotion and 
motor disability either alone or in combination with L-DOPA and did not reduce the 
expression of L-DOPA-induced dyskinesia, however, extended duration of dystonia.  
Overall, these studies support the idea that cholinergic system plays a role in mediation 
of motor control, and that selective antagonism of M4 receptors may reduce dystonia 
without inducing peripheral side effects, however, the lack of effect on motor function 
and the increase in drug-induced dystonia in the Parkinson’s disease model suggest no 
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1.1 Movement disorders  
Movement disorders are neurologic conditions resulting from problems with the 
control of the “quality” of the movement – either an excess or lack of voluntary and 
automatic movements (Fahn, 2011). They can arise from malfunctioning of the 
muscles or abnormality in motor pathways in the nervous system. In particular, 
dysfunction and pathological processes in the basal ganglia and their connections are 
associated with a number of movement disorders. 
Movement disorders can be divided into two different categories: hyperkinetic such as 
dystonia, dyskinesia, chorea, tremor, where movements are involuntary and repetitive, 
often interfering with normal motor activity, and hypokinetic, such as Parkinson’s 
disease (PD), where there is impairment of voluntary movement such that movement 
is reduced or absent (Fahn, 2011). There are many and varied forms of treatment for 
these disorders, however, anticholinergic drugs are used both for some dystonias and 
in PD.  These drugs are effective, but are also associated with unpleasant side effects 
that reduce compliance, therefore, improved anticholinergic therapy is required for 
both these disorders.  Thus, the studies in this thesis describe preclinical studies that 
aim to investigate improved anticholinergic therapy for dystonia and PD.   
1.1.1 Dystonia  
Dystonia is a neurological hyperkinetic movement disorder characterised by extreme, 
sustained and involuntary muscle contraction. It was firstly described in 1908 by a 
German physician Markus Walter Schwalbe in his doctoral thesis as he observed it in 
children of Jewish origin as a syndrome of tonic cramps (Truong & Fahn, 1988; 
Grundmann, 2005). However, three years later, a German neurologist Hermann 
Oppenheim termed this condition as dystonia musculorum deforemans based on 
observation of children affected by unusual uncontrolled muscle spasms, leading to 
twisting, rapid and rhythmic movements which were worsening on walking and 
eventually leading to abnormal and fixed postures (Klein & Fahn, 2013). This 
condition was later referred to as primary torsion dystonia (Grundmann, 2005). For 
many decades dystonia has been considered as a psychogenic disorder, however, work 
and observations made by C. David Marsden in 1975 on adult-onset dystonia have 
changed the perception and dystonia started to be considered as a neurological 
hyperkinetic movement disorder (Marsden, 1976; Skogseid, 2014). Years later in 1984 
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a scientific committee of the Dystonia Medical Research Foundation provided the first 
definition of dystonia, which stated that it is a syndrome of sustained muscle 
contractions, causing twisting and repetitive movements, or abnormal postures 
(Skogseid, 2014). This description has been widely used for years until the 
international committee of movement disorders and experts in dystonia proposed a 
new revised definition:   
“Dystonia is a movement disorder characterised by sustained or intermittent muscle 
contractions causing abnormal, often repetitive, movements, postures, or both. 
Dystonic movements are typically patterned, twisting, and may be tremulous. Dystonia 
is often initiated or worsened by involuntary action and associated with overflow 
muscle activation” (Albanese et al., 2013). 
1.1.1.1 Clinical features 
In dystonia, primary muscles normally responsible for a movement contract 
excessively together with the nearby muscles that generally do not take part in the 
movement. Hence, the dystonic symptoms are triggered by involuntary simultaneous 
contractions of agonist and antagonist muscles, resulting in repetitive and patterned 
movements. These movements can be rapid or slow and can change depending on 
activities or postures. The abnormal movement depends on the strength and 
combination of muscles involved in a particular movement. Mild dystonia results in 
exaggeration of normal movements; moderate cases comprise of stiff, slow, twisting 
or jerky movements; and severe forms lead to unnatural postures and fixed deformities 
including the trunk, neck, face and/or limbs. Generally, these sustained muscle spasms 
are painful, and tend to become worse during action, and improve during relaxation. 
Some dystonic movements occur only during voluntary activities (task-specific or 
action dystonia), others are triggered by sensory tricks, such as gently touching or 
poking the affected body part (geste antagoniste) (de Carvalho Aguiar & Ozelius, 
2002; Tarsy & Simon, 2006; Cloud & Jinnah, 2010). Dystonia can involve muscle 
groups throughout the entire body (generalised), or can be specific to a certain area of 
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Dystonia affects many people worldwide, regardless the age or gender, and is 
considered as a third most common movement disorder, after Parkinson’s disease and 
tremor disorders (Defazio et al., 2004; Langlois et al., 2014). Worldwide more than 3 
million people are diagnosed with dystonia (Jinnah et al., 2008). According to The 
Dystonia Society UK, there are around 70,000 people affected by dystonia in the UK 
(of these 8,000 children), resulting in prevalence of 1 in 900 (The Dystonia Society, 
2016).  
Despite dystonia being one of the most prevalent movement disorder, the 
epidemiological investigation is limited. Diverse aetiologies and different 
manifestations of disease make it difficult to diagnose. Additionally, dystonia is still 
considered as a rare condition, and since it is non-fatal, there is a lack of 
epidemiological studies (Jinnah et al., 2008; Langlois et al., 2014). A study conducted 
in eight European countries estimates that 15.2 per 100,000 suffers from primary 
dystonia, with the highest level for focal dystonia (11.7 per 100,000) (The 
Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group, 2000). 
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Based on this report, there is a difference in prevalence and age at onset in terms of 
gender, as women tend to be more susceptible to focal dystonia, and tend to have 
higher risk and lower age at onset for writer’s cramp, whereas men have lower age at 
onset for blepharospasm, cervical and laryngeal dystonia (The Epidemiological Study 
of Dystonia in Europe (ESDE) Collaborative Group, 2000; Defazio et al., 2004). 
In addition, a systematic review and meta-analysis of numerous studies on prevalence, 
incidence and epidemiology of dystonia reports that the prevalence of primary 
dystonia was 16.4 per 100,000 (Steeves et al., 2012).  
1.1.1.3 Classification and aetiology 
In recent years, the revised classification of dystonia has emerged and is based on two 
axes: clinical characteristics and aetiology (Albanese et al., 2013).  
The clinical characteristics important in classification of dystonia are: age at onset, 
body distribution, temporal pattern, coexistence of other movement disorders and 
coexistence of other neurological manifestations (Table 1.1).  
Dystonia can develop at any age, and is defined as infancy (0-2 years), childhood (3-
12 years), adolescence (13-20 years), early adulthood (21-40 years) and late adulthood 
(>40 years) onset. In the early adulthood onset (age <20-40 years), dystonia typically 
begins as a focal form (limbs, usually the leg) and tend to progress to other body areas 
and develops into severe generalized dystonia in majority of the patients. Late 
adulthood-onset (age >40 years) begins in the neck, face or arm and is not usually 
progressive, thus remains focal or segmental (de Carvalho Aguiar & Ozelius, 2002; 
Bhidayasiri, 2006; Tarsy & Simon, 2006; Jinnah et al., 2008). In dystonia, different 
body parts can be involved individually or in combinations, the classification in terms 
of body distribution is divided into focal, segmental, multifocal, generalized and 
hemidystonia (Table 1.1). The body distribution may change over time and can 
progress to the body parts that were not previously involved (Jinnah et al., 2008; 
Albanese et al., 2013).  
Classification in terms of temporal pattern distinguishes between static or progressive 
disease and could include four different patterns: persistent, action-specific, diurnal 





Table 1.1 Classification of dystonia by clinical characteristics and aetiology 
 (Albanese et al., 2013).  
Clinical characteristics 
Age of onset  Infancy: birth to 2 years 
 Childhood: 3 to 12 years 
 Adolescence: 13 to 20 years 
 Early adulthood: 21 to 40 years 
 Late adulthood: >40 years 
Body distribution  Focal: involving a single body region 
 Segmental: two or more contiguous body regions 
 Multifocal: two non-contiguous or more body regions 
 Generalized: the trunk and at least two other sites 
 Hemidystonia: more regions restricted to one body side 
Temporal pattern   Disease course: static or progressive 
 Variability:  
- Persistent: approximately same extend throughout the day 
- Action-specific: occurs only during a specific activity or task 
- Diurnal: fluctuating dystonia during the day, with identifiable circadian 
variations in occurrence, severity and phenomenology 
- Paroxysmal: unexpected self-limited episodes of dystonia often induced by 
a trigger with return to pre-existing neurologic state 
Associated features  Isolated or combined with another movement disorder: 
- Isolated: dystonia is the only motor feature (with the exclusion of tremor) 
- Combined: dystonia is combined with other movement disorder 
(myoclonus, parkinsonism)  




 Evidence of degeneration (e.g. neuronal loss) 
 Evidence of structural lesions 
 No evidence of degeneration and structural lesions 
Inherited or acquired  Inherited (proven genetic origin): 
- Autosomal dominant 
- Autosomal recessive 
- X-linked recessive 
- Mitochondrial  
 Acquired (due to a known specific cause): 
- Cerebrovascular (infarction or haemorrhage) 
- Perinatal brain injury (delayed-onset dystonia, dystonic cerebral palsy) 
- Traumatic brain injury (brain surgery, electrical injury) 
- Infection (syphilis, tuberculosis, HIV, viral encephalitis) 
- Drug (anticolvusants, calcium channel blockers, dopamine agonists, 
neuroleptics/antiemetics) 
- Toxic (carbon disulphide, cobalt, manganese, methanol) 









Dystonia can often occur in isolation, which means that it is the only motor disability, 
except the presence of tremor, or can be combined with another movement disorder, 
such as myoclonus or parkinsonism. In addition, other neurological or systemic 
manifestations can be present along with dystonia (Table 1.1) (Albanese et al., 2013).  
Aetiology of many forms of dystonia is still poorly understood. The classification in 
respect of aetiology involves presence or absence of nervous system pathology, which 
may involve evidence of degeneration or structural lesions, and the division between 
inherited, acquired and idiopathic forms (Albanese et al., 2013).  
Cases of inherited dystonia have a proven genetic origin and different forms can be 
distinguished: autosomal dominant, autosomal recessive, X-linked recessive or 
mitochondrial (Table 1.2) (Albanese et al., 2013).  
Acquired dystonia, previously known as secondary dystonia, usually arises due to a 
known specific underlying cause or condition and this may include perinatal brain 
injuries (dystonic cerebral palsy, delayed-onset dystonia), infections (including viral 
encephalitis, encephalitis lethargics, human immunodeficiency virus (HIV) infection, 
tuberculosis, syphilis), drugs (e.g. levodopa and dopamine agonists, neuroleptics, 
anticonvulsants, calcium channel blockers), toxic (manganese, cobalt, cyanide, carbon 
disulphide, methanol, 3-nitropropionic acid, disulfiram), vascular (ischaemia, 
haemorrhage, arteriovenous malformation), neoplastic disease (brain tumour, 
paraneoplastic encephalitis), brain injuries (head trauma, brain surgery, electrical 
injury),or psychogenic causes (functional). Idiopathic cases, so with unknown cause, 
can be divided into sporadic and familial (Albanese et al., 2013). 
 
 
Table 1.2 Genes underlying dystonia.  
AD – autosomal dominant; AR – autosomal recessive; ATP – adenosine triphosphate.  
Adapted and modified from Warner & Jarman (1998); Charlesworth et al. (2013b); Lohmann 
& Klein (2013); Waugh & Sharma (2013); Klein (2014).  
Gene 
Locus 
Designation Mode of 
inheritance  
Chromosome, mutation and gene 
product 
DYT1 Dystonia 1, torsion AD 9q34; GAG deletion in TOR1A gene 
causes abnormality in ATP-binding 
protein, torsinA 





Xq13.1; TAF1 gene 
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AD 14q22; GCH1 locus; mutations in GTP 
cyclohydrolase I gene 
Segawa syndrome AR 1p15.5; mutations in the tyrosine 
hydroxylase gene; tyrosine 
hydroxylase deficiency 
DYT6 Dystonia 6, torsion AD 8p11.21; mutations in the THAP1 
gene 











dyskinesia 1 (paroxysmal 
kinesigenic dyskinesia) 
AD 1p34.2; mutations in the SLC2A1 gene 
that encodes the glucose transporter 
type 1 
DYT10 Episodic kinesigenic 
dyskinesia 1 (paroxysmal 
kinesigenic dyskinesia)
  
AD 16p11.2; mutations in the PRRT2 gene 
DYT11 Myoclonus-dystonia AD 7q; epsilon-sarcoglycan gene (SGCE) 
DYT12 Rapid onset dystonia- 
parkinsonism 
AD 19q; ATP1A3 gene that encodes the 
Na+/K+ -ATPase alpha3 subunit 
DYT13 Dystonia 13, torsion AD 1p; gene and product unknown 
DYT14 Dopa responsive 
dystonia (now included 
under DYT5) 
Not clear  Unknown 
DYT15 Dystonia 15, myoclonic AD 18p11; gene and product unknown 
DYT16 Dystonia 16 AR 2q31.3; PRKRA gene 







induced dyskinesia with 
or without epilepsy 
and/or hemolytic anemia 
(GLUT1 deficiency 
syndrome 2) 
AD 1p34.2; mutations in the SLC2A1 gene 
that encodes the glucose transporter 
type 1 
DYT19 Episodic kinesigenic 
dyskinesia 2 (paroxysmal 
kinesigenic dyskinesia) 





AD 2q31; gene and product unknown 
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DYT21 Dystonia 21 AD 2q14.3-q21.3; gene and product 
unknown 
DYT23 Dystonia 23 AD 9q34, ?CIZ1 gene 
DYT24 Dystonia 24 AD 11p14.2, ANO3 gene 
DYT25 Dystonia 25 AD 18p11.21, GNAL gene 
1.1.1.4 Pathogenesis 
Pathophysiology of dystonia is complex and the absence of cell degeneration proposes 
that this disorder comes from abnormal cell function.  Dysfunction of basal ganglia, 
however, plays an enormous role in dystonia, but the specific mechanisms are unclear. 
Lesions within basal ganglia structures, including caudate, putamen, globus pallidus 
and thalamus were found in dystonic patients (Marsden et al., 1985). Surgical 
approaches, which lesion the GPi or STN, proved to be effective in some dystonias 
(Krauss et al., 2004; Toda et al., 2004). There is an underlying genetic component 
linked to many forms of dystonia and several genes and loci have been identified to 
the dystonia DYT loci and genes (Table 1.3) (Charlesworth et al., 2013a). 
Additionally, further evidence from neuroimaging studies, i.e. positron emission 
tomography (PET) fMRI show that dystonia can arise not only form abnormal activity 
in the basal ganglia or motor cortex but also from the cerebellum, therefore dysfunction 
of other brain regions or networks also contribute to this disorder, thus dystonia can 
be seen as neurodevelopmental circuit disorder and may involve the cortico-striato-
pallido-thalamo-cortical and cerebello-thalamo-cortical pathways (Galardi et al., 
1996; Eidelberg et al., 1998; Argyelan et al., 2009; Neychev et al., 2011; Niethammer 
et al., 2011). Imaging studies show abnormal cerebellar function in patient carrying 
DYT1 and DYT6 mutations, most commonly inherited forms of dystonia (Eidelberg 
et al., 1998; Argyelan et al., 2009). Furthermore, the lesions and tumours of the 
cerebellum have been found in patients with cervical form of dystonia (LeDoux & 
Brady, 2003; Prudente et al., 2014). Several animal models such as dtsz hamster or 3-
nitropropionic acid-induced rat model are associated with basal ganglia dysfunction, 
but there are also models associated with cerebellar involvement in the disorder, such 
as dystonic (dt) rat model, DYT1 mutant mice with the mutation of torsin1A gene or 
tottering mutant mouse, and toxin-induced mice or rat models of kainic acid 
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microinjection (LeDoux et al., 1998; Pizoli et al., 2002; Jinnah et al., 2005; Raike et 
al., 2005; Jinnah et al., 2008; Neychev et al., 2008; Alvarez-Fischer et al., 2012). 
Findings from electrophysiological studies, including transcranial magnetic 
stimulation (TMS), show a loss of inhibition at various level of the motor system in 
dystonia. This can be related to some manifestation of dystonia, such as prolonged 
muscle contractions, involuntary co-contractions of groups of muscles seen, for 
example, in blepharospasm, where there is an abnormality in recovery in the blink 
reflex (Berardelli et al., 1998; Hallett et al., 2006). Nevertheless, loss of inhibition 
cannot be always the case as these abnormalities can also be found in carriers of DYT1 
gene mutation without clinical manifestation (Edwards et al., 2006). 
Abnormal neuronal signalling within the basal ganglia and abnormal synaptic 
plasticity may contribute to the disease (Martella et al., 2009). Paired associative 
stimulation (PAS) and TMS are commonly used techniques to study plasticity at the 
cortical level. The long-term potentiation (LTP) and long-term depression (LTD) are 
recognised as models of plasticity (Bonsi et al., 2008). Patients with focal dystonia 
show increased response to different experimental plasticity protocols (Quartarone et 
al., 2003; Edwards et al., 2006; Weise et al., 2006). The abnormalities were observed 
in hand muscles of patients with focal dystonia affecting other body region who had 
no visible symptoms in hand muscles, suggesting a generalized type of the disease 
(Quartarone et al., 2008). Repetitive activity or performance of a particular movement 
for a long period of time could lead to dystonic symptoms, for instance in focal limb 
dystonia. This has been shown using primates when overtraining in specific hand 
movements made the animals unable to continue. Observed motor abnormality was 
interpreted as dystonia (Byl et al., 1996). Further studies examining somatosensory 
cortex showed that the receptive field was enlarged and overtraining led to abnormal 
sensory function causing abnormalities in motor function (Byl et al., 1996). Therefore, 
abnormality in sensorimotor cortex may contribute to pathophysiology of dystonia, 
triggering changes in plasticity, such as performance of repetitive movements 
(Quartarone & Pisani, 2011).  
Neurochemically, it has been suggested that both the dopaminergic and cholinergic 
systems are involved in the manifestation of dystonia. Imaging studies have 
demonstrated reduced D2 receptor binding in the striatum in patients with DYT1 and 
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DYT6 dystonia (Beukers et al., 2008; Carbon et al., 2010; Karimi et al., 2011). Both 
anticholinergic and dopaminergic pharmacological treatments are effective in some 
dystonias.   
1.1.1.5 Dystonia Therapy  
Notwithstanding the advances made in the understanding of the pathophysiology of 
dystonia, the underlying cause remains unknown and to date there is still no cure. The 
treatment of many forms of dystonia is generally symptomatic and consequently the 
primary aim is to decrease abnormal movements, correct and improve posture, reduce 
pain and generally improve quality of life of sufferers (Bhidayasiri, 2006; Jankovic, 
2006; Langlois et al., 2014). Treatment of dystonia is problematic due to many 
aetiologies and heterogeneous clinical appearances involving different parts of the 
body (Jankovic, 2013), therefore, many patients require combination of different forms 
of treatment (Jankovic, 2009a). For many years, the treatment was dependent on the 
use of pharmacological agents, which shows moderate effects but also their use is 
related to many side effects (see below). The treatment has changed in the past years, 
as other therapeutic options have been introduced, such as botulinum toxin or surgery, 
including peripheral denervation, pallidotomy and thalatomy or deep brain stimulation 
(DBS), with the latter the most widely currently used surgical procedure (Cloud & 
Jinnah, 2010; Lubarr & Bressman, 2011). Patients with focal form (late-onset) are 
given local injections of botulinum toxin in the affected muscles (Bhidayasiri, 2006; 
Jankovic, 2006; Langlois et al., 2014). Deep brain stimulation of the globus pallidus 
internus (GPi) is used in severe cases of early-onset primary generalized dystonia or 
sometimes in patients suffering from focal dystonia (cranial and cranial-cervical 
forms) (Jankovic, 2009b; Lubarr & Bressman, 2011). The downside is that DBS is 
only offered to treat severe cases of dystonia and is not widely available, as it has to 
be conducted by the team of specialists involving neurologists, neurosurgeons, 
psychiatrists and neuropsychologists (Jinnah & Hess, 2008; Lubarr & Bressman, 
2011). 
Pharmacological treatment is also tailored to individual patients and type of syndrome 
they experience. Patients with focal, segmental and generalized dystonia are mainly 
treated with oral medications, including anticholinergics (trihexyphenidyl), the 
dopamine precursor - levodopa, dopamine antagonists (phenothiazines, tetrabenazine) 
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and the GABAb agonist (baclofen). Other pharmacological medications, such as 
muscle relaxants, benzodiazepines (diazepam, lorazepam, clonazepam) or 
anticonvulsants may also provide benefit in improvement of some types of dystonia 
(Goldman & Comella, 2003).  
Physiotherapy is an important and useful addition to any treatment of dystonia. Its 
main aim is to improve posture, increase strength and mobility of a patient and work 
to prevent the contractures in patients suffering from generalised dystonia (Goldman 
& Comella, 2003; Lubarr & Bressman, 2011; Thenganatt & Jankovic, 2013).  
Despite the fact that there are several forms of treatment available, the broad range of 
manifestations and different causes of dystonia, they are not always effective and, 
therefore, there is an unmet need for developing more effective forms of therapy, or 
improve existing ones, and this is still the subject of further investigation.    
1.1.1.5.1 Pharmacological treatment 
Oral medications are mainly used in segmental and generalised dystonia and as an 
adjunct therapy to the botulinum toxin in focal dystonia. Treatment is usually limited 
due to many side effects, however, children often better tolerate much higher doses 
than adults with good benefit. In any case, the treatment should be slowly titrated over 
period of time to reduce the side effects (Thenganatt & Jankovic, 2013). 
Pharmacological treatment of dystonia is mostly based on empirical rationale rather 
than on data coming from clinical trials or scientific knowledge (Jankovic, 2009a).  
Among the pharmacological forms of treatment few classes of oral medications have 
demonstrated to be effective in reducing the symptoms of dystonia.  
GABA agonists 
Baclofen, a presynaptic GABAB receptor agonist, mimics the major inhibitory 
neurotransmitter gaba-aminobutyric acid (GABA) in the brain. By activation of 
GABAB sites, which are present on nerve terminals, GABAB agonists reduce 
neurotransmitter release by inhibition of calcium influx, which is associated with 
inhibition of motor neurons in spinal cord and thus preventing muscle contractions 
(Greene, 1992). Treatment with baclofen may be helpful in children with dystonic gait 
and patients suffering from segmental, generalized or oromandibular dystonia, as well 
as in Parkinson’s disease for wearing-off or early-morning foot dystonia (Greene, 
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1992; Jankovic, 2013). Despite that, the treatment with baclofen results in number of 
side effects, including drowsiness, dizziness, nausea, constipation and dry mouth 
(Goldman & Comella, 2003; Cloud & Jinnah, 2010; Lubarr & Bressman, 2011).  
Dopaminergic agents 
Dopaminergic agents can control movement by acting on the nigro-striatal dopamine 
system, which helps control muscle movement. Levodopa, the precursor of dopamine, 
is converted to dopamine in DA neurons and is used in the management of dopa-
responsive dystonia (DRD), a syndrome caused by a defect in synthesis of dopamine, 
particularly in childhood-onset dystonia (Cloud & Jinnah, 2010; Thenganatt & 
Jankovic, 2013). Studies show that in general patients respond well to low doses of 
levodopa (300 mg/day), however, many patients need higher doses (up to 1000 
mg/day) (Thenganatt & Jankovic, 2013). Side effects usually are manifested by 
dyskinesia (abnormal involuntary movements) (Thenganatt & Jankovic, 2013). By 
contrast, some patients may benefit from dopamine antagonists (neuroleptics) such as 
clozapine or dopamine depleting drugs, a vesicular monoamine transporter 2 
(VMAT2) inhibitor tetrabenazine, but their use can be restricted by side effects, such 
as weight gain or involuntary muscle movements (Bhidayasiri, 2006; Lubarr & 
Bressman, 2011) as well as tardive dyskinesia, akathisia, drowsiness, depression, 
insomnia, and parkinsonism (Jankovic, 2013; Thenganatt & Jankovic, 2013).  
Anticholinergics 
Anticholinergic agents are compounds that bind to the nicotinic and muscarinic 
acetylcholine receptors blocking the action of neurotransmitter acetylcholine in the 
central and peripheral nervous system. Most commonly used anticholinergics in the 
treatment of dystonia are muscarinic antagonists (antimuscarinics), with a first line 
choice trihexyphenidyl. Trihexyphenidyl has proven to be the most beneficial oral 
form of treatment for primary generalized and segmental dystonia (Burke, 1986; 
Jankovic, 2009a). Its efficacy was established in double-blind crossover prospective 
study three decades ago by Burke and colleagues (1986). Usually if trihexyphenidyl 
treatment starts at low dose (1 mg/day) and the dose is increased slowly, they are well 
tolerated. However, many patients may require high doses, up to 100 mg/day, and this 
may lead to dose-related side effects, e.g. drowsiness, hallucinations, impaired 
memory (Jankovic, 2006). Generally high doses are better tolerated by children than 
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adults. Although, anticholinergics are effective, they are non-selective and so non-
specifically exert their effect on parasympathetic (cholinergic) nervous system and 
block the action of acetylcholine (ACh) on centrally and peripherally located 
muscarinic receptors, resulting in inhibition of involuntary movements of smooth 
muscles present mainly in the lungs, gastro-intestinal and urinary tract and at the same 
time, causing many side effects.  Central side effects include confusion, memory loss, 
restlessness, insomnia, hallucinations, and drowsiness. Peripheral side effects include 
dry mouth, which is a severe problem preventing swallowing and speech, blurred 
vision, urinary retention, constipation and loss of appetite (Cloud & Jinnah, 2010; 
Lubarr and Bressman, 2011). While, these side effects can be reduced using locally 
active muscarinic agonists, such as pilocarpine eye drops for blurred vision, synthetic 
saliva, cevimeline or oral pilocarpine for dry mouth, and the peripheral cholinesterase 
pyridostigmine, for urinary retention (Bhidayasiri, 2006; Lubarr & Bressman, 2011), 
anticholinergics can still significantly affect quality of life and reduce compliance.  For 
this reason, improved anticholinergic therapy is required that reduces the incidence of 
peripheral side effects while still reducing the severity of the dystonia.   
 
1.1.2 Parkinson’s Disease  
Parkinson’s disease (PD) is the second most common neurodegenerative disease after 
Alzheimer’s disease (de Lau & Breteler, 2006). It was named after James Parkinson, 
who for the first time, based on observations of clinical features, described it as 
“Shaking Palsy” or “Paralysis Agitans" (Parkinson, 2002). PD is a common, chronic 
and progressive neurodegenerative disease (Lang  & Lozano 1998; Massano & Bhatia, 
2012). Clinical diagnosis is based on manifestation of cardinal symptoms consisting 
of resting tremor, rigidity, bradykinesia/akinesia (slowness or lack of movement) and 
postural and gait impairment (Jankovic, 2008; Massano & Bhatia, 2012). While 
conventionally PD was considered to be a motor complaint, nowadays it is considered 
to be more complex disorder accompanied by a diverse clinical features of non-motor 
symptoms, including sleep disturbances, cognitive decline (dementia), constipation, 
urinary dysfunction, fatigue and mood disorders (depression, anxiety) (Aarsland et al., 
1999; Fahn, 2010; Claassen & Kutscher, 2011; Massano & Bhatia, 2012). In recent 
years’ attention and research have been focusing on trying to understand the influence 
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of these non-motor features in order to improve patients’ quality of life (Chaudhuri et 
al., 2011).  
1.1.2.1 Pathology of PD  
The motor symptoms in PD are the result of progressive loss of dopaminergic neurons 
in the substantia nigra pars compacta (SNc).  Neuropathologically PD is defined by 
the presence of intracytoplasmic inclusions termed Lewy bodies, found in remaining 
dopaminergic cells, thought to be a marker of dying neurons. Lewy bodies are made 
up mainly of neurofilament-like structure and contain ubiquitin and α-synuclein (Beal, 
2001; Murakami et al., 2004). In addition to nigral dopaminergic neuronal 
degeneration, there is a more widespread degeneration involving other 
neurotransmitter systems. Loss of noradrenaline neurons of the locus coeruleus, 
cholinergic neurons in the nucleus basalis of Meynert and serotonin neurons of the 
dorsal raphe nuclei has been detected along with, alternations in the function of 
glutamatergic and GABAergic pathways (Lang  & Lozano 1998; Olanow, 2004; 
Hodaie et al., 2007). Degeneration of the cells in these other brain regions has been 
suggested to underlie the occurrence of non-motor symptoms of the disease, such as 
depression due to the loss of noradrenergic neurons in the limbic system (Remy et al., 
2005).  
Originally it was thought that the pathology of PD starts with the loss of dopaminergic 
cells in the substantia nigra, however, Braak and colleagues proposed a series of six 
disease progression stages based on α-synuclein and Lewy bodies presence, starting 
from the brain stem to the cerebral cortex (Braak et al., 2003; Braak et al., 2004).  
During the presymptomatic stages, (stage I and II) changes are confined to the dorsal 
motor nucleus and the olfactory bulb, related to loss of smell in patients prior to 
diagnosis, followed by the spread to the locus coeruleus and raphe nuclei. In the 
subsequent stages (stage III and IV), classic motor symptoms of PD start to appear and 
the pathology involves substantia nigra pars compacta, the midbrain and then the basal 
forebrain. The motor symptoms of PD usually appear when the pathology has reached 
stage where dopaminergic cell loss in SN is 50% and 80% of the striatal dopamine is 
depleted. In the final stages (stage V and VI), the pathological changes involve 
neocortical areas creating cognitive problems and dementia (Braak et al., 2004). 
Despite this, the validity of Braak’s hypothesis remains controversial, as often there is 
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no correlation between the symptoms and the progress of pathology of PD and the 
pathology does not always reflect the clinical severity of the disease (Burke et al., 
2008; Brooks, 2010). Be that as it may, approximately 70% of post-mortem brains 
from PD sufferers follow the Braak staging (personal communication, Prof David 
Dexter Parkinson’s UK Brain Bank, Imperial College London).  
1.1.2.2 Epidemiology and aetiology 
PD affects many people worldwide, regardless the ethnic group, with men more 
affected than women with a ratio 1.5:1 (Twelves et al., 2003; Farrer, 2006). It is 
estimated that the prevalence of PD is about 0.3% in general population at the age 40 
years and older, and 3% of people over the age of 65 years (Mayeux, 2003; Pringsheim 
et al., 2014). These rates suggest that 7.5 million people worldwide are affected by 
PD. The mean age of onset of PD is around the 70, however, early-onset disease is 
seen in about 4% of patients before the age of 50 (Van Den Eeden et al., 2003; Farrer, 
2006).  
The aetiology of PD still remains unknown. It is believed that both environmental and 
genetic factors have been considered as the possible underlying causes, with age and 
family history considered to be the major risk factors and contributors to development 
of PD (Jenner et al., 2013). PD is mainly considered as an idiopathic disorder, 
however, there is also a genetic cause and a small number of sufferers (5–10%) have 
a familial PD (Thomas & Beal, 2007; Wirdefeldt et al., 2011). 
Many of the genes involved in aetiology of PD implicate molecular pathways involved 
in nigral degeneration, including protein aggregation, defective proteasomal 
degradation, oxidative stress and mitochondrial dysfunction suggesting common 
molecular mechanism which underlies PD (Litvan et al., 2007).  
Several genes are associated with inherited forms of the disease, such as PARK2 
(parkin), PTEN-induced putative kinase 1 (PINK1), DJ-1, leucine-rich repeat kinase 2 
(LRRK2) and the α-synuclein mutation (SNCA) (Wirdefeldt et al., 2011) (Table 1.2).  
Many genes differ in terms of phenotype or pattern of inheritance, in case of familial 
PD, and those can be inherited as an autosomal dominant (SNCA or LRRK2) or 
autosomal recessive (PARK2 or PINK1) (Kruger et al., 2002; Warner & Schapira, 
2003; Lees et al., 2009). Nonetheless, there is also evidence showing that some genes, 
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such as LRRK2 mutation, can be involved in both familial and idiopathic PD (Paisán-
Ruı́z et al., 2004; Gilks et al., 2005).  
α-synuclein was the first gene found that the mutations were associated with familial 
early onset PD and verified as a major component of Lewy bodies.  Mutations of α-
synuclein lead to its structural modifications causing misfoldings and aggregations and 
this plays a role in pathogenesis of PD (Kruger et al., 2002).  
PARK2 is autosomal recessive disease and is associated with juvenile PD, however, 
in heterozygotes is associated with adult-onset PD (Foroud et al., 2003). 
Mutation of PINK1 gene can be responsible for a rare familial form of PD. Although, 
its actual role is not clarified, it seems to encode a mitochondrial protein and could 
have a role in neuroprotection (Valente et al., 2004) (Table 1.3) 
One of the most common mutation LRRK2 gene is G2019S and it affects majority of 
Portugese, Ashkenazi Jews, North African Arabs PD patients (Fahn, 2010).  
Furthermore, mutations in the gene encoding for glucocerebrosidase (GBA) is a 
significant risk factor for PD. GBA is a lysosomal enzyme catalysing the hydrolysis 
of the membrane glycolipid, glucocerebroside, to glucose and ceramide (Velayati et 
al., 2010; Beavan & Schapira, 2013). Deficiency in the glucocerebrosidase activity are 
associated with the autosomal recessive lysosomal storage disorder, Gaucher disease 
(GD), which frequently affects Ashkenazi Jewish population (Beavan & Schapira, 
2013). Mutations of GBA have been implicated in PD through lysosomal deficiency 
and autophagic dysfunction. This causes reduction of α-synuclein degradation leading 
to the accumulation of undesirable misfolded proteins and as a consequence further 
disruption of the autophagic system (Velayati et al., 2010). The phenotype is 
indistinguishable clinically, pathologically and pharmacologically from sporadic PD, 
except the mutation in GBA (Beavan & Schapira, 2013). While heterozygous 
mutations of GBA lead to GD, both homozygous and heterozygous mutations increase 
the risk of developing PD by 20 to 30-fold. Approximately 5 – 10% of PD sufferers 
have a GBA mutation (Velayati et al., 2010; Beavan & Schapira, 2013). 
In addition to the genetic factors, environmental agents are thought to contribute to 
aetiology of the disease. Numerous epidemiological studies have indicated that use 
and exposure to pesticides (paraquat), and herbicides (rotenone) have made farmers 
more susceptible to develop PD (Hubble et al., 1993; Priyadarshi et al., 2001; Monte, 
2003). Also, drinking well water, living in rural areas, exposure to heavy metals, 
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including copper, iron, manganese or lead, and some occupations, such as mining and 
welding, contribute to aetiology of the disease (Priyadarshi et al., 2001; de Lau & 
Breteler, 2006). 
 
Table 1.3 Genes underlying monogenic parkinsonism. 
AD – autosomal dominant; AR – autosomal recessive.          
Adapted and modified from Klein & Westenberger (2012).  
 
PARK locus Gene Gene locus Mode of inheritance 
PARK1 SNCA 4q21-22 AD 
PARK2 Parkin 6q25.2-q27 AR 
PARK3 Unknown 2p13 AD 
PARK4 SNCA 4q21-q23 AD 
PARK5 UCHL1 4p14 AD 
PARK6 PINK 1 1p35-36 AR 
PARK7 DJ-1 1p36 AR 
PARK8 LRRK2 12q12 AD 
PARK9 ATP13A2 1p36 AR 
PARK10 Unknown 1p32 Not clear 
PARK11 GIGYF2 2q37 AD 
PARK12 Unknown Xq21-q25 Not clear 
PARK13 HTRA2 2p12 Not clear 
PARK14 PLA2G6 22q13.1 AR 
PARK15 FBXO7 22q12-q13 AR 
PARK16 Unknown 1q32 Not clear 
PARK17 VPS35 16q11.2 AD 




1.1.2.3 PD Therapy   
Regardless of all the advances and effort made in trying to understand the 
pathophysiology of the disease, PD remains incurable and there are no proven 
treatments to slow the disease progression. Surgical techniques, such as pallidotomy 
and deep brain stimulation (DBS) of internal segment of the globus pallidus (GPi) and 
subthalamic nucleus (STN) have broadened the therapeutic options and proved to be 
effective in providing improvement in cardinal symptoms of PD, as well as reducing 
motor complications associated with dopaminergic treatment (Olanow, 2004; 
Volkmann, 2004). Despite that, currently the treatment is largely symptomatic and 
relies mainly on pharmacotherapy targeting the motor symptoms. The treatment is 
mainly focused on replacement of dopamine, however, there are other useful forms of 
pharmacotherapy.  
L-DOPA 
Since the first description of the beneficial effect of high dosage of L-DOPA in 1968, 
it remains the most effective and a gold standard symptomatic treatment for PD 
(Barbeau, 1969; Fahn, 2008). Orally administered L-DOPA is metabolised into 
dopamine in the periphery, and only 1% of the drug crosses the blood brain barrier, 
reducing the efficacy and resulting in side effects, such as nausea or vomiting, 
therefore L-DOPA is given in conjunction with dopa decarboxylase inhibitors (DDCI) 
– benserazide or carbidopa (Schapira, 2005; Hauser, 2009). The combination of 
treatment results in increased plasma half-life of L-DOPA, which in turn increases 
efficacy in the brain and reduces peripheral side effects of dopamine (nausea, 
vomiting) (Hauser, 2009). 
In addition to that, other treatments are given as an adjunct to L-DOPA to increase its 
effects and minimize the side effects. Catechol-O-methyltransferase (COMT) 
inhibitors (entacapone, tolcapone) decrease metabolism of L-DOPA to 3-O-
methyldopa, only the latter having an effect centrally.  The result is a small but 
effective prolongation of the duration of the central effects of L-DOPA (Smith et al., 
2012).  
Monoamine oxidase (MAO)-B inhibitors (selegiline, rasagiline) increase the effect of 
dopamine in the brain by preventing the enzymatic breakdown of endogenous 
dopamine into 3,4-dihydroxyphenylacetic acid (DOPAC) thus enhancing levels of 
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both endogenous and L-DOPA-derived dopamine (Fahn, 2008; Goldenberg, 2008; 
Smith et al., 2012).  
Amantadine, originally an antiviral drug, has mild antiparkinsonian properties. It 
inhibits excessive stimulation of glutamate receptors in the brain by acting as a weak 
NMDA receptor antagonist, increases dopamine release and blocks dopamine uptake 
into the nerve terminals and has anticholinergic properties (Hallett et al., 2006). 
Amantadine therapy results in number of unwanted effects, including nausea and 
insomnia, increased risk of seizure, and not all patients respond to the treatment.  
However, amantadine has been shown to reduce the severity of dyskinesia and now is 
the only clinically prescribed drugs to reduce these unwanted movements and so is 
mainly used in combination with L-DOPA in affected patients if they tolerate the high 
doses (Thomas et al., 2004). 
While short term use of L-DOPA provides exceptional symptomatic relief of the motor 
symptoms, chronic use is associated with the development of motor complications, 
such as “wearing off” (a decrease in duration of L-DOPA effect), “on-off” (changeable 
switching between beneficial response and immobility in PD state) and dyskinesia 
(abnormal involuntary movements) during “on” periods (Iravani & Jenner, 2011). In 
the early stage of the disease, L-DOPA can be stored in synaptic vesicles in presynaptic 
dopamine terminals in the striatum, where is converted to dopamine and then slowly 
released. However, the prolonged use of L-DOPA, pulsatility in plasma and brain 
exposure due to its short half-life, as well as the progression of the disease, result in 
loss of dopaminergic neurons in the striatum are all though to contribute to the 
shortening duration action of L-DOPA. Thus, it becomes harder to predict the duration 
of effect of a single dose resulting in “wearing off” and extended “off” phases causing 
immobility of a patient. The reoccurring symptoms require more frequent drug 
administration, which in turn requires intermittent L-DOPA administration resulting 
in more pulsatile stimulation and disturbances of postsynaptic dopamine receptor 
regulation in the striatum, causing dyskinesia. The rate in which dyskinesia develops 
depends on the striatal denervation and pulsatile nature of the oral L-DOPA treatment 





Dopamine agonists  
A variety of dopamine agonists are used in the treatment, either as a monotherapy or 
as an adjunct to other treatments, and are classified as ergot (bromocriptine, lisuride, 
pergolide and cabergolide) and non-ergot derivatives (apomorphine, pramipexole, 
ropinirole and rotigotine) (Jenner, 2003a; Schapira, 2005). They directly stimulate 
postsynaptic dopamine receptors in the striatum (Jenner, 2003). Dopamine agonists 
bind to different classes of dopamine receptors, however, most commonly used agents 
activate mainly D2 and D3 receptors. Despite that, pergolide and apomorphine show 
affinity for D1 receptor, a target of anti-parkinsonian treatment (Jenner, 2003).  With 
the exception of apomorphine, their half-life tends to be longer than L-DOPA, 
therefore they usually have longer effect depending on type of the compound.  
Similarly as with L-DOPA, dopamine agonists produce number of side effects, 
including hypotension, nausea and vomiting (Stowe et al., 2008), as well as psychiatric 
disturbances (hallucinations and confusion), and impulse control disorders 
(hypersexuality, pathological gambling, compulsive shopping or binge eating), 
requiring cessation of therapy (Lees et al., 2009).  
Anticholinergics 
Anticholinergics were the first drugs to be used in the treatment of PD. The 
antiparkinsonian effect of anticholinergics was described in 1867 by Ordenstein who 
defined effect of belladonna alkaloids, naturally occurring anticholinergics, in the 
treatment of parkinsonian tremor (Goetz, 2011). Decades later, in the 1940s, first 
synthetic anticholinergic trihexyphenidyl was introduced.   
The mechanism of anticholinergics action is not well understood, however, their use 
is intended to improve the striatal imbalance between the dopaminergic and 
cholinergic system by blocking the action of acetylcholine (ACh) and to reduce motor 
symptoms (Duvoisin, 1967; Schapira et al., 2006). Cholinergic and dopaminergic 
system are closely related, and ideally, they should be in persistent balance, however, 
in PD reduced production of dopamine caused by degeneration of nigral neurons leads 
to the imbalance between both neurotransmitters (Duvoisin, 1967).  
Centrally acting anticholinergics, such as trihexyphenidyl and benztropine, have been 
used for many years, however, their use have declined in recent years mainly after the 
introduction of L-DOPA and dopamine agonist, as the latter have proven to be more 
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useful in alleviating the PD symptoms. Nevertheless, anticholinergics are still used, as 
they show useful effect in reducing some of the troublesome motor symptoms, 
particularly tremor (Fox, 2013). They are often used in younger PD patients (≤60 years 
old) as a monotherapy, before the L-DOPA treatment commences. They are also used 
in combination with other drugs where L-DOPA treatment can possibly be delayed, 
consequently extending the use of the “gold standard drug”, and also are used together 
with L-DOPA. Anticholinergics are also useful in the treatment of dystonia in PD, 
which is seen in early stages of young-onset of PD, and commonly seen as an early 
morning “wearing off” occurrence (Brocks, 1999; Katzenschlager et al., 2003). In 
recent years, a review study looking at the use and effect of anticholinergics in the 
treatment of motor symptoms of PD was conducted by Cochrane (Katzenschlager et 
al., 2003). In this study, the results from nine clinical trials with the use of various 
anticholinergics were compared. Tremor was the main outcome measure, and in five 
studies there was a significant improvement of tremor in patients administered 
anticholinergic compared to placebo. Additionally, bradykinesia and rigidity were 
found to be significantly improved in patients receiving anticholinergic therapy 
(Katzenschlager et al., 2003).  
Regardless of the positive effect, currently used anticholinergics are non-selective, 
hence their clinical potential is limited due to the large number of unfavourable central 
and peripheral side effects, which are particularly poorly tolerated in elderly patients, 
as they are more susceptible to memory impairments, sedation, confusion, 
hallucinations, urinary retention, dry mouth or blurred vision (Schapira et al., 2006; 
Langmead et al., 2008; Pirtosek, 2009; Fox, 2013). Therefore, the side effects are the 
main fundamental reason of their reduced use in patients. Since there is an evidence 
that anticholinergics can improve motor symptoms of PD (Katzenschlager et al., 2003) 
the research should focus on finding more selective compounds, which would bring 
benefit of reducing cholinergic activity and controlling motor disability with the 




1.2 Cholinergic function in the basal ganglia  
Clearly anticholinergics play an important role in the treatment of both dystonia and 
PD, although in both diseases their use is limited due to unpleasant peripheral side 
effect that affect compliance.  There is, therefore, an unmet need for improved 
anticholinergic therapy.  In order to address this, it is important to have an 
understanding of the role of ACh in the control of movement, in particular in basal 
ganglia function. 
1.2.1 The neurochemistry of the basal ganglia  
The basal ganglia (BG) are a group of subcortical nuclei which, together with the 
cortex and brain stem, coordinate and incorporate a range of actions, including motor, 
cognitive and motivational processes (Grillner et al., 2013). The BG are comprised of 
input and output nuclei (DeLong & Wichmann, 2007; Lanciego et al., 2012). The input 
nuclei encompass the structures that obtain information from other areas of the brain, 
and consist of striatum, subdivided for caudate nucleus and putamen, and subthalamic 
nucleus (STN). The input pathways comprise of the nigrostriatal dopaminergic 
pathway, the corticostriatal glutamatergic pathway, the thalamostriatal glutamatergic 
pathway, the cholinergic and glutamatergic tracts from the pedunculopontine nucleus, 
the serotoninergic inputs from the raphe nuclei, and a sparse noradrenergic innervation 
from the locus coeruleus. The output nuclei send information to the thalamus and 
consists of internal and external segment of the globus pallidus (GPi and GPe, 
respectively), substantia nigra pars reticulata (SNr) and substantia nigra pars compacta 
(SNc) (Fig. 1.3.) (Lanciego et al., 2012). These structures are functionally connected 
with cerebral cortex and thalamus and involved in the cortico–basal ganglia–
thalamocortical loop (Alexander et al., 1986; Parent & Hazrati, 1995a). The main 
function of the BG is the execution of movement by balanced activity of the direct and 
indirect striatal output pathways (Gerfen, 2000). Disruptions of the basal ganglia 
circuits is related to the large range of psychiatric and neurological diseases, including 
dystonia and PD (Obeso et al., 2008).  
The main integration center of the BG is the striatum, which receives the afferents 
from various cortical and subcortical structures and project to numerous BG nuclei, in 
particular the internal and external segments of the globus pallidus (Crittenden & 
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Graybiel, 2011). Excitatory glutamatergic connections from cerebral cortex and 
thalamus enter the striatum via corticostriatal and thalamostriatal pathway 
respectively, and terminate at the projection neurons called medium spiny neurons 
(MSN). MSN constitute nearly 95% of all striatal neurons and are inhibitory using 
GABA as the neurotransmitter (Rouse et al., 2000; Lanciego et al., 2012). They form 
the basis of the GABAergic neostriatal output, innervating the structures of BG and 
making up the start of the direct and indirect output pathways (DeLong & Wichmann, 
2009). In addition, the activity of the striatum is also controlled by dense projections 
from midbrain dopaminergic neurons (SNc and ventral tegmental area) as well as giant 
aspiny cholinergic and GABAergic interneurons (Kawaguchi et al., 1995; Benarroch, 
2012).  
1.2.1.1 The basal ganglia in the control of movement  
As mentioned earlier, components of the BG form a closed circuit which leads to 
differential effects. Numerous neurotransmitters can be distinguished within the 
circuits and their release results in transmission of signals. These are GABA, acting as 
inhibitory neurotransmitter, excitatory glutamate (GLU) and dopamine (DA), which 
has both excitatory and inhibitory function. In addition, ACh has a major role in 
controlling the direct and indirect pathways by acting directly on MSN, presynaptic 
effects on corticostriatal pathways and interaction with dopamine (DeLong & 
Wichmann, 2009).  
The direct efferent pathway from the striatum is made up of GABAergic MSN 
projection directly to the GPi/SNr which also contain the neuropeptide dynorphin and 
substance P as co-transmitters.   This pathway is controlled by glutamatergic inputs 
from the cortex and dopaminergic inputs from the SNc, the latter stimulated by 
excitatory dopamine D1 receptors.  Stimulation of the direct pathway, either by 
glutamate or dopamine, results in the promotion of movement (Fig. 1.2 A) (DeLong, 
1990; Parent & Hazrati, 1995a; DeLong & Wichmann, 2007). 
The indirect pathway is made up of striato-pallidal efferent MSN which project to the 
GPe which are GABAergic and contain encephalin as co-transmitter.  These then 
connect with GABAergic projections to the STN, synapsing with glutamatergic 
outputs to the GPi/SNr.  The striatal efferents are controlled by excitatory 
39 
 
glutamatergic inputs from the cortex, and dopaminergic inputs from the SNc, the latter 
connecting to inhibitory D2 receptors (Hauber et al., 1998). These inputs have 
opposing effects such that stimulation of the indirect pathway by glutamate results in 
inhibition of movement, whereas dopamine, via inhibitory D2 receptors, results in the 
promotion of movement (Fig. 1.2 A) (DeLong, 1990; Parent & Hazrati, 1995a; Parent 
& Hazrati, 1995b). 
1.2.1.2 Interneurons 
Several classes of local-circuit neurons, termed interneurons, can be found in the 
striatum, and these are cholinergic, GABAergic and tyrosine-hydroxylase-
immunoreactive (Kawaguchi et al., 1995; Zhou et al., 2002; Kreitzer, 2009).  
The GABAergic interneurons are divided into three subtypes. Firstly, parvalbumin-
immunoreactive interneurons which express the calcium-binding protein parvalbumin. 
They are characterized by a fast-spiking phenotype and short-lasting action potential. 
Secondly, the calretinin-immunoreactive interneurons which express calcium-binding 
protein calretinin. There are three or four different types of these interneurons, 
however, their exact function is not known.  Thirdly, a set of interneurons that are 
immunoreactive for somatostatin and nitric oxide, known as persistent and low 
threshold spike (PLTS) interneurons that are able to produce calcium-dependent low 
threshold spikes and large and stable sodium potentials as a response to synaptic 
stimulation (Kawaguchi et al., 1995; Beatty et al., 2012; Lanciego et al., 2012). Studies 
on rodents suggested that there is an interaction between these, the cholinergic 
interneurons (ChI) and parvalbumin-positive fast spiking interneurons (Chang & Kita, 
1992; Lanciego et al., 2012) resulting in suppression of striatal GABA release most 
likely through muscarinic M2 receptors (Marchi et al., 1990; Raiteri et al., 1990; 
Bernard et al., 1992).  
Four types of striatal tyrosine-hydroxylase-immunoreactive interneurons have been 
identified using electrophysiological studies, however, their functional role is 
unknown (Ibáñez-Sandoval et al., 2010).  
From all of the interneurons, the large aspiny cholinergic interneurons (ChI) are the 
most abundant (1–3% of total striatal neurons) (Aosaki et al., 1995; Kawaguchi et al., 
1995; Zhou et al., 2002). They have large cell bodies (20 – 50 µm diameter) and 
extensive axonal fields (Kawaguchi et al., 1995). Their electrophysiological properties 
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include long lasting action potential and continuous and persistent spontaneous firing 
activity, hence they are termed as tonically active neurons (TAN) (Aosaki et al., 1995; 
Kawaguchi et al., 1995; Zhou et al., 2002). They have burst-pause pattern during their 
firing, and the burst is mediated by excitatory glutamatergic inputs, whereas the pause 
is triggered by dopaminergic connections from the SNc, mediated by inhibitory D2 
receptors (Aosaki et al., 2010). Whereas their axonal aborizations are mainly restricted 
to the matrix of the striatum, the ChI possess large dendrites which are spread across 
both the matrix and striosomes of the striatum, and they integrate with the MSN of 
both the direct and indirect pathways (Kawaguchi et al., 1993). These features suggest 
that ACh is tonically released from the interneuron, and this is controlled by 
cholinergic receptors in the striatum.  ChI express both dopamine D2 and D5 receptors 
and muscarinic M2 and M4 receptors (Hersch et al., 1994). Activation of D2 receptors 
mediates inhibition of Na+ channels that reduces excitability, whereas activation of D5 
results in depolarization of ChI through cAMP-dependent mechanism (Maurice et al., 
2004). Muscarinic M2/M4 autoreceptors mediate a negative feedback control on ACh 
release by reducing the opening of Cav2 Ca2+ channels connected to exocytosis and 
by promoting opening of Kir3 K+ channels that cause hyperpolarization and decrease 
of Ca2+ channel opening (Calabresi et al., 1998; Ding et al., 2006; Pisani et al., 2007). 
ChI are the synaptic targets of striatal afferents from the cerebral cortex, thalamic 
nuclei, substantia nigra, locus coeruleus, dorsal raphe nuclei and MSN (Aosaki et al., 
2010; Bonsi et al., 2011). They receive glutamatergic input, producing excitatory 
postsynaptic potentials, from the thalamic nucleus and in low amount from the cerebral 
cortex.  
In turn, excitability of the ChI can be elevated by D1/D5 receptor activation (Aosaki 
et al., 2010).  The connection between the ChI and the MSN of the direct and indirect 
pathway result in an important modulatory role of movement, mainly via M1 and M4 
muscarinic receptors (Breakefield et al., 2008).  
1.2.1.3 Basal ganglia in dystonia 
The development of hyperkinetic movement disorders such as dystonia occurs due to 
the changes in neuronal activities in the BG and thalamus, changes in the metabolic 
and excitability in the cerebral cortex and loss of inhibition to spinal and brain stem 
reflexes leading to the changes in muscle activity during movement (Berardelli et al., 
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1998; Quartarone & Hallett, 2013). Thus, the increase in the inhibitory output from 
the striatum to GPe and GPi via indirect and direct pathways, respectively (Vitek, 
2002). The overactivity of the spiny projection neurons in the direct pathway leads to 
disinhibition of motor circuits to facilitate movements (Fig. 1.2 C) (Gittis & Kreitzer, 
2012). Additionally, elevated cortical excitability and changes in spinal and brainstem 
reflexes have been documented (Vitek, 2002). 
1.2.1.4 Basal ganglia in PD 
Basal ganglia function is altered in PD due to the loss of dopaminergic afferents which 
control the direct and indirect striatal output pathways. The loss of excitatory input to 
the direct pathways results in understimulation, and ultimately reduced thalamo-
cortical stimulation.  The reduced inhibitory effect of dopamine on the indirect 
pathway increases the activity of the striato-GPi pathway which, via connection to the 
STN, GPe and thalamus, also reduces thalamo-cortical activity.  Thus, the result of the 
loss of dopamine in PD causes reduced activity of the motor cortex, and hypokinesia 
(DeLong & Wichmann, 2010; Lanciego et al., 2012).  As described above, treatment 
of PD with L-DOPA and dopamine agonists can reverse these motor deficits by 
replacing the activity of the DA receptors (Fig. 1.2 B) (Schapira, 2005; Hauser, 2009).  
1.2.1.4.1 Basal ganglia with long-term L-DOPA (in dyskinesia) 
In dyskinesia, treatment with L-DOPA causes excessive stimulation of D1 and D2 
receptors, leading to underactivity of the indirect output pathway and overactivity of 
the direct output pathway. This decreases the GABAergic input to the thalamus and 
increase firing of the thalamic neurons, resulting in an involuntary movement (Fig. 1.2 





                                      
Figure 1.2 The basal-ganglia-thalamocortical circuits. 
Normal conditions (a), parkinsonian (b) and in L-DOPA-induced dyskinesia (c). In (b) and (c) changes in the average activity rate of specific projection pathways 
are shown as thickening (increased activity) or thinning (decreased activity) compared to the normal state. Alterations in firing pattern are represented by dashed 
lines. The striatum and STN provide the input layer for incoming cortical information to the basal ganglia. The GPi and SNr provide the output layer communicating 
with the rest of the brain. These structures exert strong inhibitory control on their projection targets in the thalamus and the brainstem and this tonic inhibitory output 
must be released to enable normal movements to occur. The striatum exerts the opposite influences via two classes of efferent neurons, the D1 receptor of direct 
pathway, positively modulated by dopamine, and D2 receptor of indirect pathway, negatively modulated by dopamine. Additionally, the STN receives excitatory 
direct input from the cerebral cortex through hyperdirect pathway. The loss of dopamine in PD (b) causes an imbalance of the activity of the two pathways and their 
corresponding cortical inputs. During the expression of dyskinesia and dystonia (c) the direct pathway is overactive resulting in reduction of output of the GPi and 
the thalamic input to the cortex is enhanced (Berardelli et al., 1998; Cenci, 2007). (GPe, external segment of globus pallidus, GPi, internal segment of globus pallidus, 




Figure 1.3 The simplified basal-ganglia-thalamocortical circuits under normal conditions. 
Figure representing the innervation of the striatum by the nigrostriatal dopamine system and mediation 
of excitatory and inhibitory influence, through dopamine D1 and D2 receptors and ACh muscarinic 
receptors (M1, M2, M4), of direct and indirect GABAergic striatal output pathways to the globus 
pallidus internus (GPi) and substantia nigra pars reticulata (SNr), respectively. ACh modulate DA and 
Glu release by acting on presynaptic nicotinic receptors located on striatal dopaminergic terminals, as 
well as via M1 receptors located on neurons in the substantia nigra pars compacta (SNc). ACh also acts 
on M1 and M2/M4 receptors on striatal  GABAergic spiny neurons, reduces Glu release 
from glutamatergic terminals acting on M2 receptors, and controls its own release by acting on 
M2/M4 autoreceptors. Nigrostriatal DA may also interact with striatal cholinergic interneurons to 
mediate corelease of adenosine triphosphate (ATP) and adenosine (ADO) to act on A1 and A2a 
receptors. ACh, acetylcholine; GABA, gamma-aminobutyric acid; Glu, glutamate; DA, dopamine; Enk, 
enkaphalin; SP, Substance P; + and – represents the excitatory and inhibitory influence of each receptor 




1.3 The role of acetylcholine in the basal ganglia  
Balance between the two main neurotransmitters acetylcholine and dopamine is vital 
in maintaining normal function of basal ganglia.  In the striatum, cholinergic 
neurotransmission is regulated by release of acetylcholine from ChI (Ponterio et al., 
2012). Acetylcholine exerts its effect though nicotinic and muscarinic receptors which 
both are found in abundance in basal ganglia and contribute to basal ganglia function 
(Wess et al., 2007). 
1.3.1 Nicotinic receptors 
Nicotinic receptors are ligand-gated ionotropic cholinergic receptors composed of five 
subunits arranged symmetrically forming a central pore (Hurst et al., 2013). They are 
activated by endogenous ACh, exogenous nicotine or other ligand. There are two 
subfamilies of nicotinic subunits: alpha (α2 – α10) and beta (β2 – β4) (Gotti et al., 
2006). They can be accumulated and form homomeric or heteromeric subunits 
combinations which define characteristic pharmacological and biophysical properties 
of the receptor (Gotti et al., 2006). Alpha subunits are necessary for binding of 
acetylcholine, and beta subunits can alter binding and dissociation constant of nicotinic 
agonists and antagonists, thus regulating their activity (Wang et al., 1996).  
The most highly expressed nicotinic receptors in the striatum are α4, α6, α7, β2 and 
β3, however, other subtypes can also be present but in lower levels (Zoli et al., 2002). 
α4β2* receptors are localized on dopaminergic neurons, serotonergic efferents, striatal 
GABAergic and ChI. Additionally, other subtypes of nicotinic receptors are expressed 
on dopaminergic terminals, including α6β2β3, α6α4β2β3 and α4α5β2 (Zoli et al., 
2002; Champtiaux et al., 2003). Striatal non-dopaminergic terminals express α2α4β2, 
whereas corticostraital afferents, glutamate terminals, and GABA neurons can express 
α7* subunits on nerve endings (Marchi et al., 2002; Zoli et al., 2002). They have a role 
in synaptic plasticity, mainly LTP, due to their Ca2+ permeability and initiation of 
Ca2+dependent processes (Dajas-Bailador & Wonnacott, 2004). Nicotinic receptors 
control release of dopamine on nigrostriatal terminals (Threlfell et al., 2012) and have 
been the target for new therapies for PD, as agonists have been shown to reduce 
dyskinesia in animal models (Quik et al., 2015).  
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1.3.2 Muscarinic receptors  
Muscarinic receptors belong to the G-protein coupled receptors (GPCRs) (Caulfield, 
1993; Jinnah & Hess, 2008). Five types of muscarinic receptors (M1 – M5) have been 
cloned, characterised and divided into two distinct groups according to the signal 
transduction. M1, M3 and M5 receptors couple via Gq/G11 proteins to activate 
phospholipase C (PLC) and mobilise intracellular calcium, whereas M2 and M4 
receptors inhibit activation of adenylyl cyclase (AC), by coupling to Gi/Go, which 
results in reduction of the intracellular concentration of cyclic AMP (cAMP) 
(Langmead et al., 2008).  
1.3.2.1 Location and major functions of muscarinic receptors  
Muscarinic receptors are broadly distributed in various regions of the central and 
peripheral nervous system where they are responsible for regulation of vital 
physiological processes (Wess et al., 2007; Nathanson, 2008). For instance, in the CNS 
they are responsible for cognition, memory, behaviour, motor control and sensory 
function, and in the periphery, they regulate the heart rate, smooth muscle contraction 
and stimulation of glandular secretion (Caulfield, 1993; Wess, 2004; Wess et al., 
2007). Moreover, different tissues may express more than one subtype of the receptor, 
which makes it difficult to determine the exact location and function of the particular 
receptor (Wess et al., 2007) (Table 1.4). 
The M1, M4 and M5 receptors are predominantly located in the CNS, whereas the M2 
and M3 receptors are mainly located in the CNS and in peripheral tissues (Wess et al., 
2007). In the CNS, depending on subtype and neuron where they are present, the 
muscarinic receptors are located pre- and postsynaptically (Nathanson, 2008).  
M1 receptors are reported to be largely found in the CNS, in the cerebral cortex, 
striatum, hippocampus and thalamus where are found postsynaptically and are 
involved in learning and memory processes (Caulfield, 1993). Muscarinic agonists or 
acetylcholinesterase inhibitors enhance cholinergic receptor activation which results 
in improvement of cognitive deterioration, thus selective M1 agonism has been 
proposed as a therapeutic approach in dementia, including Alzheimer’s disease, and 
other memory and cognitive impairments associated with age (Fisher et al., 2003; 
Terry & Buccafusco, 2003). Low levels of M1 subtype of muscarinic receptors have 
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been also associated with schizophrenia, with links to changes in long-term synaptic 
plasticity, auditory and visual hallucinations and memory deficits (Dean et al., 2016). 
In the periphery, they are mainly present in secretory glands (salivary, gastric, 
lacrimal), where they are responsible for increase of saliva and gastric acid secretion 
(Caulfield, 1993).  
Muscarinic M3 receptors centrally are identified in the cerebral cortex and 
hippocampus and a very low amount of M3 is expressed in the striatum (Hersch et al., 
1994; Eglen et al., 1996). Peripherally they are found in the exocrine glands (gastric, 
salivary), smooth muscle (gastrointestinal, eye, airways and bladder) and blood vessels 
(endothelium) (Eglen et al., 1996). Generally, their role is to mediate contraction of 
smooth muscles, including respiratory and gastrointestinal, where they help to promote 
gastric emptying and contraction of the gut, contraction of the iris and stimulate 
secretion from the glands (Eglen et al., 1996; Stengel et al., 2002; Tobin et al., 2002).  
M5 receptors are distributed in the cortex, hippocampus, substantia nigra, ventral 
tegmental area (VTA), region involved in reward and addiction and low amount in the 
striatum (Hersch et al., 1994; Eglen, 2006; Langmead et al., 2008). Blockade of M5 
receptors may be effective in the treatment of drug dependence by inhibition of 
dopamine release in the VTA (Langmead et al., 2008). Peripherally they are expressed 
in salivary gland and in the eye (Langmead et al., 2008). 
Muscarinic M2 receptors in the CNS are expressed in the brainstem, thalamus, cerebral 
cortex, hippocampus and striatum (Eglen, 2006; Langmead et al., 2008). In the cortex, 
they can be found as cholinergic autoreceptors and in the striatum they are located on 
cholinergic interneurons (Bernard et al., 1998; Mesulam, 1998; Piggott et al., 2003). 
Function of autoreceptors can be reduced by selective blockade of M2 resulting in an 
increases cholinergic overflow. Additionally, selective antagonism of M2 receptors 
may provide a therapeutic approach in treatment of schizophrenia, as in the caudate 
putamen M2 receptors acts as inhibitory heteroreceptors on dopaminergic terminals 
(Eglen, 2006). Nevertheless, the major role of M2 receptors is in periphery, where they 
are abundantly expressed in the heart muscle, particularly postsynaptically in the 
myocardium, where they decrease heart rate and force of contraction (Langmead et al., 
2008). M2 receptors are also co-expressed with M3 receptors in smooth muscles, 
including gastrointestinal (Eglen et al., 1996) and in the bladder detrusor muscle 
(Abrams et al., 2006).  
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By contrast, muscarinic M4 receptors are mainly located centrally and are abundantly 
expressed in the striatum and at lower levels pre- and postsynaptically in the cortex 
and hippocampus (Rouse et al., 1999; Piggott et al., 2003). Furthermore, they are 
involved in motor control and may play a role in cognition. It has been suggested that 
muscarinic M4 receptors may play a role in restoring the balance between the DA and 
ACh in PD and dystonia. Preclinical studies with the use of various animal models 
showed that blockade of M4 receptors increases locomotor activity, however, the 
blockers used in these studies were not highly selective for M4 subtype (Gomeza et 
al., 1999a; Mayorga et al., 1999; Karasawa et al., 2003; Betz et al., 2007).  
 
Table 1.4 Central and peripheral location and main functions of muscarinic M1 – M5 
receptors.  




Location Main function 
M1 Cortex, hippocampus, striatum, thalamus, 
glands (gastric, lacrimal, salivary) 
Involved in learning and 
memory processes; 
increase secretion of 
gastric acid, saliva, tears 
M2 Brainstem, thalamus, cortex, 
hippocampus, striatum, heart, smooth 
muscle 
Regulate heart rat 
 
M3 Cortex, hippocampus, exocrine glands 
(gastric, salivary), smooth muscle (GI 
tract, eye, airways, bladder), blood 
vessels (endothelium) 
Mediate contraction of 
smooth muscles 
(respiratory, GI), 
contraction of iris, 
stimulate gland secretion 
M4 Striatum, cortex, hippocampus  Involved in locomotor 
activity and cognition 
M5 Cortex, hippocampus, substantia nigra, 
ventral tegmental area, salivary glands, 
eye  
Involved in cognition, role 




As described previously cholinergic antagonist are widely used clinically in the 
treatment of many disorders. Due to the action of anticholinergics on peripherally 
located muscarinic receptors, patients experience unpleasant side effects, including dry 
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mouth (mediated mainly by M3 and with less extend by M1 receptor), decreased 
sweating (M3 receptor), constipation (M3 receptor), urinary retention (M3 receptor), 
dilated pupils (M3 receptor), blurred vision (M1 and M4 receptors) and increased heart 
rate (M2 receptor). Although, these symptoms may not appear serious, eventually they 
may lead to more serious medical complications, such as gums ulceration, respiratory 
complications or even myocardial infarction (Lieberman, 2004). With this regard, 
although anticholinergics are a useful treatment for dystonia and PD, these side effects 
can reduce compliance. For this reason, it is important to focus attention on 
development of novel muscarinic agents that would selectively target specific receptor 
subtype, as there is still unmet clinical need. Table 1.5 shows antagonists and their 
selectivity at muscarinic mammalian (including human) receptors commonly used in 
the clinic, as well as a number of compounds that are used as research tools in order to 
specifically determine receptor subtype involved in particular disease.  
Values for binding affinities (pKi) of the anticholinergics were obtained from the 
literature. pKi of benztropine, trihexyphenidyl, scopolamine, tropicamide, pirenzepine 
and AFDX-116 were obtained from Lazareno et al., (1990). M1 binding sites were 
acquired from [3H]Pirenzepine binding to rat cortex; whereas [3H]N-
methylscopolamine was labelled to the other sites – M2 binding was from rat heart; 
M3 binding was from rat submandibular glands; M4 binding was from rabbit lung 
(Lazareno et al., 1990). pKi of darifenacin were determined using Chinese hamster 
ovary cell lines (CHO-K1) (Napier & Gupta, 2002) and membranes of Sf-9 cells (Ikeda 
et al., 2001) expressing M1 – M5 receptors.  
Affinity constants for PD102807 were obtained from CHO expressing human M1 – 
M5 receptors (Olianas & Onali, 1999).  
For the selective M4 NBI-675 compound, binding affinity was measured by inhibition 
of radioligand binding to membranes from CHO cells expressing human M1 – M5 







Table 1.5 Muscarinic antagonists affinity constants  
Log affinity constant for pKi values (Lazareno et al. (1990); Caulfield (1993); Olianas & Onali 





M1 M2 M3 M4 M5 
Trihexyphenidyl 9.13 7.86 8.53 8.71  
Benztropine 9.6 8.42 9.15 9.05  
Pirenzepine 7.8-8.5 6.3-6.7 6.7-7.1 7.1-8.1 6.2-7.1 
Darifenacin 7.5-7.8 7.0-7.4 8.4-8.9 7.7-8.0 8.0-8.1 
Tropicamide 7.18 7.3 7.42 7.85  
Scopolamine 9.73 8.85 9.74 9.03  
AFDX-116 5.9-6.7 6.7-7.3 5.8-6.4 6.2-6.4 5.5 
PD102807 5.6 5.4 6.1 7.7 5.3 
NBI-675* 6.63 7.72 6.67 9.52 5.75 
1.3.2.2 Muscarinic receptors expression in the striatal circuity 
All five subtypes of muscarinic receptors are located in the striatum showing different 
distribution and concentrations, therefore they are the main target in order of 
improving the symptoms of PD and dystonia.   
M1 subtypes are mainly excitatory receptors expressed in the medium spiny neurons 
(MSN) of both direct and indirect basal ganglia pathways, positioned either 
extrasynaptically or on dendritic spine necks (Hersch et al., 1994). Their activation 
reduces the activity of potassium channels thus increasing responsivity to 
glutamatergic stimulation (Ben-Ari et al., 1992). In addition, they interact with 
adenosine A2a receptors in the direct pathway and activate signalling of DARP-32 in 
striatopallidial neurons. While on corticostriatal glutamatergic neurons they act as 




By contrast, there is a very low expression of M3 receptors in the striatum, mainly on 
dendrites of MSN (Hersch et al., 1994). The exact role of the M3 receptor is unclear, 
but may be involved in the presynaptic control of drive to the SNc (Miller & Blaha, 
2005). Thus, presynaptic M3 receptors serve to counter excessive excitation of nigral 
dopamine cell activity. 
M5 receptor subtypes are also expressed in the striatum in low amounts, their role is 
not well understood but they may be found on the nigrostriatal dopaminergic terminals 
and could facilitate inhibition of dopamine release (Hersch et al., 1994; Foster et al., 
2014). 
Muscarinic M2 receptors are located on cholinergic interneurons (ChI) where they 
perform as inhibitory autoreceptors and in addition they act as presynaptic inhibitory 
heteroreceptors on corticostraital glutamatergic and dopaminergic nigrostriatal 
terminals (Hersch et al., 1994; Bernard et al., 1998; Mesulam, 1998; Piggott et al., 
2002). 
High levels of inhibitory M4 receptors are found on the striatal MSN, where they are 
colocalised with D1 dopamine receptor on the direct pathway (Bernard et al., 1992; 
Ince et al., 1997; Eglen, 2006). They are present in cholinergic neurons and on 
presynaptic corticostriatal glutamatergic neurons, where they reduce release of 
glutamate (Bernard et al., 1998). They are also expressed on dopaminergic terminals 
(Oldenburg & Ding, 2011). 
1.3.3 Effect of acetylcholine on MSN, corticostriatal, nigrostriatal and 
GABAergic neurons 
ACh exerts a direct effect on MSN via M1 and M4 receptors. The main effect of ACh 
is mediated through excitatory M1 receptors of the indirect pathway (Calabresi et al., 
2006). The striatal MSN are silent at “down” state due to the presence of K+ currents, 
however, due to the inputs from cortical glutamatergic neurons, mediated by NMDA 
receptors they fire a burst of action potentials (“up” state) (Shen et al., 2007). ACh 
causes a slow depolarization of the MSN of the indirect pathway via M1 receptors, 
thus inhibition of these K+ currents, and enhancing the excitability of the striatal 
efferents. Additionally, activation of M1 receptors suppresses the L-type channels 
stopping influx of Ca2+ activating K+ channels that would normally result in after 
hyperpolarisation (Shen et al., 2007). The overall effect on ACh on the indirect 
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pathway is to enhance the effect of glutamate and oppose the effect of dopamine, and 
so promote movement. 
ACh can also inhibit the MSN in the direct pathway by activation of postsynaptic 
inhibitory M4 receptors (Aosaki et al., 2010; Oldenburg & Ding, 2011). This would 
oppose the stimulatory effect of glutamate and dopamine (via D1 receptors), thus 
reducing motor function. 
ACh has an indirect effect on BG function via presynaptic neurotransmitter release 
regulation from cortical, nigral and local afferents. A tonic inhibition of corticostriatal 
glutamate release on MSN is triggered by ACh acting via presynaptic M2/M4 receptor. 
Activation of presynaptic nicotinic receptors at nigrostriatal terminals may also 
contribute to release of dopamine (Ding et al., 2010).  In addition, GABA release from 
terminals of fast spiking inhibitory interneurons is also under control ACh via 
inhibitory M4 and excitatory nicotinic receptors (Wang et al., 2006) (Fig. 1.3). ACh 
act also indirectly on synapses through activing M1 receptors with the used of 
endocannabinoid system (Narushima et al., 2007).  
Clearly ACh plays an important role in the regulation of striatal output and hence the 
fine control of motor function mediated through the thalamocortical output.  However, 
interactions with other neurotransmitters also help regulate the control of movement. 
1.3.4 Dopamine-acetylcholine interaction   
There is an interaction between DA and ACh in the striatum that further modulates the 
activity of the direct and indirect output pathways. Action of both dopamine, via D2 
receptors, and acetylcholine, via M2/M4 receptors, triggers suppression of glutamate 
release from corticostriatal terminals and this results in a “down” state of the MSN. 
However, in the indirect pathway, the “up” state of the MSN is induced directly by 
ACh acting via M1 receptors, whereas in the direct pathway DA induces the “up” state 
by acting on D1 receptors (Pisani et al., 2007; Benarroch, 2012). ACh acts via nicotinic 
receptors on DA terminals to stimulate the release of DA and DA has a direct effect 
on ChI, mainly by activation of D2 receptors, resulting in decrease of striatal ACh 
efflux and lessening autonomous action potential firing and synaptic input to ChI (Fig. 
1.3) (Yan et al., 1997; Aosaki et al., 2010; Bonsi et al., 2011).  
Striatal acetylcholine is acting through different subtypes of cholinergic receptors, as 
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described in section 1.2.1.2, and evokes various effects, for instance controls release 
of dopamine (Fig. 1.3) (Smolders et al., 1997; Lester et al., 2010). Studies on knock-
out mice showed that absence of M4 and M5 receptors significantly reduced release 
of striatal dopamine, whereas the lack of M1 and M2 receptors had no effect (Zhang 
et al., 2002). Since the M4 receptors are present on cell bodies of MSN of the direct 
pathway, their activation inhibits release of GABA in the striatum causing reduction 
of GABAA- mediated inhibition of release of dopamine from striatal nerve terminals 
(Ronken et al., 1993; Lester et al., 2010).  
1.3.5 Cholinergic interneurons in disease  
1.3.5.1 Dystonia 
It is unknown how the anticholinergics work in dystonia, but studies show that they 
are important in modifications to the coupling of D2 receptor in the ChI in mutant mice 
overexpressing torsinA (transgenic DYT1 mouse model). Usually signalling of D2 
receptor decrease interneuronal autonomous spiking, while in these transgenic mice, 
activation of D2 resulted in increased excitation and not reduction in the ChI (Pisani 
et al., 2006). Based on the results, Pisani and colleagues (2006) showed an increased 
inhibitory coupling of D2 receptors to Cav2 Ca2+ channels regulating opening of Ca2+-
dependent K+ channels after the spike (Pisani et al., 2006). It has been suggested that 
regulator of G-protein signalling, RGS9 may have a role (Cabrera-Vera et al., 2004). 
Stimulation of the D2 receptor caused increase in interneuron spiking and increased 
ACh release, which could give an explanation to the use of anticholinergics in dystonia 
(Pisani et al., 2007).  
1.3.5.2 Parkinson’s disease  
The reduction of motor activity in PD is a consequence of the loss of striatal 
dopaminergic innervation from the SNc, caused by increased activity of basal ganglia 
output nuclei to the motor cortex (see above).  DA depletion, as seen in PD, results in 
an increase in cholinergic activity, and, although the cholinergic interneurons are rich 
in muscarinic autoreceptors which employ a feedback control on ACh release, the 
interneurons remain hyperactive.  
Cholinergic interneurons express high levels of D2 receptors, which decrease release 
of ACh by weakening the Cav2 Ca2+ channels in response to membrane depolarization 
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(Yan et al., 1997; Ding et al., 2006). In addition, it has been suggested that a decrease 
in the M4 autoreceptor efficacy, which is a consequence of DA depletion, contributes 
to this increase in ACh signaling (Ding et al., 2006; Pisani et al., 2007).  
Possibly more importantly, ACh subsequently acts at muscarinic M1 and M4 receptors 
on MSN output neurons, validating the use of anticholinergics in the treatment of PD. 
Non-selective anticholinergics are used to treat PD, however, targeting the cholinergic 
neurons specifically located in the striatum may still alleviate the motor symptoms but 
with reduced side effects.  In particular, the M4 muscarinic receptor is found in 
abundance in the striatum, and not in the periphery, where they have inhibitory action 
on D1 receptor-mediated locomotor stimulation (Gomeza et al., 1999a). Therefore, we 
propose that inhibition of muscarinic M4 receptors may disinhibit the direct pathway, 
and potentially enhance its activity in the presence of dopamine, for example following 
treatment with L-DOPA.  
Currently used anticholinergics are not particularly selective for the specific subtypes 
of muscarinic receptors (Table 1.5), and the lack of subtype-specific compounds 
makes it difficult to understand the involvement of exact muscarinic subtype in control 
of movement, without inducing unfavorable, bothersome side effects associated with 
the use of the non-selective anticholinergics, including dry mouth, cognitive 
impairment or blurred vision. The highly selective muscarinic M4 antagonists appears 
as a good as a promising therapeutic approach, therefore the studies described in this 
thesis would assess the effect of the novel highly selective muscarinic M4 antagonist, 
NBI-675, and compare its effect with the currently used anticholinergics on motor 
control using animal models of dystonia and PD.  
1.4 Thesis hypothesis  
Anticholinergics are commonly used in the treatment of dystonia and Parkinson’s 
disease but currently used anticholinergics are non-selective for different subtypes of 
muscarinic receptors located both centrally and peripherally, therefore, their use is 
limited due to unwanted side effects. There is a strong evidence suggesting that 
muscarinic M1 and M4 receptors, which are highly abundant in the striatum, are 
associated with the control of involuntary movements. Since the M4 receptors are 
largely located in this part of the brain, they are a target for the treatment with 
minimised side effects profile. Thus, it is hypothesised that muscarinic M4 selective 
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antagonists control abnormal involuntary movements and motor deficits in dystonia 
and Parkinson’s disease with reduced side effect profile.  
1.5 Thesis aims 
In order to test the hypothesis, the studies described in this thesis investigated the role 
of muscarinic antagonists (anticholinergics), and particularly a novel selective 
muscarinic M4 antagonist, NBI-675, as a potential treatment in reduction of 
involuntary movements, without inducing peripheral side effects, such as oral dryness, 
in established in vivo animal models.  
Specifically, the following aims were addressed:  
1) To determine if selective antagonism of muscarinic M4 receptors controls 
dystonic movements with reduced side effects profile; 
2) To determine if selective antagonism of M4 muscarinic receptors reverses 
motor disability in MPTP-treated common marmoset model of Parkinson’s 
disease;  
3) To determine if selective antagonism of M4 muscarinic receptors reverses 















2.1 Introduction  
The aim of the studies reported in this thesis was to investigate the central and 
peripheral activity of anticholinergics of different relative selectivity for muscarinic 
receptors using in vivo animal models with a view of improving the treatment of 
dystonia and Parkinson’s disease with the use of the selective muscarinic M4 
antagonists.  
2.2 Experimental animal models  
Animal models play important role in the research, as they not only give insights into 
the underlying mechanisms, but also help to improve existing treatment and contribute 
to explore different avenues for therapeutic development. In an ideal world, animal 
models should present all the relevant symptoms and pathology seen in humans, 
however, this is rarely the case. Since it is hard to model every aspect of the disease, 
particularly motor function and disability such as PD, dystonia and dyskinesia, as they 
are very heterogeneous conditions, animal models should be tailored to the type of the 
disease and requirements from the model. Currently, there are number of different 
animal models that display features associated with particular line of investigation, 
including genetic models, such as transgenic or knock-out rodent models, for example 
mouse models expressing mutant proteins involved in familial PD (Goldberg et al., 
2003) or Cacna1a knock-out mouse model of generalised dystonia (Jinnah et al., 
2005). Furthermore, toxin-induced models are broadly used in research, as they can be 
useful in evaluating new or improved treatments. To date, there is no ideal model to 
reflect dystonia seen in man, however, numerous toxin-induced animal models are 
extensively employed to investigate motor complications and abnormal movements, 
such as 6-hydroxydopamine (6-OHDA)-lesioned rodent model and 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primate, which are considered as 
the gold standard models, since they reliably reproduce motor complications seen in 
man (Cenci & Ohlin, 2009; Duty & Jenner, 2011). Furthermore, there is a lack of 
models that could be utilised to investigate the cholinergic component involved in PD 
and dystonia, nevertheless the use of cholinergic agonists has been reported to induce 
involuntary oral movements in rats, resembling chewing, thus this model together with 
the MPTP-treated primate model provides useful and excellent tool in the assessment 
of novel treatments with potential antiparkinsonian and antidystonic properties 
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(Salamone et al., 1986; Stewart et al., 1988). For this purpose, the pilocarpine-induced 
purposeless chewing movement model in rat was established. In addition, motor 
disability and dyskinesia with dystonia and chorea was assessed in the MPTP-treated 
common marmoset. These models were specifically used to probe the process of 
expression of dystonia and its inhibition by anticholinergic agents, including a 
selective M4 antagonist. Drug-induced expression of dystonia was assessed by using 
a manual behavioural scoring system. Peripheral side effect profile of anticholinergics 
was investigated by measuring M3-mediated saliva production in rats. The general 
methodologies employed in these studies are described in detail below. 
2.2.1 Pilocarpine-induced purposeless chewing model in rats  
Substantial evidence indicates that imbalance between cholinergic and dopaminergic 
system is involved in formation of involuntary movements (Duvoisin, 1967) and 
hence, anticholinergics have been used in the treatment of both PD and dystonia since 
decades. Studies on rodents, particularly on rats, demonstrate that administration of 
cholinomimetic agents provoke involuntary movements in the form of oral movements 
of the lower jaw, which resemble chewing and are a result of central stimulation of 
muscarinic receptors located in the striatum (Salamone et al., 1986; Stewart et al., 
1989; Finn et al., 1997; Mayorga et al., 1997). Furthermore, systemic administration 
of a non-selective cholinergic agonist, pilocarpine, acts both centrally and peripherally 
on muscarinic receptors, causing series of effects, including increased salivation, 
lachrymation, urination, diarrhoea, piloerection. These effects can be reversed by 
anticholinergics (Stewart et al., 1989; Mayorga et al., 1999). Previous studies have 
indicated that the vertical movements of the jaw are caused by stimulation of centrally 
located muscarinic receptors (Stewart et al., 1988; Mayorga et al., 1999). Therefore, 
the model of pilocarpine-induced chewing has been used previously to assess the 
cholinergic component in the formation of involuntary movements. Since this effect is 
mediated centrally, previous studies have suggested that M4 receptor are responsible 
for this motor activity (Mayorga et al., 1999; Betz et al., 2007), hence this model may 
provide important information about the central cholinergic function and its 
involvement in production of involuntary movements, such as dystonia.   
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2.2.1.1 Rat  
Male Wistar rats (150 – 350 grams, Harlan, Bicester, UK) were used in all rat 
procedures. Animals were housed in groups of 2 – 4 per cage in a temperature (22 ± 
2°C) and humidity controlled housing unit with 12 hours of light and dark. Nesting 
material and cardboard pipes were provided as a form of enrichment. Food and water 
was available ad libitum, except during the time of behavioural testing. Rats were 
habituated to the testing environment at least one week prior testing, and had 30 min 
of acclimation to testing room before the experiment.  All efforts were made to 
minimize the number of animals used and their suffering. All experiments were 
performed in accordance with the UK Animals (Scientific Procedures) Act 1986 under 
UK Home Office Project licence number 70/6898 and 70/7977 approved by the King’s 
College London Ethical Review Panel. 
2.2.1.2 Assessment of chewing behaviour in response to increasing doses of 
pilocarpine 
This method was adapted and modified from Stewart et al. (1988). Animals were 
placed in a Perspex observation boxes (21 x 35 x 17 cm) with mirrors placed behind 











Figure 2.1 Perspex boxes set up for measuring purposeless chewing behaviour in rats. 
Mirrors are placed behind cages to allow for the viewing of animals from several angles as 
animals move around. 
 
The number of purposeless chewing movements was recorded for 1 min every 10 min 
using a mechanical hand counter by a trained observer. Chewing behaviour was 
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characterised as rapid and repetitive jaw movements, which were not directed at any        
particular object or stimulus (Salamone et al., 1986; Stewart et al., 1988). Counting 
was halted if an animal groomed, yawned or bit during the observation, until 5 s after 
the termination of activity (Stewart et al., 1988). 
2.2.1.3 Statistical analysis  
Data and statistical analysis were performed using GraphPad Prism 5.02 (San Diego, 
CA, USA). Area under curve (AUC) for the time courses was calculated by trapezoid 
method. Data are expressed as mean ± SEM and were analysed by sigmoidal nonlinear 
regression analysis 4-parameter fit. ED50 value was derived from the curve fit. 
Differences between treatment and vehicle control for AUC data was analysed by non-
parametric Friedman’s followed by post hoc Dunn’s test.  
2.2.1.4 Results of the assessment of purposeless chewing behaviour induced by 
pilocarpine  
Animals were placed in a Perspex observation boxes and basal assessment was 
conducted. Pilocarpine (0.1 – 32 mg/kg), a non-selective cholinergic agonist, or 
vehicle were administered intraperitoneally (i.p.) in a randomised manner according 
to a modified Latin square design, to a group of six rats. Purposeless chewing 
assessment started 10 min post pilocarpine administration as described in section 
2.2.3.1. Systemic administration of pilocarpine (0.1 – 32 mg/kg i.p.) produced rapid 
up and down jaw movements. These purposeless chewing-like movements were 
visible after administration of all doses of pilocarpine within 10 min of drug 
administration, with maximal response between 20 and 30 min post-injection (Fig. 2.2 
A).  The present work confirms previous findings (Salamone et al., 1986; Stewart et 
al., 1988; Stewart et al., 1989; Mayorga et al., 1999; Betz et al., 2007) that purposeless 
chewing behaviour in rats can be induced by systemic administration pilocarpine.  
The effect of pilocarpine-induced chewing was dose-dependent and it was 
significantly different for the four higher doses (4 – 32 mg/kg) when compared to 
vehicle (Fig. 2.2 B). The ED50 in the current study was 3.4 mg/kg (Fig. 2.2 B) and 
agrees with previously published data, where a dose of 4 mg/kg was used to induce 
chewing behaviour (Stewart et al., 1988; Stewart et al., 1989; Mayorga et al., 1999; 
Betz et al., 2007). Consequently, based on the results of this study, a single dose of 
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pilocarpine (3.4 mg/kg i.p.) was selected for use in the remaining experiments, where 
anticholinergic agents were tested (Chapter 3).  
Along with induction of rapid chewing movements, administration of pilocarpine 
resulted in other visible manifestations, such as excessive piloerection, lacrimation, 
salivation, increased urination and defecation. This is also consistent with studies 
published in the literature (Stewart et al., 1988; Mayorga et al., 1999; Betz et al., 
2007), and is the result of stimulation of peripherally located muscarinic receptors in 
the skin (M1), salivary glands (M1 and M3), bladder (M3) and gut (M3) (Eglen, 2006; 








Figure 2.2 Pilocarpine-induced purposeless chewing behaviour in rats.  
Pilocarpine 0.1 – 32 mg/kg i.p. A) Time course. Data are mean ± SEM (n=6); B) Log-dose 
chewing (AUC of time course). Data were analysed by a non-linear curve fit (variable slope). 
ED50 = 3.4 ± 1.5 mg/kg (dotted line); (95% CI = 1.48 – 7.89 mg/kg); r2 = 0.78 p<0.05; 
**p<0.01; ***p<0.001 compared to vehicle (Friedman’s test followed by post hoc Dunn’s 
test).  
 
2.2.2 Measurement of salivation as an index of peripheral muscarinic activity 
Administration of anticholinergics, in treatment of dystonia or Parkinsonism, causes 
countless central and peripheral side effects (Chapter 1, section 1.3.2.1), in particular 
oral dryness (Goldman & Comella, 2003; Adam & Jankovic, 2007) due to their 
inhibitory effect on muscarinic receptors.  
To confirm whether selective muscarinic M4 receptor antagonists are a viable 
treatment for dystonia without associated peripheral side effects, measurements of 













































































agonist, stimulates saliva secretion by acting directly on M3 acetylcholine receptors 
located in the salivary glands (Eglen, 2006; Langmead et al., 2008).  
2.2.2.1 Methods of measurement of salivation  
This method was adapted and modified from Flynn et al. (1980). Briefly, a 15 cm 
cotton tipped swab (Johnson’s & Johnson) was weighed. By holding an animal in non-
dominant (left) hand, the swab was inserted into the mouth (usually left cheek side) 
and kept there for a period of 10 sec. The swab was immediately reweighed to measure 
the weight of saliva, which was calculated by subtracting the initial from final weight 
of the swab (Flynn et al., 1980). 
2.2.2.2 Statistical analysis  
Data and statistical analysis were performed using GraphPad Prism 5.02 (San Diego, 
CA, USA). Area under curve (AUC) for the time courses was calculated by trapezoid 
method. Data are expressed as mean ± SEM and were analysed by sigmoidal nonlinear 
regression analysis 3-parameter fit. ED50 value was derived from the curve fit. 
Differences between treatment and vehicle control for AUC data was analysed by One-
way ANOVA followed by post hoc Dunnett’s test. 
2.2.2.3 Results of the assessment of pilocarpine-induced saliva secretion 
Pilocarpine (0.5 – 8 mg/kg i.p.) or vehicle were administered in a randomised manner 
according to a modified Latin square design to a group of five rats and saliva 
production was measured before (time 0) and every 10 min for 40 min after injection 
of pilocarpine, as described in section 2.2.2.1. Administration of increasing doses of 
pilocarpine (0.5 – 8 mg/kg) produced a dose-related increase in saliva secretion in rats. 
Excessive saliva production was visible within 3 – 5 min, with maximal response 10 
min after drug administration (Fig. 2.3 A). The effect was significant for doses 0.5 – 8 
mg/kg when compared to vehicle treated animals (Fig. 2.3 B). The ED50 was 2.65 
mg/kg, however, for the consistence of the studies, an ED50 dose obtained from study 
on purposeless chewing behaviour (section 2.2.1.4) of 3.4 mg/kg was chosen to be 












Figure 2.3 Pilocarpine-induced saliva secretion in rats.  
Pilocarpine (0.001 – 8 mg/kg i.p.) A) Time course. Data are mean ± SEM (n=5); B) Log dose-
related induction of saliva secretion (mg/10 sec/40 min) (AUC time course). Data were 
analysed by a non-linear curve fit; the bottom was constrained to the mean of vehicle alone 
values using GraphPad Prism. ED50 = 2.65 ± 1.38 mg/kg; (95% CI = 1.38 – 5.09 mg/kg); r2 = 
0.85 p<0.05; *p<0.05; ***p<0.001 compared to vehicle (One-way ANOVA followed by post 
hoc Dunnett’s test).  
 
 
2.2.3 The MPTP-treated primate model 
The parkinsonian-like symptoms of MPTP were discovered in 1908s following the 
unintentional administration of contaminated street drugs. This event led to the major 
changes in the research and modelling of PD (Langston et al., 1984).  
MPTP crosses the BBB and becomes oxidised by MAO-B to its active metabolite (1-
methyl-4-phenylpyridinium (MPP+), which inhibits mitochondrial respiratory chain 
Complex I, leading to formation of cytotoxic free radicals (Smeyne & Jackson-Lewis, 
2005). Systemic administration of MPTP results in degeneration of dopaminergic 
neurons in the SN (Iravani et al., 2005) triggering appearance of motor symptoms, 
including bradykinesia, rigidity and postural abnormalities (Jenner et al., 1984). 
Humans, non-human primates and some strains of mice are particularly susceptible to 
the effects of the MPTP, however, rats remain resistant to the effects of the toxin. It is 
thought that possibly due to their high capacity for vesicular sequestration of MPTP. 
The toxin found the usefulness in modelling PD in non-human primates, particularly 
behavioural symptoms have been characterised in cynamologous monkeys (Macaca 
fascicularis), common marmosets (Callithrix jacchus), squirrel and rhesus monkeys 





























































































Non-human primates treated with MPTP respond well to L-DOPA and dopaminergic 
drugs. Moreover, as seen in humans, chronic administration of L-DOPA results in a 
development of dyskinesia with the manifestation of chorea, dystonia and athetosis, 
closely resembling those seen in PD patients (Jenner, 2003b). Furthermore, “on-off” 
and “end of dose deterioration” occurrences and rebound worsening are also exhibited 
(Pearce et al., 1995; Kuoppamaki et al., 2002) therefore, the model provides high 
predictability in assessing novel treatment and in translating preclinical drug studies 
into the clinical setting (Kuoppamaki et al., 2007). Nevertheless, the limitation of the 
model is absence of progressive pathology and prompt development of dyskinesia 
(Langston et al., 1984). Administration of MPTP results mainly in nigrostriatal 
degeneration but lesions and cell loss were also reported in hypothalamus and locus 
coeruleus (Langston et al., 1984; Crossman et al., 1985; Gibb et al., 1986). The loss 
of dopaminergic neurons is not progressive and Lewy bodies are not exhibited in 
MPTP-treated primates (Forno et al., 1993; Kowall et al., 2000).  
2.2.3.1 Animals  
Adult common marmosets (Callithrax Jacchus) (Harlan, UK, 350 – 500 g, n = 6-8 per 
group) of either sex were used in this study. Animals were previously treated with 
MPTP and primed with L-DOPA and were not drug naïve prior to the study.  
2.2.3.1.1 Animal husbandry  
Upon arrival animals were given at least two weeks to acclimatise to their new 
environment. During this period, animals were assessed for general health. Animals 
were housed singly or in pairs (mixed ♂♀or single sex ♀♀) in controlled environment 
suitable for the species (temperature 25 ± 1° with 50% relative humidity on a 12 hour 
light/dark cycle). All animals had ad libitum access to water and Mazuri food pellets 
(Mazuri Primate Diet, Special Diet Services Ltd., UK) and received two meals each 
day, mashed up Mazuri pellets, forage mix and pumpkin seeds in the morning, and 
fresh fruits in the afternoon. All experiments were carried out in accordance with 
Home Office regulations under the Animals (Scientific Procedures) Act 1986 and 
project licence number 70/7146 and 70/8541.  
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2.2.3.2 MPTP-lesion induction 
Between 2.5 – 5.5 years prior to these studies common marmosets were treated with 
MPTP in order to induce the motor symptoms of PD according to previously 
established protocols (Pearce et al., 1995). Animals received subcutaneous injections 
of MPTP (2 mg/kg) (Sigma, UK/Research Biochemicals International) in sterile saline 
0.9% daily for 5 consecutive days. Within a few days following MPTP treatment, 
animals exhibited symptoms that resemble Parkinson’s disease, including 
bradykinesia, akinesia and rigidity, along with loss of vocalisation, diminished 
blinking and action tremor. Animals initially became unable to feed or take care of 
themselves, therefore were hand fed up to twice a day every day with marmoset 
jelly/liquid diet until they were able to take care of themselves and their body weight 
had stabilised (8 – 10 weeks) (Pearce et al., 1995; Goula et al., 2012). Animals 
recovered gradually and at this stage behavioural assessment indicated all animals had 
similar stable level of motor deficits. MPTP treatment leads to a syndrome where 
behavioural deficits remain stable over the years (Jenner et al., 1984).  
MPTP treatment and subsequent animal husbandry were performed by Michael 
Jackson and Ria Fisher.  
2.2.3.2.1 L-DOPA priming for dyskinesia 
L-DOPA priming had been carried out prior to this study in order to establish stable 
and reproducible expression of dyskinesia in animals. Following recovery from acute 
effects of MPTP treatment, animals were primed by the daily administration of L-
DOPA methyl ester (8 mg/kg p.o.) + benserazide (10 mg/kg p.o.) twice daily for 5 
days a week (5 days of treatment followed by a period of 2 days with no treatment), 
for up to 30 days. During this period, animals progressively developed dyskinesia with 
increasing severity, which eventually remained stable. The overall effect of L-DOPA 
resulted in an increase of locomotor activity, reversal of motor disability and 
expression of moderate to severe dyskinesia.  
L-DOPA priming and assessment were performed by Michael Jackson and Ria Fisher.  
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2.2.3.2.2 L-DOPA challenge and animal selection  
The animals were used in previous studies and were not drug naïve. Following the 
priming period, subsequent administration of L-DOPA elicits the same dyskinetic 
response for subsequent studies.  
Prior to studying the effects of anticholinergics in MPTP-treated L-DOPA-primed 
marmosets, animals (n = 12) were re-challenged with L-DOPA (8 mg/kg p.o.) + 
benserazide (10 mg/kg p.o.) to ensure a good motor response and dyskinesia 
expression. Animals were placed in the automated test cages fitted with photo beams, 
as described in section 2.2.3.3. Locomotor activity and reversal of motor disability and 
dyskinesia (dystonia and chorea) were assessed as described in section 2.2.3.3.  
 The animals demonstrating best overall L-DOPA response, i.e. increase in locomotor 
activity and dyskinesia (dystonia and chorea) and reversal of motor disability were 
used in subsequent experiments. The response to L-DOPA administration was visible 
within few minutes of dosing the drug, and it was manifested by improvement of 
locomotor activity (Fig. 2.4 A) and reversal of motor disability (Fig. 2.4 B) with the 
appearance of dyskinesia which manifested as chorea and dystonia (Fig. 2.4 C). Based 
on the obtained results, the eight animals which produced the greatest overall response 
to L-DOPA (improvement in locomotor activity, expression of dyskinesia and reversal 





Figure 2.4 The effect of L-DOPA on locomotor activity, motor disability and dyskinesia 
in MPTP-treated common marmosets  
Time course effect on A) Locomotor Activity; B) Motor Disability and C) Dyskinesia; AUC 
of time course A’) Locomotor Activity; B’) Motor Activity and C’) Dyskinesia. (n = 12). 
Animals were placed into the test units and baseline behaviour assessed. After 1 hour (t = 0) 
animals were treated with L-DOPA (8 mg/kg p.o. + benserazide 10 mg/kg p.o.) and 
behavioural assessment was conducted for further 4.5 hours. Animals which showed the best 
overall increase in locomotor activity, reversal of motor disability and expression of dyskinesia 
were selected for further studies.   
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2.2.3.3 Behavioural assessment  
All behavioural assessments were carried out between the hours 7.00 am and 3.00 pm. 
The assessment consisted of examining and scoring locomotor activity, motor 
disability reversal and dyskinesia (chorea, dystonia and overall dyskinesia) in specially 
designed aluminium test units (50 x 60 x70 cm) with Perspex doors (50 x 70 cm), fitted 
with photocells to measure locomotor activity (Fig. 2.5). Animals were given 60 min 
of acclimatization, during which a baseline score was determined (Smith et al., 2003). 
Test units were housed in a behaviour test room and animals were observed by 
experienced observers blinded to the drug treatment through one-way mirror, as 
described below.   
2.2.3.3.1 Locomotor activity assessment  
Each test unit was fitted with eight horizontally orientated infrared beams to detect 
movement of the animals (Fig. 2.5 B). Beam interruptions were automatically recorded 
as a single locomotor count and transmitted to the computer software (DASYLab data 
acquisition system, laboratory version 11 and a software custom made by Dave 
Leyman using Activity Monitor National Instruments CVI Windows platform) 
throughout the test period and accumulated in 1 min intervals. The data was plotted as 
total counts per 30 min periods for the 7 hrs experiment duration to produce a time 
course of the drug activity (Smith et al., 2003). From the time course data, the AUC 
(GraphPad Prism) was calculated and presented as a total locomotor activity over 








Figure 2.5 Marmosets test units (A) and the position of infrared beams detecting 
movement (B).  
 
 
2.2.3.3.2 Motor disability assessment 
Motor disability was scored simultaneously with locomotor activity measurement 
through one-way mirror during the last 10 min of each consecutive 30 min time 
intervals. Baseline scores were being collected at the end of acclimatisation period, at 
50 – 60 min after animals had been placed into the test units, prior to the drug 
treatment. The assessment of motor disability scoring was based on previously 





score consisted of sub-scores given to each of individual criterion. A maximum 
possible score for motor disability was 18, which indicates a severely disabled 
marmoset, however, MPTP-treated marmosets usually have score of 10 – 14 without 
the drug treatment, while normal naïve marmosets usually score 0 for motor disability. 
Additional behavioural observations, including stereotypy, vomiting, scratching, 
tracking or staring at non-apparent stimuli, explorative behaviour, repetitive 
movements (i.e. head checks in the same direction or circling cage floor with jumps) 
were recorded as additional notes, which were not used for analysis, but were used 
qualitatively to help to determine overall effect of the drug tested. A typical example 
of score sheet for motor disability is shown in Figure 2.6.  
 
Table 2.1 Motor Disability and dyskinesia scoring scale.  
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Normal Impaired Unstable Spontaneous 
falls
Reactions Normal Reduced Slow Absent


















































2.2.3.3.3 Dyskinesia assessment  
Dyskinesia was assessed at the same time as motor disability, using previously 
established dyskinesia rating scale as shown in Table 2.1 (Pearce et al., 1995). Animals 
were also scored separately for chorea and dystonia. Chorea manifests as rapid, dance-
like, flicking movements predominantly of the limbs and head; whereas dystonia is 
characterised by abnormal sustained movements and postures, encompassing mainly 
arm, leg and trunk. Other features that are included in overall dyskinesia score include 
athetosis (sinuous writhing limb movements) and akathisia (motor limb restlessness, 
piano playing-like movements) (Pearce et al., 1995). The score recorded for these three 
parameters reflects the quality and quantity of dyskinetic activity over the 10 min 





Figure 2.6 An example of the score sheet for motor disability and dyskinesia.  
Assessment following treatment with NBI-675 (1 mg/kg p.o.) + L-DOPA (8 mg/kg p.o. + 





2.2.3.4 Drug treatment 
Benztropine mesylate (0.25 & 0.5 mg/kg), scopolamine hydrobromide (0.1 & 0.3 
mg/kg) and methylscopolamine (0.1 & 0.3 mg/kg) were dissolved in 0.9% saline and 
administered subcutaneously (s.c.) at the dose volume 1 ml/kg.  DL-Trihexyphenidyl 
hydrochloride (0.5 & 1 mg/kg) was dissolved in 10% sucrose made up in deionised 
water and administered by oral gavage (p.o.). NBI-675 (1, 5 & 7.5 mg/kg) was 
dissolved in 5% Tween80 and 0.5% methylcellulose made up in deionised water, 
vortexed and sonicated for 1 hr. The pH was adjusted to 4 – 6 with 1M NaOH. NBI-
675 was administered by oral gavage (p.o.). Drugs administered orally were given at 
a dose volume of 2 ml/kg.  
All anticholinergics were administered 1 hour prior L-DOPA (8 mg/kg p.o.) + 
benserazide (10 mg/kg p.o.) in 10% sucrose. Doses of the drugs were chosen according 
to the previously published studies (Jackson et al., 2013) and according to information 
based on the PK and PD studies (NBI-675) received from Neurocrine Biosciences Inc.  
Animals were placed into the testing units. Following the 60 min acclimatisation 
period which provided baseline activity data, animals were dosed with appropriate 
anticholinergic or vehicle followed by L-DOPA (8 mg/kg p.o.) + benserazide (10 
mg/kg p.o.) 60 min later. Behavioural assessment was then carried out as described in 
Section 2.2.3.3. A repeated crossover design was used, so each marmoset was treated 
with all doses of a single drug or vehicle with at least 72 hrs washout between the tests. 
A typical modified Latin square was used to randomise drug treatments and is shown 
in Table 2.2.  
Locomotor activity was recorded throughout the study. Motor disability and 
dyskinesia were scored immediately before each drug treatment and then every 30 








Figure 2.7 Timeline presenting the study design.  
Animals were placed into the test units at t=-120 min and were given 60 min of habituation 
before the anticholinergic treatment t=-60 min, followed by L-DOPA 60 min later (t=0 min). 
Locomotor activity was recorded throughout the study. Motor disability and dyskinesia were 
scored immediately before each drug treatment and then every 30 minutes for 10 minute 
periods throughout the study for up to 5 hours (red arrows).  
 
 
Table 2.2 Typical example of a latin square with a crossover designed treatment for 
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1 2 3 4 5 6
1 A B C D E F
2 D A E B F C
3 C F A E D B
4 B D F A C E
5 E C B F A D
6 D B E C F A
7 A E C D B F
8 F A D E C B
1) A = vehicle anticholinergic + L-DOPA
2) B = dose 1 anticholinergic + vehicle L-DOPA
3) C = dose 1 anticholinergic + L-DOPA
4) D = dose 2 anticholinergic + vehicle L-DOPA
5) E = dose 2 anticholinergic + L-DOPA




Figure 2.8 Typical example of the effect of scopolamine on L-DOPA-induced locomotor 
activity in MPTP-treated common marmosets  
Scopolamine (0.1 & 0.3 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.)  (n = 8) 
A) Locomotor activity time course and B) Total locomotor activity (AUC0-5h). Data are 
expressed as time course with median values with error bars omitted for clarity (A) and median 
with individual counts (B). A) No statistical analysis performed; (B) Data analysed by repeated 
measures ANOVA transformed y=√y; (B) F=5.212; Df (5, 47); p=0.0011; followed by 





Figure 2.9 Typical example of the effect of scopolamine on L-DOPA-induced reversal of 
motor disability in MPTP-treated common marmosets 
Scopolamine (0.1 & 0.3 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n = 8) 
A) Motor disability time course and B) Total motor disability reversal (AUC0-5h). Data are 
expressed as time course with median values with error bars omitted for clarity (A) and median 
with individual counts (B). A) No statistical analysis performed; (B) Data analysed by repeated 
measures ANOVA and transformed y=√y; (B) F=8.247; Df (5,47); p<0.0001 followed by 
Newman-Keuls post hoc test *p<0.05; **p<0.01. 
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Figure 2.10 Typical example of the effect of scopolamine on L-DOPA-induced dyskinesia 
in MPTP-treated common marmosets  
Scopolamine (0.1 & 0.3 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n = 8) 
A) Dyskinesia time course and B) Total dyskinesia (AUC0-5h), Data are expressed as time 
course with median values with error bars omitted for clarity (A) and median with individual 
counts (B). A) No statistical analysis performed; B) Data analysed by repeated measures 
ANOVA and transformed y=√y; F=14.29; Df (5, 47); p<0.0001followed by Newman-Keuls 
post hoc test. ***p<0.001.  
 
 
2.2.3.5 Statistical analysis  
Statistical analysis was performed using GraphPad Prism 5.02 (San Diego, CA, USA). 
Locomotor activity data was collected as 1 minute intervals and then 10 and 30 minute 
time periods were calculated in Excel for individual animals. The 10 minute period 
data was used to calculate the locomotor activity “on-time”, where locomotor counts 
greater than 100 per 10 minutes were considered as an increase in activity. The 30 
minute data were used to determine the total locomotor activity (AUC).  
Motor disability was assessed for 10 minutes every 30 minutes for individual animals. 
“On-time” for reversal of motor disability was defined as the duration of the test period 
that an animal scored below 8 on the motor disability scale.  
Dyskinesia (dystonia and chorea) was assessed for 10 minutes every 30 minutes for 
individual animals. “On-time” for dyskinesia (dystonia and chorea) was defined as the 
duration of the test period that an animal scored above 0 on the dyskinesia rating scale. 
“On-time > 2” refers to troublesome (marked to severe) dyskinesia (dystonia and 
chorea) and indicates time when scores are greater than 2. The 30 minute scores were 
Dyskinesia Scopolamine
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used to determine the total dyskinesia (dystonia and chorea) (AUC) for individual 
animals.  
Peak activity/score was taken as the maximum count/score achieved per 30 min within 
the full assessment period.  
Area under the curve (AUC) was calculated by GraphPad Prism 5.02 (San Diego, CA, 
USA) using the trapezoid method. AUC was calculated from the baseline (defined as 
the 30 min prior administration of anticholinergic) until 6 hr post-treatment for each 
individual animal.  
Time course data were plotted as means at 30 min intervals over 6 hr following drug 
administration with baseline (pre-treatment) plotted at time -60 (t=-60 min). L-DOPA 
were administered at t=0 min on the graphs. The statistical analysis was performed as 
follows: 
The statistical analysis for locomotor activity and motor disability data was performed 
as follows: 
1) No statistical analysis was performed on time course data; 
2) Totals (AUC-1-0h) and (AUC0-5h) and Peak data were transformed by square 
root (Y=√Y). 
3) Totals (AUC-1-0h) and (AUC0-5h), Peak, On-time, On-time > 2 were analysed 
by Two-way ANOVA (variables: L-DOPA and anticholinergic) and repeated 
measures ANOVA followed by post hoc Newman-Keuls multiple comparisons 
test. 
 
2.3 General materials  
Table 2.3 List of drugs 
 
Item Supplier 
AF-DX 116 HelloBio, UK 
Benserazide hydrochloride  Sigma-Aldrich,  UK 
Benztropine mesylate Santa Cruz, USA 
Darifenacin hydrobromide Kemprotec Ltd, UK 






NBI-675 Neurocrine Biosciences, Inc, USA 
Pilocarpine hydrochloride Sigma-Aldrich, UK 
Pirenzepine dihydrochloride Sigma-Aldrich,  UK 
Scopolamine hydrobromide Sigma-Aldrich, UK 
DL-Trihexyphenidyl hydrochloride Sigma-Aldrich,  UK 
Tropicamide Sigma-Aldrich,  UK 
 
Table 2.4 List of chemicals and reagents 
 
Item Supplier 
Baytril Bayer HealthCare A.G, UK 
Buprenorphine (Vetergesic) Reckitt Benckiser Healthcare Ltd, UK 
Carprieve 5.0%  Norbrook Laboratories Ltd, UK 
Dimethyl sulfoxide (DMSO) sterile Sigma-Aldrich, UK 
EMLA Cream AstraZeneca, UK 
Ethanol Fisher Scientific, UK 
Isoflurane Abbott Laboratories Ltd, UK 
Methyl cellulose Sigma-Aldrich, UK 
Sodium pentobarbitone (Euthanal) Merial, UK 
Sodium pentobarbitone (Dolethal) Vetoquinol, UK 
Sucrose Merck Biosciences Ltd, UK 
Tween 80 Sigma-Aldrich, UK 
 
Table 2.5 List of equipment and consumables 
 
Item  Supplier 
23G stainless steel tubing/cannula Cooper’s Needleworks, Birmingham, UK 
30G stainless steel tubing/cannula Cooper’s Needleworks, Birmingham, UK 
Autoclave Meadowrose Scientific Ltd, UK 
Bulldog clips World Precision Instruments (WPI), UK 
CMA Microinjection Pump Carnegie Medicin, Sweden 
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Acrylic denture repair material Dentsply 
Rapid Repair 
Skillbond Direct, High Wycombe, UK 
Disposable scalpel no 10 Swann Morton, Sheffield, UK 
Hamilton Syringe ESSLAB, UK 
Nanoliter Infusion Pump WPI, UK 
pH meter (pocket) Camlab Ltd, UK (Shindengen Electric) 
Portex fine bore polythene tubing Sims Portex Ltd, Ashford, UK 
Stainless steel screws Clerkenwell Screws Ltd, London, UK 
Stereotaxic Frame 
David Kopf Instruments (World Precision 
Instruments, Stevenage, UK) 

















3.1. Introduction  
Anticholinergics show therapeutic utility in the treatment of some types of dystonia, 
particularly segmental and generalised forms (Adam & Jankovic, 2007), but tend to 
induce strong unwanted side effects that limit their use (Cloud & Jinnah, 2010; Lubarr 
& Bressman, 2011). One of the commonly prescribed relatively M1 selective 
anticholinergic, trihexyphenidyl, despite its therapeutic effects, has been reported to 
cause central (drowsiness, confusion, memory problems, hallucinations) and 
peripheral (urinary retention, constipation, blurry vision and dry mouth) side effects 
(Goldman & Comella, 2003; Adam & Jankovic; 2007; Cloud & Jinnah, 2010; Lubarr 
& Bressman, 2011). 
The exact mechanism of action of anticholinergics in dystonia is not known, but it is 
thought that they work by blocking muscarinic ACh receptors in the basal ganglia.  
In recent years, considerable effort has been made to better understand and examine 
the muscarinic receptors activity in motor control. Animal studies show that 
administration of cholinergic agonists, mainly pilocarpine, induces perioral 
movements in rats (Salamone et al., 1986; Stewart et al., 1988; Stewart et al., 1989; 
Mayorga et al., 1999). These involuntary, drug-induced movements are defined in the 
literature as tremulous, vacuous or purposeless (Salamone et al., 1986; Stewart et al., 
1989) and described as rapid vertical deflections of the jaw not directed at any 
particular object (Cousins et al., 1997; Mayorga et al., 1997). They have been 
associated with Parkinsonian tremor (Salamone et al., 2001; Betz et al., 2007) and 
dystonia (Stewart et al., 1988) and are the effect of central stimulation of muscarinic 
receptor subtypes in the striatum (Salamone et al., 2001).  Since pilocarpine is a non-
selective cholinergic agonist, it stimulates all subtypes of muscarinic ACh receptors to 
induce salivation, urination, defecation, lachrymation, piloerection and oral 
movements (Mayorga et al., 1999). 
The central effect of pilocarpine on induction of purposeless chewing is known to be 
reversed by non-selective and relatively subtype selective anticholinergic agents 
(Stewart et al., 1989; Mayorga et al., 1999), however, the exact subtype of muscarinic 
receptor involved in formation of pilocarpine-induced purposeless chewing has been 
difficult to assess due to the high homology, similarity and distribution of these 
receptors and poor selectivity of the anticholinergics. All five muscarinic receptors 
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subtypes are distributed with different intensity in various areas of the brain, including 
striatum (M1 – M5), hippocampus (M1 – M5), cerebral cortex (M1 – M5), thalamus 
(M1, M2) and periphery, in the smooth muscle (M2, M3), glands (M1, M3, M5), heart 
(M2), where they play different functions (Eglen, 2006; Langmead et al., 2008) as 
described in Chapter 1 section 1.3.2. Muscarinic M1 and M4 receptors are 
predominantly expressed in the striatum, where they play important role in regulation 
of motor control. In addition, M1 receptors are in the hippocampus where they have a 
role in learning and memory. They are also expressed in the periphery, mainly in 
glands (salivary, gastric, lacrimal) (Eglen, 2006; Langmead et al., 2008) and all these 
may contribute to reported side effects of anticholinergic treatment (Goldman & 
Comella, 2003; Adam & Jankovic, 2007; Cloud & Jinnah, 2010; Lubarr & Bressman, 
2011). The most recent studies with partially selective M4 antagonist suggested that 
striatal muscarinic M4 receptors are involved in pilocarpine-induced chewing (Betz et 
al., 2007) and hence muscarinic M4 receptors may be the target for a development of 
improved treatment for dystonia with reduced side effects profile.   
3.1.1. Hypothesis 
It is hypothesised that pilocarpine-induced purposeless chewing, as a model of 
centrally mediated motor dysfunction generating abnormal involuntary movements, is 
supressed by anticholinergics through inhibition of muscarinic M4 receptors. 
3.1.2. Aims 
Specific aims of this study were to: 
1) Establish that central muscarinic receptors are responsible for pilocarpine-
induced purposeless chewing. 
2) Determine the subtypes of muscarinic receptors responsible for pilocarpine-
induced purposeless chewing.  
3) Determine the role of M4 receptors on pilocarpine-induced purposeless 




3.2 Materials and Methods 
In order to address these aims the following studies were performed: 
1) The role of central muscarinic receptors in mediation of pilocarpine-induced 
purposeless chewing in rats was confirmed by treating rats with scopolamine 
and methylscopolamine 30 min prior to pilocarpine. Purposeless chewing was 
measured as described below.  
2) To confirm subtype of muscarinic receptor involved in mediation of 
pilocarpine-induced purposeless chewing rats were treated with relatively 
selective anticholinergics 30 min prior pilocarpine, and the purposeless 
chewing was assessed as described below.  
3)  The role of the M4 muscarinic receptor in pilocarpine-induced purposeless 
chewing was determined using the novel selective M4 antagonist NBI-675. 
NBI-675 was administered 60 min prior to pilocarpine, and purposeless 
chewing was measured as described below.   
Detailed methodology is described below. 
3.2.1 Animal husbandry 
Male Wistar rats (160 – 300 g, Harlan, UK) were housed in groups of 4 – 5 per cage 
at a temperature of 22 ± 2ºC and humidity controlled housing unit on a 12 hours light 
– dark cycle. Water and food were available ad libitum except during the surgery and 
experiments. All experiments were performed in accordance with the UK Animals 
(Scientific Procedures) Act 1986 under UK Home Office Project licence number 
70/6898 and 70/7977, approved by the King’s College London Ethical Review Panel. 
3.2.2 Assessment of pilocarpine-induced purposeless chewing  
Systemic administration of pilocarpine to rats induces purposeless chewing 
movements, as described in Chapter 2, section 2.2.1.2. Animals were placed in a 
Perspex observation boxes (21 x 35 x 17 cm) with mirrors placed behind to allow for 
the viewing of animal from several angles and had 30 min of acclimatisation to the 
testing room before the experiment. Pilocarpine (3.4 mg/kg i.p.) was administered 30 
min after anticholinergics administration. Purposeless chewing was assessed before 
and every 10 min after pilocarpine administration and the number of movements was 
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recorded for 1 min every 10 min using a mechanical hand counter as described in 
section 2.2.1.2. 
3.2.3 Drug treatment  
3.2.3.1 Peripheral administration of anticholinergics 
DL-Trihexyphenidyl hydrochloride (0.3 – 5 mg/kg), benztropine mesylate (0.3 – 5 
mg/kg), darifenacin hydrobromide (0.75 – 24 mg/kg), tropicamide (1.25 – 20 mg/kg), 
AF-DX 116 (1 – 30 mg/kg), scopolamine hydrobromide (0.01 – 1 mg/kg), (-) 
scopolamine methyl bromide (methylscopolamine) (0.01 – 1 mg/kg) and NBI-675 (0.1 
– 30 mg/kg) were administered i.p. 30 min prior pilocarpine (3.4 mg/kg i.p.).  Doses 
of the drugs were chosen according to previously published studies (Stewart et al., 
1989; Mayorga et al., 1999; Betz et al., 2007) or according to the PK and PD studies 
(NBI-675) received from Neurocrine Biosciences, Inc. 
Trihexyphenidyl was dissolved in deionised water; darifenacin and AF-DX 116 were 
dissolved in a sterile dimethyl sulphoxide (DMSO) and diluted in 0.9% saline (for 
darifenacin 5:1 saline to DMSO, and for AF-DX 116 3:1 saline to DMSO) and 
tropicamide was dissolved in a minimal amount of ethanol (200 µl) and diluted in 0.9% 
saline. NBI-675 was dissolved in 5% Tween80 and 0.5% methylcellulose made up in 
deionised water, vortexed and sonicated for 1 hr. The pH was adjusted to 4 – 6 with 
1M NaOH. All other drugs were dissolved in 0.9% saline and administered 
intraperitoneally at a dose volume of 1 ml/kg, except the highest dose of AF-DX 116 
(30 mg/kg) which, due to the problems with solubility, was administered at a dose 
volume of 2 ml/kg.  
Drug treatments were administered on a crossover design, so each rat was treated with 
all doses of a single drug or vehicle with at least 48 hr between the tests. Typical latin 
square used to randomise drug treatments in shown in Table 3.1. Different animal 
groups were used to assess the effect of anticholinergics. Benztropine, 
trihexyphenidyl, tropicamide and darifenacin were assessed in one group of rats (group 
I); NBI-675, scopolamine and methylscopolamine – group II; pirenzepine and AF-
DX-116 – group III. Drugs were tested individually in separate studies, following by 





Table 3.1 Typical latin square with a crossover designed treatment for administration of 
different doses of anticholinergics prior to pilocarpine. 
 
3.2.3.2 Central administration of anticholinergics 
3.2.3.2.1 Stereotaxic guide cannula implantation into the lateral ventricle 
In order to administer drugs centrally, a stainless steel guide cannula (23 G, Coopers 
Needle Works Ltd, UK) was implanted into the lateral ventricle (AP: -0.8 mm; ML: -
1.4 mm; DV: -2.8 mm) (Fig. 3.1) using standard stereotaxic techniques. Rats were 
placed in an induction chamber and anesthetised with isoflurane 4% – 5% in 100% 
medical oxygen (BOC, Manchester, UK). Animals were then transferred into the Kopf 
stereotaxic frame (Fig. 3.2) with the incisor bar set at -3.3 mm and ear bars positioned 
symmetrically. Isoflurane anaesthesia (2.5% – 3% in medical oxygen) was maintained 
throughout through a mask.  The body temperature was maintained at 37°C using 
thermostatic heating pad and a rectal probe. After shaving and disinfecting the head, a 
topical local anaesthetic cream (EMLA cream, Astra Zeneca) was applied. An anterior 
to posterior skin incision was made and the skull exposed. Connective tissue was 
cleared using a disposable blade, and bulldog clips were used to retract the skin. 
Bregma was located and coordinates recorded. A hole was drilled through the skull 
directly above the point of insertion and a stainless steel guide 23 G cannula was 
lowered into the lateral ventricle. Coordinates for location of the guide cannula relative 
to bregma are shown in Figure 3.1 (Paxinos & Watson, 1986). The cannula was held 
in place using acrylic denture cement (Rapid Repair, Skillbond Direct, UK) attached 
to the skull by two stainless steel screws (Clerkenwell Screws Ltd, UK).  A stainless 
steel stylet was inserted into the cannula to keep it free from blockage. The wound was 
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closed using two to three separate stitches of dissolvable vicryl sutures. EMLA cream 
was applied on the sutured wound. Animals were given 5 ml of 0.9 % saline 
subcutaneously (s.c.) to prevent dehydration and the analgesic buprenorphine (0.2 
mg/kg s.c.) and analgesic/anti-inflammatory carprieve (5 mg/kg s.c.) were 
administered. Animals were placed in cages with a heat-controlled pad underneath 
until completely recovered from anaesthesia. The post-operative weight was 
monitored daily (Fig. 3.3) and a mash diet (softened food pellets) provided until 
animals regained their pre-operative weight. They were allowed 6 days to recover prior 
behavioural testing.  
The placement of the cannula was verified by microinjection of a trypan blue dye (1 










Figure 3.1 Location of cannula implanted in the right lateral ventricle (red line).  





Figure 3.2 Stereotaxic frame for the cannula implantation.  
 
 
Figure 3.3 Typical example of body weight changes post cannula implantation into the 
lateral ventricle.  
Day 0 is a day of the surgery. Data are expressed as mean ± SEM (n = 8) of body weight of 
animals.   
 
3.2.3.2.2 Intracerebroventricular administration of anticholinergics  
Pirenzepine dihydrochloride (2.4 – 377 nmol/µl i.c.v., equivalent of 1 – 160 µg/µl) 
was dissolved in 0.9% saline and, due to limited solubility, administered in a dose 
volume of 2 µl and 3 µl (the highest dose) at a rate 1 µl/min. Darifenacin hydrobromide 
(0.2 – 295.5 nmol/µl, equivalent of 0.1 – 150 µg/µl) was dissolved in a sterile DMSO 
and diluted with 0.9% saline (4:1 saline to DMSO) and administered i.c.v. at a dose 
volume of 2 µl at a rate 1 µl/min. Trihexyphenidyl (3 – 59 nmol, equivalent of 1 – 20 






















µg/µl) was dissolved in a deionised water and administered i.c.v. at a dose volume of 
1 µl (3 nmol), 2 µl (29.5 nmol) and 4 µl (59 nmol), due to poor solubility, at a rate 1 
µl/min. Tropicamide (3.5 – 422 nmol/ µl, equivalent of 1 – 120 µg/µl) was dissolved 
in a minimal amount of ethanol (20 µl) and diluted in 0.9% saline and administered 
i.c.v. at a dose volume of 2 µl at a rate 1 µl/min. 
A stainless steel guide cannula was stereotaxically implanted into the lateral ventricle 
of rats, as described in section 3.2.3.2.1, in order to allow repeated microinjection of 
anticholinergics or vehicle.  
Drug injection was made through a stainless steel injection needle (30 G, Coopers 
Needle Works Ltd, UK) placed inside the guide cannula. Injection needles were 1 mm 
longer than the tip of guide cannula (coordinates of injection site: AP: -0.8 mm; ML: 
-1.4 mm; DV: -3.8 mm). Animals were hand restrained (Fig. 3.4). The end of injection 
needle was connected via tubing to the 100 µl Hamilton gastight syringe containing 
anticholinergic or vehicle (saline) and attached to the CMA Microinjection Pump 
(Carnegie Medicin, Sweden) or Nanoliter Infusion Pump (WPI, UK) (Fig. 3.4). Total 
injected volume was either 1 – 4 µl (as stated above) at a rate of 1 µl/min. 
Anticholinergics administered centrally (i.c.v.) were assessed on individual groups of 




Figure 3.4 Microinjection of substances via guide cannula implanted to the brain.      
Rat is being hand restrained and the end of injection needle is connected via tubing to a 100 
µl Hamilton syringe with a drug solution and attached to a Nanoliter Infusion Pump.  
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Injection needle was left in place for a further 4 min to allow drug diffusion into the 
surrounding area and to prevent reflux up the needle tract and cannula. Injections were 
conducted in a randomised manner according to a modified Latin square design, at 
least 48 hrs between the tests (Table 3.1). Drugs were tested individually in separate 
studies.  Rats were placed in boxes and assessment of chewing was conducted as 
described in section 2.2.3.1.  
3.2.4 Statistical analysis  
Data and statistical analysis for pilocarpine-induced purposeless chewing were 
performed using GraphPad Prism 5.02 (San Diego, CA, USA). Area under curve 
(AUC) for the time course was calculated by trapezoid method. Data are expressed as 
mean ± SEM and were analysed by sigmoidal nonlinear regression analysis 3-
parameter fit. ID50 value was derived from the curve fit. Bottom was constrained to 
the value 0. Differences between treatment and vehicle control for AUC data was 
analysed by non-parametric Friedman’s test followed by a post hoc Dunn’s test.  
Peripheral effects of anticholinergics on pilocarpine-induced salivation, piloerection, 
defecation, urination, lachrymation were measured qualitatively and scored for a 






Based on results from Chapter 2, section 2.2.1.4, an ED50 dose of pilocarpine (3.4 
mg/kg) was chosen to induce purposeless chewing in rats in these studies. As expected, 
this dose of pilocarpine induced chewing behaviour which was visible within few 
minutes of administration, peaked between 10 – 20 min, and lasted about 100 min. 
Baseline number of pilocarpine-induced chews differs between animals as the 
experiments were conducted on different groups of animals.  
Overall, pre-treatment with anticholinergics resulted in a dose-dependent inhibition of 
pilocarpine-induced purposeless chewing, which was consistent for all centrally acting 
agents tested. Administration of vehicle did not alter chewing behaviour in rats.  
3.3.1 Central effect of pilocarpine-induced chewing  
In order to confirm that pilocarpine-induced chewing is mediated through central 
muscarinic receptor, the effect of the centrally acting anticholinergic scopolamine, and 
its peripherally acting derivative, methylscopolamine, were investigated.  
 Scopolamine (0.01 – 1 mg/kg), a non-selective centrally acting antimuscarinic, 
produced dose-related inhibition of purposeless chewing induced by pilocarpine (Fig. 
3.5 A). Scopolamine significantly reduced purposeless chewing at the two higher 
doses (0.1 and 1 mg/kg) (Fig. 3.5 B). There was a nearly complete inhibition of 
purposeless chewing at the highest dose administered (1 mg/kg) (Fig. 3.5 A). The ID50 
for scopolamine was 0.04 mg/kg (95% CI = 0.02 – 0.06 mg/kg). 
Peripherally acting methylated derivative of scopolamine, methylscopolamine (0.01 – 
1 mg/kg), produced total suppression of pilocarpine-induced purposeless chewing 
accounting for 16% when compared to vehicle-treated animals, which was significant 
















































































Figure 3.5 Effect of scopolamine (i.p.) on pilocarpine-induced purposeless chewing.  
A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for scopolamine (0.01 
– 1 mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) purposeless chewing 
(AUC time course). Data were analysed by a non-linear curve fit. Bottom was constrained to 
0. ID50 = 0.04 ± 1.4 mg/kg (dotted line); (95% CI = 0.02 – 0.07 mg/kg; r2 = 0.81 p< 0.05); 
*p<0.05; ***p<0.001 compared to vehicle-treated animals (Friedman’s test (FS = 18.75; 
***p<0.001; p=0.0003) followed by post hoc Dunn’s test).  
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Figure 3.6 Effect of methylscopolamine (i.p.) on pilocarpine-induced purposeless 
chewing.  
A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for methylscopolamine 
(0.01 – 1 mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) purposeless 
chewing (AUC time course). Data were analysed by a non-linear curve fit. Bottom was 
constrained to 0. ID50 > 1 mg/kg; r2 = 0.02 NS; *p<0.05; **p<0.01 compared to vehicle-treated 




3.3.2 The effect of subtype selective anticholinergics  
3.3.2.1 Muscarinic M1 selective anticholinergics  
Peripheral administration of trihexyphenidyl (0.3 – 5 mg/kg i.p.), an M1 selective 
muscarinic antagonist, 30 min before pilocarpine, produced a dose-dependent 
inhibition of pilocarpine-induced purposeless chewing (Fig. 3.7 A). Trihexyphenidyl 
significantly reduced chewing at doses of 1.25 – 5 mg/kg when compared to vehicle-
treated animals (Fig. 3.7 B). The ID50 for trihexyphenidyl was 1.6 mg/kg (95% CI = 
1.2 – 2.2 mg/kg).  
 
Central administration of trihexyphenidyl (3 – 59 nmol i.c.v.) into the lateral ventricle 
resulted in a small inhibition of pilocarpine-induced purposeless chewing (Fig. 3.8 A 
& B). Purposeless chewing was significantly reduced at the doses of 3 and 29.5 nmol 
when compared to vehicle-treated animals. However, this inhibition amounted to 
about 36% at all doses tested. Higher doses could not be tested due to the poor 
solubility of the compound. 
 
 
Figure 3.7 Effect of trihexyphenidyl (i.p.) on pilocarpine-induced purposeless chewing.  
A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for trihexyphenidyl (0.3 
– 5 mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) purposeless chewing 
(AUC time course). Data were analysed by a non-linear curve fit. Bottom was constrained to 
0. ID50 = 1.6 ± 1.1 mg/kg (dotted line); (95% CI = 1.2 – 2.2 mg/kg; r2 = 0.82 p< 0.05); *p<0.05; 
***p<0.001 compared to vehicle-treated animals (Friedman’s test (FS = 35.71; ***p<0.001; 
p<0.0001) followed by post hoc Dunn’s test). 
 
 





















































































Figure 3.8 Effect of trihexyphenidyl (i.c.v.) on pilocarpine-induced purposeless chewing.  
A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for trihexyphenidyl (3 
– 59 nmol i.c.v., equivalent to 1 – 20 µg) on suppression of pilocarpine-induced (3.4 mg/kg 
i.p.) purposeless chewing (AUC time course). Data were analysed by a non-linear curve fit. 
Bottom was constrained to 0. ID50 > 59 nmol; (r2 = 0.21 NS); *p<0.05; **p<0.01 compared to 
vehicle-treated animals (Friedman’s test (FS = 10.95; *p<0.05; p=0.0120) followed by post 
hoc Dunn’s test). 
 
 
Benztropine (0.3 – 5 mg/kg i.p.), a selective M1 anticholinergic, produced a dose-
dependent reduction of pilocarpine-induced purposeless chewing behaviour (Fig. 3.9 
A). Benztropine significantly reduced pilocarpine-induced purposeless chewing 
except the lowest dose (0.3 mg/kg). The ID50 for benztropine was 0.7 mg/kg (95% CI 
= 0.5 – 0.9 mg/kg). At the highest dose tested little or no chewing was observed (Fig. 



























































































Figure 3.9 Effect of benztropine (i.p.) on pilocarpine-induced purposeless chewing.  
A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for benztropine (0.3 – 
5 mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) purposeless chewing 
(AUC time course). Data were analysed by a non-linear curve fit. Bottom was constrained to 
0. ID50 = 0.7 ± 1.1 mg/kg (dotted line); (95% CI = 0.5 – 0.9 mg/kg; r2 = 0.84 p<0.05); *p<0.05; 
**p<0.01; ***p<0.001 compared to vehicle-treated animals (Friedman’s test (FS = 36.07; 
***p<0.001; p<0.0001) followed by post hoc Dunn’s test). 
 
 
Systemic administration of putative M1 selective antagonist, pirenzepine (0.1 – 50 
mg/kg i.p.) produced total suppression of pilocarpine-induced chewing accounting for 
18% when compared to vehicle-treated animals, which was significant for 1 and 10 
mg/kg (Fig. 3.10 A & B).  
Central administration of putative M1 selective antagonist, pirenzepine (2.4 – 377 
nmol i.c.v.) into the lateral ventricle resulted in a dose-related inhibition of purposeless 
chewing induced by pilocarpine (Fig. 3.11 A), which was significant for the two 
highest doses (189 and 377 nmol) (Fig. 3.11 B), with ED50 of 29 nmol (95% CI = 19 
– 43.5 nmol). The highest dose of pirenzepine (377 nmol) completely blocked 






















































































































































Figure 3.10 Effect of pirenzepine (i.p.) on pilocarpine-induced purposeless chewing.  
A) Time course. Data are mean ± SEM (n = 7). B) Log-dose response for pirenzepine (0.1 – 
50 mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) purposeless chewing 
(AUC time course). Data were analysed by a non-linear curve fit. Bottom was constrained to 
0. ID50 > 50 mg/kg; r2 = 0.005 NS; *p<0.05; **p<0.01 compared to vehicle-treated animals 
(Friedman’s test (p<0.01; FS = 15.08; p=0.010) followed by post hoc Dunn’s test). 
 
 








































































Figure 3.11 Effect of pirenzepine (i.c.v.) on pilocarpine-induced purposeless chewing.  
A) Time course. Data are mean ± SEM (n = 7). B) Log-dose response for pirenzepine (2.4 – 
377 nmol i.c.v., equivalent to 1 – 160 µg) on suppression of pilocarpine-induced (3.4 mg/kg 
i.p.) purposeless chewing (AUC time course). Data were analysed by a non-linear curve fit. 
Bottom was constrained to 0. ID50 = 29 ± 1.2 nmol (dotted line); (95% CI = 19.0 – 45.5 nmol; 
r2 = 0.90 p<0.05); **p<0.01; ***p<0.001 compared to vehicle-treated animals (Friedman’s 





3.3.2.2 Muscarinic M2 selective anticholinergics  
AF-DX 116 (1 – 30 mg/kg i.p.), an M2 selective antagonist, significantly inhibited 
pilocarpine-induced purposeless chewing only at the top dose (30 mg/kg) (Fig. 3.12 A 
& B), however, higher doses could not be tested due to the poor solubility of the drug, 
so the ID50 could not be determined.   
AF-DX 116



































































Figure 3.12 Effect of AF-DX 116 (i.p.) on pilocarpine-induced purposeless chewing. 
A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for AF-DX 116 (1 – 30 
mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) purposeless chewing (AUC 
time course). Data were analysed by a non-linear curve fit. Bottom was constrained to 0. ID50 
> 30 mg/kg; (r2 = 0.56 NS) **p<0.01 compared to vehicle-treated animals (Friedman’s test 
(FS = 15.45; **p<0.01; p=0.0015) followed by post hoc Dunn’s test). 
 
 
3.3.2.3 Muscarinic M3 selective anticholinergics  
Systemic administration of darifenacin (0.75 – 24 mg/kg), an M3 selective antagonist, 
produced dose-dependent inhibition of pilocarpine-induced chewing (Fig. 3.13 A). 
Darifenacin significantly reduced chewing at three higher doses (6 – 24 mg/kg) (Fig. 
3.13 B) when compared to vehicle-treated animals. The ID50 for darifenacin was 9 
mg/kg (95% CI = 7.2 – 11.3 mg/kg).  
Central administration of darifenacin (0.2 – 295.5 nmol i.c.v.) into the lateral ventricle 
resulted in a small and variable inhibition of pilocarpine-induced chewing (Fig. 3.14 
A). Chewing was significantly reduced following doses of 2 – 295.5 nmol when 
compared to vehicle-treated animals. The complete inhibition of chewing was not 
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achieved and the highest dose tested (295.5 nmol) produced only moderate suppression 
of chewing (Fig. 3.14 B). 
 
 
Figure 3.13 Effect of darifenacin (i.p.) on pilocarpine-induced purposeless chewing. 
 A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for darifenacin (0.75 – 
24 mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) purposeless chewing 
(AUC time course). Data were analysed by a non-linear curve fit. Bottom was constrained to 
0. ID50 = 9 ± 1.1 mg/kg (dotted line); (95% CI = 7.2 – 11.3 mg/kg; r2 = 0.85 p<0.05); *p<0.05; 
***p<0.001 compared to vehicle-treated animals (Friedman’s test (FS = 40.87; ***p<0.001; 
p<0.0001) followed by post hoc Dunn’s test).  
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Figure 3.14 Effect of darifenacin (i.c.v.) on pilocarpine-induced purposeless chewing.  
A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for darifenacin (0.2 – 
295.5 nmol i.c.v., equivalent to 0.1 – 150 µg) on suppression of pilocarpine-induced (3.4 
mg/kg i.p.) purposeless chewing (AUC time course). Data were analysed by a non-linear curve 
fit. Bottom was constrained to 0. ID50 > 295.5 nmol; (r2 = 0.24 NS); *p<0.05; **p<0.01; 
***p<0.001 compared to vehicle-treated animals (Friedman’s test (FS = 32.25; ***p<0.001; 
p<0.0001) followed by post hoc Dunn’s test). 
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3.3.2.4 Muscarinic M4 selective anticholinergics  
Tropicamide (1.25 – 20 mg/kg), the putative M4 selective anticholinergic, dose-
dependently suppressed pilocarpine-induced chewing in rats (Fig. 3.15 A) when 
administered peripherally. Chewing was significantly reduced at the three higher doses 
(5 – 20 mg/kg) (Fig. 3.15 B) with ID50 of 8.6 mg/kg (95% CI = 6.3 – 11.8 mg/kg). 
Nevertheless, complete inhibition of chewing was not observed with the highest dose 
tested.   
Central administration of tropicamide (3.52 – 422 nmol i.c.v.) into the lateral ventricle 
showed no effect on pilocarpine-induced purposeless chewing in rats (Fig. 3.16 A & 
B). Higher doses were not tested due to the poor solubility of the compound.  
 
 
Figure 3.15 Effect of tropicamide (i.p.) on pilocarpine-induced purposeless chewing.  
A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for tropicamide (1.25 – 
20 mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p) purposeless chewing 
(AUC time course). Data were analysed by a non-linear curve fit. Bottom was constrained to 
0. ID50 = 8.6 ± 1.2 mg/kg (dotted line); (95% CI = 6.3 – 11.8 mg/kg; r2 = 0.76 p<0.05); *p<0.05; 
**p<0.01; ***p<0.001 compared to vehicle-treated animals (Friedman’s test (FS = 31.77; 
***p<0.001; p<0.0001) followed by post hoc Dunn’s test). 
  
 















































































































































Figure 3.16 Effect of tropicamide (i.c.v.) on pilocarpine-induced purposeless chewing.  
A) Time course. Data are mean ± SEM (n = 7). B) Log-dose response for tropicamide (3.52 – 
422 nmol i.c.v., equivalent to 1 – 120 µg) on suppression of pilocarpine-induced (3.4 mg/kg 
i.p.) purposeless chewing (AUC time course). Data were analysed by a non-linear curve fit. 
Bottom was constrained to 0. ID50 > 422 nmol; r2 = 0.06 NS; NS compared to vehicle-treated 
animals (Friedman’s test (FS = 7.971; NS; p=0.0466)). 
 
The novel M4 selective antagonist NBI-675 (0.1 – 30 mg/kg i.p.) produced a dose-
related inhibition of pilocarpine-induced purposeless chewing (Fig. 3.17 A). NBI-675 
significantly reduced chewing at the two highest doses (10 and 30 mg/kg) (Fig. 3.17 
B). The highest dose (30 mg/kg) of NBI-675 resulted in a nearly complete inhibition 
of pilocarpine-induced chewing. The ID50 for NBI-675 was 9.5 mg/kg (95% CI = 6.7 


















































































Figure 3.17 Effect of NBI-675 (i.p.) on pilocarpine-induced purposeless chewing. 
 A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for NBI-675 (0.1 – 30 
mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) purposeless chewing (AUC 
time course). Data were analysed by a non-linear curve fit. Bottom was constrained to 0. ID50 
= 9.5 ± 1.2 mg/kg (dotted line); (95% CI = 6.7 – 13.5 mg/kg; r2 = 0.83 p<0.05); **p<0.01; 
***p<0.001 compared to vehicle-treated animals (Friedman’s test (FS = 29.69; ***p<0.001; 
p<0.0001) followed by post hoc Dunn’s test). 
 
Table 3.2 Summary of the inhibitory effect of anticholinergics on pilocarpine-induced 
chewing. 




Scopolamine i.p. Non-selective +++ 
Methylscopolamine i.p. Non-selective - 
Trihexyphenidyl i.p. M1 +++ 
Trihexyphenidyl i.c.v. M1 + 
Benztropine i.p. M1 +++ 
Pirenzepine i.p. M1 - 
Pirenzepine i.c.v. M1 +++ 
AF-DX 116 i.p. M2 ++ 
Darifenacin i.p. M3 ++ 
Darifenacin i.c.v. M3 + 
Tropicamide i.p. M4 +++ 
Tropicamide i.c.v. M4 - 
NBI-675 i.p. M4 +++ 
 
3.3.3 Other effects of anticholinergic treatment   
Pilocarpine produced peripheral side effects including increased salivation, diarrhoea, 
urination, lachrymation, piloerection, which were visible within few minutes of 
administration. Within few minutes of administration all anticholinergics suppressed 
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these peripheral effects induced by pilocarpine (Table 3.3), which was observed during 
the assessment of chewing, but not quantified.  
In addition, higher doses of centrally acting anticholinergics not only reduced 
pilocarpine-induced chewing movements and peripheral effects, but also some 
compounds, specifically pirenzepine and NBI-675, produced CNS effects which were 
observed in animals. These were manifested by reduced activity and movement, 
recumbency, and overall somnolence, which could be an indication of the CNS 
anticholinergics effects.  
Table 3.3 Effect of inhibition of pilocarpine-induced peripheral side effects of different 
anticholinergics following intraperitoneal administration measured qualitatively during 
assessment of chewing. 
 The effects are based on the middle dose.   
+ low inhibition; ++ moderate inhibition; +++ high inhibition; NS non-selective 
 
 




The studies described in this chapter focused on examining the effect of muscarinic 
antagonists on suppression of pilocarpine-induced purposeless chewing in rats. Since 
striatally located muscarinic acetylcholine (mACh) M4 receptors are thought to be 
responsible for the production of purposeless chewing movements in rats (Salamone 
et al., 1986; Stewart et al., 1989; Salamone et al., 1990) it was hypothesised that 
centrally acting M4 antagonists could be utilized clinically to aid regulation of 
abnormal movements associated with motor dysfunction, such as dystonia.  
This hypothesis was tested using anticholinergics with different relative selectivity to 
muscarinic receptors subtype, including the novel selective M4 antagonist, NBI-675, 
on inhibition of pilocarpine-induced purposeless chewing in rats. 
3.4.1 The effect of peripherally administered anticholinergics 
Administration of a non-selective centrally acting scopolamine nearly completely 
inhibited purposeless chewing, and this agrees with previous findings (Salamone et 
al., 1986; Stewart et al., 1989). Moreover, its peripherally acting methylated 
derivative, methylscopolamine, showed no effect on pilocarpine-induced purposeless 
chewing. These findings are in agreement with observation by Stewart et al., (1989) 
who demonstrated inhibitory effect of methylscopolamine on pilocarpine-induced 
purposeless chewing only when administered via central route into the lateral ventricle, 
and not via systemic route (Stewart et al., 1988). In addition to the above, systemic 
administration of pirenzepine, an M1 selective antagonist, was unable to block 
pilocarpine-induced chewing. This result is not unexpected, knowing its poor brain 
penetrant properties (Carmine & Brogden, 1985). It has, however, blocked peripheral 
effects of pilocarpine, including piloerection, salivation, defecation, urination and 
lachrymation. Therefore, these results confirm first aim of the study that centrally 
located muscarinic receptor is responsible for mediation of purposeless chewing.  
Overall, some drugs were more potent that others in suppression of pilocarpine-
induced purposeless chewing in the current study, and this could correspond to the 
relative potency of the compounds used (Chapter 1 section 1.3.2.1).  The rank order of 
potency, according to the obtained ID50 values for i.p. administration, on inhibition of 
purposeless chewing was scopolamine > benztropine > trihexyphenidyl > NBI-675 = 
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tropicamide > darifenacin > AF-DX 116 > pirenzepine = methylscopolamine. 
However, these values are dependent on PK and brain penetration, and not subtype 
selectivity.  
The relative inhibition of purposeless chewing, binding affinities of these drugs to 
muscarinic receptors subtypes (Chapter 1, section 1.3.2.1) and central location of 
muscarinic receptor subtypes, suggest that muscarinic M2 and M3 receptors have a 
minor role in mediation of purposeless chewing (Waelbroeck et al., 1990; Eglen, 2006; 
Langmead et al., 2008). AF-DX 116 (M2) and darifenacin (M3) showed the least 
potency in inhibition of purposeless chewing movements. Although, evidence suggests 
that these receptors are found in the striatum, they are not highly expressed in this area 
of the brain (Waelbroeck et al., 1990). AF-DX 116 evoked partial inhibitory effect on 
pilocarpine-induced chewing. These data confirm results from study by Stewart and 
colleagues (1989), where AF-DX 116 showed moderate inhibition of pilocarpine-
induced chewing, for both central and systemic administration of the compound. 
According to their study, a maximum inhibition of chewing was seen at the dose of 30 
mg/kg and above, for systemic administration, and the effect of increasing doses of 
AF-DX 116 was not significant. Due to a poor solubility of the compound, maximal 
dose used in the current study was 30 mg/kg, and it cannot be fully concluded whether 
the maximal inhibition of chewing was seen at that dose.  
Likewise, peripheral injection of darifenacin showed a moderate effect on inhibition 
of pilocarpine-induced purposeless chewing. Darifenacin is an M3 selective 
compound and muscarinic M3 receptors are expressed in low levels in the CNS (Eglen, 
2006; Langmead et al., 2008). As stated in Chapter 1, high doses and high homology 
of different subtypes of muscarinic receptors to each other may lead to the possibility 
that the compound has lost its selectivity or might be acting on other subtypes of 
muscarinic receptors, or even other types of receptors in the brain. In addition, 
although, the fact that darifenacin is a lipophilic compound and is a substrate for P-
glycoprotein, so in theory it should have been carried via the BBB, however, according 
to Skerjanec (2006) darifenacin can penetrate the BBB and to confirm this (Skerjanec, 
2006), results from the PET and audioradiographic studies by Yoshida and colleagues 
(2010) show that darifenacin has a tendency to bind to muscarinic receptors located in 
the CNS, although not as effectively when compared with other centrally acting M3 
receptor antagonist (Yoshida et al., 2010). 
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In contrast to M2 and M3 antagonists, relatively M1 and M4 selective compounds 
showed the highest potency in inhibition of pilocarpine-induced purposeless chewing. 
These findings are not unexpected and are consistent with the observation that both 
subtypes of receptors are the most abundantly expressed in the striatum and play a role 
in motor control (Waelbroeck et al., 1990; Eglen, 2006; Langmead et al., 2008). 
Based on obtained results, systemic administration of centrally acting relatively M1 
selective benztropine and trihexyphenidyl, nearly completely inhibited pilocarpine-
induced purposeless chewing in a dose dependent manner. These findings are in 
accordance with previously published studies, where these compounds showed similar 
pattern of effect on inhibition of chewing (Salamone et al., 1986; Stewart et al., 1988; 
Stewart et al., 1989). In addition, both benztropine and trihexyphenidyl are commonly 
used clinically to aid the treatment of neurologic disorders such as dystonia, PD, 
tremor or drug-induced movement disorders (Pidcock et al., 1999; Jankovic, 2006). 
Moreover, recent results from preclinical investigations suggest that selective 
antagonism of muscarinic M1 receptors could be useful in the treatment of dystonia or 
PD (Xiang et al., 2012; Erosa-Rivero et al., 2014).  
Similarly, to M1 antagonists, M4 relative selective compounds also had an inhibitory 
effect on purposeless chewing. Results show that tropicamide, partially selective M4 
antagonist, was effective and significantly inhibited pilocarpine-induced purposeless 
chewing which was seen in a dose-dependent manner. These data support findings by 
Betz et al., (2007) who also used tropicamide as the only moderately selective M4 
antagonist which readily crosses BBB, and demonstrated antiparkinsonian properties 
of this compound.  Based on results from current and previous study, since tropicamide 
shows only moderate selectivity for M4 receptors, further examination with highly 
selective M4 compounds was essential to elucidate whether these effects are indeed 
due to the M4 receptors. Therefore, the clinical need for a selective M4 antagonist has 
led to the development of the novel highly selective NBI-675.  
As anticipated, NBI-675 showed significant inhibition of pilocarpine-induced 
purposeless chewing in a dose-dependent manner. Nevertheless, its effects were 
similar to the effects of tropicamide, which was unforeseen, considering the fact that 
the novel compound shows 46-fold higher selectivity for M4 receptors than 
tropicamide, when tested in vitro (Chapter 1 Table 1.5 of pKi). A possible reason for 
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this could be caused by differences in PK, drug stability, its effect on the organism, 
BBB penetration or as mentioned earlier, reduction of selectivity with increase of dose 
or other yet unknown parameters that affect drug activity in vivo.   
3.4.2 The effect of centrally administered anticholinergics  
As mentioned earlier, pirenzepine is a hydrophilic compound and does not cross the 
BBB (Carmine & Brogden, 1985), therefore to test its central effects on pilocarpine-
induced purposeless chewing, pirenzepine was administered i.c.v. Pirenzepine nearly 
completely suppressed pilocarpine-induced chewing, which was seen in a dose-
dependent manner and this again shows and supports the findings that purposeless 
chewing is centrally mediated. These results are in accordance with the study by 
Mayorga et al., (1999) where pirenzepine was seen to inhibit chewing in a dose-
dependent fashion.  
Interestingly, other drugs administered via central route do not show such strong 
inhibition. Intracerebroventricular (i.c.v.) administration of trihexyphenidyl only 
partially suppressed purposeless chewing, and this result was unforeseen, as peripheral 
administration of the drug showed strong inhibitory properties. In addition, small 
inhibition of chewing was observed after central injection of darifenacin. This effect 
was not unexpected, since darifenacin is a M3 selective antimuscarinic and according 
to the evidence, high levels of M3 receptors are located in the periphery (Eglen 2006; 
Langmead et al., 2008). Lastly, tropicamide had no inhibitory effect on pilocarpine-
induced chewing after central administration.  
It is highly probable that inability of centrally administered antagonists, except of 
pirenzepine, was caused by limited drug solubility and, thus, the higher doses could 
not be tested.  
Overall, based on the results obtained in this chapter, selective M1 and M4 muscarinic 
antagonists showed the most potent inhibitory properties of pilocarpine-induced 
chewing. As mentioned earlier (Chapter 1, section 1.3.2.2) both M1 and M4 subtypes 
of muscarinic receptors are highly expressed in the striatum, where they play different 
roles including regulation of motor control (M1 and M4). M1 subtypes also have a 
function in memory control and attention and in addition, they are expressed in the 
periphery, mainly in the glands. Thus, since both types of these receptors are present 
in the striatum, which comprises connection of different nuclei involved, among 
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others, in motor planning and execution, there is a possibility that both subtypes might 
be responsible for the motor movement (Graybiel et al., 1994; Ponterio et al., 2012).  
In addition, these findings agree with the studies on muscarinic receptors knock out 
mice, which indicated that absence of M1 and M4 receptors improves locomotor 
activity. Behavioural tests, including elevated plus maze, light/dark transition test, 
open field test in M1 receptor deficient mice (M1R-/-) showed that the M1R-/- were 
more hyperactive than their wild type (WT) littermates (Miyakawa et al., 2001). 
Similarly, deactivation of M4 receptors in mice (M4R-/-) led to increase in basal 
locomotor activity in M4R-/- when compared to the control littermates, as it was shown 
by an interruption of photo-beams in an open field test (Gomeza et al., 1999b). By 
contrast, M2, M3 and M5 receptor knock out mice showed comparable locomotor 
responses when compared with their WT littermates (Gomeza et al., 1999a; Yamada 
et al., 2001a; Yamada et al., 2001b). 
3.5. Conclusion 
In conclusion, this study confirms involvement of central muscarinic receptors in 
production of purposeless chewing in rats. Majority of all centrally acting 
anticholinergics tested, after systemic administration, showed inhibitory effect on 
pilocarpine-induced purposeless chewing. However, it is hard to conclude the exact 
muscarinic receptor subtype involved in mediation of purposeless chewing. 
Muscarinic M1 receptors play a role in pilocarpine-induced purposeless chewing, as 
central administration of pirenzepine nearly completely suppressed chewing. 
Similarly, benztropine and trihexyphenidyl inhibited chewing when administered 
systemically. AF-DX 116 only partially reduced purposeless chewing induced by 
pilocarpine suggesting, limited involvement of M2 receptors. Likewise, there is little 
contribution in mediation of purposeless chewing by M3 receptors, since darifenacin 
has shown little effect on suppression of pilocarpine-induced purposeless chewing. 
Nevertheless, clearly there is a role of M4 receptors in pilocarpine-induced purposeless 
chewing, as both tropicamide and NBI-675 showed highly antagonistic effect on this 
chewing behaviour. This suggests that our hypothesis that centrally mediated motor 
dysfunction (abnormal involuntary movements) is supressed by anticholinergics 
through inhibition of muscarinic M4 receptors can be accepted. 
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Overall, compounds showing the highest potency in inhibition of pilocarpine-induced 
purposeless chewing are selective for M1 and M4 receptor, indicating that selective 
inhibition of these receptors may be of therapeutic benefit in management of locomotor 
activity and coordination. However, involvement of M1 receptors provides huge 
disadvantage for clinical use, since these receptors are located in the periphery, as well 
as the CNS (Eglen 2006; Langmead et al., 2008), thus increasing the risk of side 
effects, which have been well documented as a limiting factor in the treatment of 
movement disorders, in particular, oral dryness (Jankovic, 2006; Cloud & Jinnah, 
2010; Lubarr & Bressman, 2011).  Therefore, the studies in the following chapter will 
focus on investigation of the effect of anticholinergics on pilocarpine-induced saliva 
secretion in rats, in order to determine if selective suppression of muscarinic receptor 
M1 and M4 receptors would provide aid in the treatment of dystonia without inducing 














Chapter 4 The effect of anticholinergics treatment on 




4.1. Introduction  
In the preceding chapter, it was reported that anticholinergics have a differential 
inhibitory effect on pilocarpine-induced purposeless chewing in rats and it was 
concluded that centrally located muscarinic M1 and M4 receptors are largely 
responsible for this effect. From this study, it was suggested that M1 or M4 receptor 
subtypes located in the striatum could be beneficial in the management of dystonia. 
Currently, anticholinergics are effectively used in the treatment of dystonia, but their 
use is limited due to their unpleasant centrally and peripherally mediated side effects, 
in particular the impairment in salivary flow resulting in a dry mouth (Cloud & Jinnah, 
2010; Lubarr & Bressman, 2011). For many patients, oral dryness (xerostomia) is often 
a limiting factor of anticholinergic therapy and in many cases is uncomfortable and 
causes not only difficulties related to ingestion of food and swallowing but also 
prevents speech (Wiseman & Faulds, 1995) and can lead to oral health complications, 
such as dental caries or candidiasis. All these can have a negative impact on quality 
of life (Wiseman & Faulds, 1995; Sreebny & Schwartz, 1997).  
Pilocarpine, as a non-selective muscarinic agonist, not only acts on central muscarinic 
receptors to produce purposeless chewing in rats, as described in Chapter 3, but also, 
by acting on ACh receptors in the salivary glands, stimulates saliva secretion. Indeed, 
for this reason, pilocarpine is commonly used for the treatment of oral dryness in 
patient that suffer from dysfunction of salivary gland (Ferguson, 1993; Wiseman & 
Faulds, 1995; Fox et al., 2001). However, for the purpose of this study, pilocarpine 
can be used to test the properties of antagonists to induce oral dryness, by oral 
introduction of a pre-weighted swab into rats cheek (Flynn et al., 1980). 
Evidence from rat studies show that salivation is mediated mainly by muscarinic M3 
receptors (Baum, 1993; Gautam et al., 2004; Proctor & Carpenter, 2007). However, 
other studies suggest partial involvement of M1 receptors in addition to M3 (Culp et 
al., 1991; Tobin, 1995; Tobin et al., 2002) and some propose that M5 receptors may 
also play a role (Gautam et al., 2004).  
In light of the results presented in the previous chapter, it was suggested that central 
M1 and M4 receptor subtypes play a role in mediation of abnormal involuntary 
movements resulting in dystonia. Importantly, with respect to potential side effects of 
antagonists at these receptors, muscarinic M1 receptors are not only present in the 
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brain, including striatum, but also the periphery, where they regulate exocrine 
secretion, whereas M4 receptors are largely expressed in the CNS, suggesting limited 
propensity to elicit these peripheral effects.  For this reason, it is important to 
investigate the involvement of these receptors in the mediation of peripheral side 
effects and in particular salivation, and this form the basis of current investigation 
(Waelbroeck et al., 1990; Eglen, 2006; Langmead et al., 2008). 
4.1.1. Hypothesis 
It is hypothesised that selective antagonism of muscarinic M4 receptors which reduce 
dystonia will not induce unfavourable oral dryness.  
4.1.2. Aims 
Specific aims of this study were to: 
1) Use pilocarpine to induce salivation in rats and to compare the ability of non-
selective and subtype selective anticholinergics to inhibit pilocarpine-induced 
salivation.   
2) Confirm that peripheral muscarinic receptors are responsible for pilocarpine-
induced saliva secretion.  
3) Confirm the muscarinic receptor subtype responsible for mediation of 
salivation.  
4) Determine the role of M4 receptors on pilocarpine-induced salivation using a 






4.2 Materials and Methods 
In order to address these aims the following studies were performed: 
1) The role of peripheral muscarinic receptors in mediation of pilocarpine-induced 
saliva secretion was confirmed by treating rats with peripherally and centrally 
acting anticholinergics 30 min prior to pilocarpine. Saliva secretion was measured 
for up to 120 min.  
2) In order to confirm subtype of muscarinic receptor involved in mediation of 
pilocarpine-induced salivation, rats were treated with relatively selective 
anticholinergics 30 min prior pilocarpine and the saliva secretion was measured for 
up to 120 min.  
3) The role of the M4 muscarinic receptor in pilocarpine-induced salivation was 
determined using the novel selective M4 antagonist NBI-675. NBI-675 was 
administered 60 min prior to pilocarpine, and saliva secretion was measured as 
described below.   
Detailed methodology is described below. 
4.2.1 Animal husbandry 
Male Wistar rats (160 – 300 g, Harlan, UK) were housed in groups of 4 – 5 per cage 
at a temperature of 22 ± 2ºC and humidity controlled housing unit on a 12 hours light 
– dark cycle. Water and food were available ad libitum except during the surgery and 
experiments. All experiments were performed in accordance with the UK Animals 
(Scientific Procedures) Act 1986 under UK Home Office Project licence number 
70/6898 and 70/7977, approved by the King’s College London Ethical Review Panel. 
4.2.2 Assessment of saliva secretion 
As described in Chapter 2, section 2.2.2, systemic administration of pilocarpine 
stimulates saliva secretion. This can be suppressed by the administration of 
anticholinergics.  
Animals were placed in a Perspex observation boxes (21 x 35 x 17 cm) and pilocarpine 
(3.4 mg/kg i.p.) was administered 30 min after anticholinergics (i.p. or i.c.v.) 
administration. Measurement of salivation was conducted 10 min before 
administration of anticholinergics (time 0, baseline), 10 min before and 20, 60, 90 and 
120 min after pilocarpine administration. 
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Measurement of salivation was conducted by inserting a pre-weighted cotton tipped 
swab into the rat’s cheek for 10 s and reweighing it. The saliva weight was calculated 
by subtracting the initial from final weight of the swab. Detailed methodology is 
described in Chapter 2 section 2.2.2.1.  
4.2.3 Drug treatment 
4.2.3.1 Peripheral administration of anticholinergics 
Trihexyphenidyl hydrochloride (0.001 – 5 mg/kg), benztropine mesylate (0.001 – 5 
mg/kg), darifenacin hydrobromide (0.001 – 24 mg/kg), tropicamide (0.001 – 20 
mg/kg), AF-DX 116 (0.1 – 30 mg/kg), scopolamine hydrobromide (0.01 – 1 mg/kg), 
methylscopolamine (0.01 – 1 mg/kg) and NBI-675 (0.1 – 30 mg/kg) were administered 
i.p. 30 min prior pilocarpine (3.4 mg/kg i.p.).  Additionally, NBI-675 (0.1 – 30 mg/kg) 
was administered 1 hr prior pilocarpine by oral gavage (p.o.). Doses of the drugs were 
chosen according to the ID50 doses for inhibition of pilocarpine-induced purposeless 
chewing described in the previous chapter of this thesis, based on previously published 
studies (Stewart et al., 1989; Mayorga et al., 1999; Betz et al., 2007) and according to 
data from the PK and PD studies (NBI-675) received from Neurocrine Biosciences 
Inc. 
Trihexyphenidyl was dissolved in deionised water, darifenacin and AF-DX 116 were 
dissolved in a sterile dimethyl sulphoxide (DMSO) and diluted in 0.9% saline (for 
darifenacin 5:1 saline to DMSO, and for AF-DX 116 3:1 saline to DMSO) and 
tropicamide was dissolved in a minimal amount of ethanol (200 µl) and diluted in 0.9% 
saline. NBI-675 was dissolved in 5% Tween80 and 0.5% methylcellulose made up in 
deionised water, vortexed and sonicated for 1 hr. The pH was adjusted to 4 – 6 with 
1M NaOH. All other drugs were dissolved in 0.9% saline and administered 
intraperitoneally at a dose volume of 1 ml/kg, except the highest dose of AF-DX 116 
(30 mg/kg) which, due to the problems with solubility, was administered at a dose 
volume of 2 ml/kg.  
Rats were placed in observation boxes and measurement of salivation was conducted 
as described in section 2.2.2.1. Drug treatments were administered following a 
crossover design, so each rat was treated with all doses of a single drug or vehicle with 
at least 48 hr between the tests. A typical modified latin square was used to randomise 
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drug treatments, and is shown in Table 3.1 Section 3.2.3.1. Individual anticholinergics 
were tested in separate groups of animals.  
4.2.3.2 Central administration of anticholinergics 
4.2.3.2.1 Stereotaxic guide cannula implantation into the lateral ventricle 
A stainless steel guide cannula (23 G) was implanted into the lateral ventricle (AP: -
0.8 mm; ML: -1.4 mm; DV: -2.8 mm) using standard stereotaxic techniques as 
described in Chapter 3, Section 3.2.3.2.1. 
The post-operative weight was monitored daily and a mash diet (softened food pellets) 
provided until animals regained their pre-operative weight, as shown in Figure 3.3, 
Section 3.2.3.2.1. Animals were allowed 6 days to recover prior behavioural testing. 
4.2.3.2.2 Intracerebroventricular drug administration 
Pirenzepine dihydrochloride (2.4 – 377 nmol/µl i.c.v., equivalent of 1 – 160 µg/µl) 
was dissolved in 0.9% saline and, due to limited solubility, administered in a dose 
volume of 2 µl and 3 µl (the highest dose) at a rate 1 µl/min. Darifenacin hydrobromide 
(0.2 – 98.5 nmol/µl, equivalent of 0.1 – 50 µg/µl) was dissolved in a sterile DMSO 
and diluted with 0.9% saline (4:1 saline to DMSO) and administered i.c.v. at a dose 
volume of 2 µl at a rate 1 µl/min. Trihexyphenidyl (3 – 59 nmol, equivalent of 1 – 20 
µg/µl) was dissolved in a deionised water and administered i.c.v. at a dose volume of 
1 µl (3 nmol), 2 µl (29.5 nmol) and 4 µl (59 nmol), due to the poor solubility, at a rate 
1 µl/min. Tropicamide (3.5 – 422 nmol/ µl, equivalent of 1 – 120 µg/µl) was dissolved 
in a minimal amount of ethanol (20 µl) and diluted in 0.9% saline and administered 
i.c.v. at a dose volume of 2 µl at a rate 1 µl/min. 
Drug or vehicle was administered into the lateral ventricle via previously implanted 
guide cannula (described in Section 3.2.3.2.1) 30 min before pilocarpine. 
Microinjection was made via stainless steel injection needle set to extend 1 mm beyond 
the tip of the guide cannula implanted previously into right lateral ventricle. Detailed 
methodology is described in Chapter 3, section 3.2.3.2.1. Rats were placed in boxes 
and measurement of salivation was conducted as described in section 2.2.4.1. Drug 
treatments were administered on a crossover design, so each rat was treated with all 
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doses of a single drug or vehicle at least 48 hr between the tests (Table 3.1 Section 
3.2.3.1). Drugs were tested individually in separate studies.   
4.2.4 Statistical analysis  
Data and statistical analysis were performed using GraphPad Prism 5.02 (San Diego, 
CA, USA). Area under curve (AUC) for the time course was calculated by trapezoid 
method. Data are expressed as mean ± SEM and analysed by sigmoidal nonlinear 
regression analysis 3-parameter fit. ID50 value was derived from the curve fit. The 
basal salivation levels within 20 min of antagonist administration and the differences 
between treatment and vehicle control (mean for both vehicle treatment before 
pilocarpine administration) for AUC negative peaks data was analysed by One-way 
ANOVA followed by a post hoc Dunnett’s Multiple Comparison test. Differences 
between treatment and vehicle control for AUC data was analysed by One-way 








The IC50 dose of pilocarpine, 3.4 mg/kg i.p., was chosen according to previous studies 
(Chapter 2 section 2.2.1.4) to induce saliva secretion in rats. As expected, this dose of 
pilocarpine stimulated salivary secretion, which was visible within few minutes, with 
a peak about 20 min of administration (Figs. 4.1 – 4.13). Administration of vehicle did 
not have effect on saliva secretion (Figs. 4.1 – 4.13).    
In order to confirm muscarinic receptor subtype responsible for mediation of saliva 
secretion, the effect of non-selective and subtype selective anticholinergics was 
investigated on pilocarpine-induced saliva secretion.  
4.3.1 The effect of non-selective anticholinergics on pilocarpine-induced 
salivation  
Scopolamine (0.01 – 1 mg/kg), a centrally and peripherally acting non-selective 
anticholinergic, produced a small, dose-related, reduction in basal salivation, which 
was significant at 20 min following 0.1 and 1 mg/kg when compared to vehicle-treated 
animals (Fig. 4.1 C).  
Following administration of pilocarpine, the lowest dose of scopolamine (0.1 mg/kg) 
had no effect on suppression of pilocarpine-induced salivation, while the highest dose 
(1 mg/kg) produced about 71% inhibition of pilocarpine-induced saliva secretion, 
which was significantly different when compared to vehicle-treated animals (Fig. 4.1 










Figure 4.1 Effect of scopolamine (i.p.) on pilocarpine-induced saliva secretion. 
 A) Time course. Data are mean ± SEM (n = 7). B) Log-dose response for scopolamine (0.01 
– 1 mg/kg i.p.)  on suppression of pilocarpine-induced (3.4 mg/kg i.p.) saliva secretion (AUC 
time course). Data were analysed by a non-linear curve fit; the bottom was constrained to the 
mean of vehicle alone values (black line).  Estimated ID50 = 0.25 mg/kg; (95% CI = 0.05 – 1.2 
mg/kg; r2 = 0.35, NS); *p<0.05 compared to vehicle-treated animals (One way ANOVA 
(p<0.01; F = 6.002; Df = 3, 24) followed by Dunnett’s Multiple Comparison test). C) Effect 
of scopolamine on saliva within the first 20 min (AUC negative peaks time course). *p<0.05; 




Administration of methylscopolamine (0.01 – 1 mg/kg), the peripherally acting non-
selective muscarinic antagonist, also reduced basal salivation within the first 20 min, 
which was significantly different when compared to vehicle-treated animals at the 
highest dose (Fig. 4.2 C).  
Methylscopolamine produced a dose-related reduction of pilocarpine-induced 
salivation, with a significant effect at the two highest doses (0.1 and 1 mg/kg) when 
compared to vehicle-treated animals (Fig. 4.2 A & B). Indeed, the highest dose tested 
(1 mg/kg) resulted in a complete inhibition of pilocarpine-induced saliva secretion, 
Scopolamine
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and in fact tended to reduce salivation to below baseline values (Fig 4.2 B). The ID50 
for methylscopolamine was 0.024 mg/kg (95% CI = 0.004 – 0.5 mg/kg). 
 
 
Figure 4.2 Effect of methylscopolamine (i.p.) on pilocarpine-induced saliva secretion.  
A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for methylscopolamine 
(0.01 – 1 mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) saliva secretion 
(AUC time course). Data were analysed by a non-linear curve fit; the bottom was constrained 
to the mean of vehicle alone values (black line). ID50 = 0.02 mg/kg; (95% CI = 0.004 – 0.5 
mg/kg; r2 = 0.55 *p<0.05; ***p<0.001 compared to vehicle-treated animals (One way 
ANOVA (p<0.001; F = 12.89; Df = 3, 28) followed by Dunnett’s Multiple Comparison test). 
C) Effect of methylscopolamine on saliva within the first 20 min (AUC negative peaks time 
course). **p<0.01 (One way ANOVA (p<0.01; F =4.784; Df = 3, 28) followed by Dunnett’s 
Multiple Comparison test).  
 
4.3.2 The effect of subtype selective anticholinergics  
4.3.2.1 Muscarinic M1 selective anticholinergics  
Treatment with the M1 selective antagonist, trihexyphenidyl (0.001 – 5 mg/kg i.p.), 
had no effect on basal salivation during the first 20 minutes of administration (Fig. 4.3 
C).  
Methylscopolamine










































































































































Following administration of pilocarpine, trihexyphenidyl produced a small, non-dose-
related reduction of pilocarpine-induced salivation (Fig. 4.3 A & B). The effect was 
significantly reduced at the doses of 0.01, 1.5 and 5 mg/kg when compared to vehicle-
treated animals (Fig. 4.3 B).  The highest dose tested showed about 46 % of inhibition. 
As the effect was not dose-related (r2 = 0.06; NS), the ID50 could not be determined.  
Central administration of trihexyphenidyl (3 – 59 nmol i.c.v., equivalent to 1, 10 and 
20 µg) into the lateral ventricle had no effect on basal salivation within the 20 min of 
administration (Fig. 4.4 C), and no effect on pilocarpine-induced salivation (Fig. 4.4 
A & B). Due to the lack of significant inhibition, the ID50 could not be obtained.  
 
Figure 4.3 Effect of trihexyphenidyl (i.p.) on pilocarpine-induced saliva secretion.  
A) Time course. Data are mean ± SEM (n = 7). B) Log-dose response for trihexyphenidyl 
(0.001 – 5 mg/kg i.p) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) saliva secretion 
(AUC time course). Data were analysed by a non-linear curve fit; the bottom was constrained 
to the mean of vehicle alone values (black line). ID50 > 5 mg/kg; (r2 = 0.06 NS); *p<0.05; 
**p<0.01 compared to vehicle-treated animals (One way ANOVA (p<0.01; F = 3.501; Df = 
6, 42) followed by Dunnett’s Multiple Comparison test). C) Effect of trihexyphenidyl on saliva 
within the first 20 min (AUC negative peaks time course). NS (One way ANOVA (p=0.0859; 
F = 2.008; Df = 6, 42)). 
Trihexyphenidyl












































































































































Figure 4.4 Effect of trihexyphenidyl (i.c.v.) on pilocarpine-induced saliva secretion. 
 A) Time course. Data are mean ± SEM (n = 7). B) Log-dose response for trihexyphenidyl (3 
– 59 nmol i.c.v., equivalent to 1 – 20 µg) on suppression of pilocarpine-induced (3.4 mg/kg 
i.p.) saliva secretion (AUC time course). Data were analysed by a non-linear curve fit; the 
bottom was constrained to the mean of vehicle alone values (black line). ID50 > 59 nmol; (r2 = 
0.26; NS); NS compared to vehicle-treated animals (One way ANOVA (p=0.0671; F = 2.716; 
Df = 3, 24). C) Effect of trihexyphenidyl on saliva within the first 20 min (AUC negative peaks 
time course). NS (One way ANOVA (p=0.1330; F = 2.055; Df = 3, 24)). 
 
 
The M1 antagonist benztropine (0.001 – 5 mg/kg i.p.), had no effect on basal salivation 
levels within 20 min of administration (Fig. 4.5 C).  
Following pilocarpine administration, benztropine had little or no effect on inhibition 
of pilocarpine-induced saliva secretion at lower doses. The highest dose (5 mg/kg) 
tended to reduce pilocarpine-induced salivation, however, this was not significant 
when compared to vehicle-treated animals (Fig. 4.5 B). The ID50 was greater than 5 
mg/kg, the highest dose administered.   
Trihexyphenidyl i.c.v.







































































































































Figure 4.5 Effect of benztropine (i.p.) on pilocarpine-induced saliva secretion.  
A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for benztropine (0.001 
– 5 mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) saliva secretion (AUC 
time course). Data were analysed by a non-linear curve fit. ID50 > 5 mg/kg; the bottom was 
constrained to the mean of vehicle alone values (black line). NS compared to vehicle-treated 
animals (One way ANOVA (p=0.1002; F = 2.111; Df = 4, 35)). C) Effect of benztropine on 
saliva within the first 20 min (AUC negative peaks time course). NS (One way ANOVA 
(p=0.1354; F = 1.883; Df = 4, 35)). 
 
 
Systemic administration of pirenzepine, the selective M1 antagonist, reduced basal 
salivation levels within 20 min of administration at all doses tested (0.1 – 50 mg/kg 
i.p.), with significant effect at 30 and 50 mg/kg when compared to vehicle-treated 
animals (Fig. 4.6 C).  
Pirenzepine dose-dependently reduced secretion of saliva induced by pilocarpine with 
significant effect at the doses 30 and 50 mg/kg when compared to vehicle-treated 
animals (Fig. 4.6 A & B). The two highest doses resulted in a complete suppression of 
salivation with the values reaching basal levels (Fig. 4.6 B). The ID50 for pirenzepine 
was 4.9 mg/kg (95% CI = 1.6 – 14.98 mg/kg). 
Central administration pirenzepine (2.4 – 377 nmol i.c.v., equivalent to 1 – 160 µg) 
produced a dose-related reduction of basal salivation levels with significant effect at 
Benztropine









































































































































189 and 377 nmol during the first 20 min when compared to vehicle-treated animals 
(Fig. 4.7 C). 
Intracerebroventricular administration of pirenzepine did not reduce pilocarpine-
induced salivation however, the higher doses (47 – 377 nmol) resulted in increased 
secretion of saliva, which was significantly different for the two high doses (189 and 
377 nmol) when compared to vehicle-treated animals (Fig. 4.7 A & B). The ID50 could 
not be determined.  
 
  
Figure 4.6 Effect of pirenzepine (i.p.) on pilocarpine-induced saliva secretion.  
A) Time course. Data are mean ± SEM (n = 7). B) Log-dose response for pirenzepine (0.1 – 
50 mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) saliva secretion (AUC 
time course). Data were analysed by a non-linear curve fit; the bottom was constrained to the 
mean of vehicle alone values (black line).  ID50 = 4.9 mg/kg ± 1.74 mg/kg; (95 % CI = 1.6 – 
14.98; r2 = 0.57; *p<0.05) ***p<0.001 compared to vehicle-treated animals (One way 
ANOVA (p<0.001; F = 11.45; Df = 5, 36) followed by Dunnett’s Multiple Comparison test). 
C) Effect of pirenzepine on saliva within the first 20 min (AUC negative peaks time course). 
*p<0.05; *** p<0.001 (One way ANOVA (p<0.001; F = 5.565; Df = 5, 36) followed by 
Dunnett’s Multiple Comparison test). 
Pirenzepine














































































































































Figure 4.7 Effect of pirenzepine (i.c.v.) on pilocarpine-induced saliva secretion. 
 A) Time course. Data are mean ± SEM (n = 7). B) Log-dose response for pirenzepine (2.4 – 
377 nmol i.c.v., equivalent to 1 – 160 µg) on suppression of pilocarpine-induced (3.4 mg/kg 
i.p.) saliva secretion (AUC time course). Data were analysed by a non-linear curve fit, not 
converged); **p<0.01; ***p<0.001 compared to vehicle-treated animals (One way ANOVA 
(p<0.001; F = 11.70; Df = 4, 30) followed by Dunnett’s Multiple Comparison test). C) Effect 
of pirenzepine on saliva within the first 20 min (AUC negative peaks time course). *p<0.05; 
***p<0.001 (One way ANOVA (p<0.01; F = 6.090; Df = 4, 30) followed by Dunnett’s 
Multiple Comparison test). 
 
 
4.3.2.2 Muscarinic M2 selective anticholinergics  
The M2 antagonist AF-DX 116 (0.1 – 30 mg/kg i.p.) had no effect on basal salivation 
levels (Fig. 5.8 C) and no significant effect on pilocarpine-induced salivation (Fig. 5.8 










































































































































Figure 4.8 Effect of AF-DX 116 (i.p.) on pilocarpine-induced saliva secretion.  
A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for AF-DX 116 (1 – 30 
mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) saliva secretion (AUC time 
course). Data were analysed by a non-linear curve fit; the bottom was constrained to the mean 
of vehicle alone values (black line). ID50 > 30 mg/kg; (r2 = 0.08 NS); NS compared to vehicle-
treated animals (One way ANOVA (p=0.2496; F = 1.414; Df = 4, 35)). C) Effect of AF-DX 
116 on saliva within the first 20 min (AUC negative peaks time course). NS (One way 




4.3.2.3 Muscarinic M3 selective anticholinergics  
Administration of darifenacin (0.001 – 24 mg/kg i.p.), M3 selective antagonist, tended 
to show a dose-related inhibition of basal salivation, although the effect was not 
significant during the first 20 min when compared to vehicle-treated animals.  
Darifenacin dose-dependently inhibited pilocarpine-induced saliva secretion (Fig.4.9 
A) with significant effect at doses 0.1 – 24 mg/kg when compared to vehicle-treated 
animals (Fig. 4.9 B). The highest tested dose resulted in 96% of suppression of 
pilocarpine-induced salivation. The ID50 for darifenacin was 0.4 mg/kg (95% CI = 0.2 
– 0.9 mg/kg).  
AF-DX 116






































































































































Central administration of darifenacin (0.2 – 98.5 nmol i.c.v., equivalent to 0.1 – 50 µg) 
into the lateral ventricle tended to reduce basal salivation levels within 20 min of 
administration, although this effect was not dose related or statistically significant. 
  
Darifenacin had no significant effect on pilocarpine-induced saliva secretion (Fig. 4.10 
A). Due to the lack of effect the ID50 could not be determined.  
 
 
Figure 4.9 Effect of darifenacin (i.p.) on pilocarpine-induced saliva secretion. 
 A) Time course. Data are mean ± SEM (n = 8); data were normalised to the baseline to 
calculate AUC. B) Log-dose response for darifenacin (0.001 – 24 mg/kg i.p.) on suppression 
of pilocarpine-induced (3.4 mg/kg i.p.) saliva secretion (AUC time course). Data were 
analysed by a non-linear curve fit; the bottom was constrained to the mean of vehicle alone 
values (black line). ID50 = 0.4 ± 1.5 mg/kg; (95% CI = 0.2 – 0.9 mg/kg; r2 = 0.72, p<0.05); 
**p<0.01; ***p<0.001 compared to vehicle-treated animals (One way ANOVA (p<0.001; F 
= 25.15; Df = 8, 63) followed by Dunnett’s Multiple Comparison test). C) Effect of darifenacin 
on saliva within the first 20 min (AUC negative peaks time course). NS (One way ANOVA 
(p<0.01; F = 3.240; Df = 8, 63) followed by Dunnett’s Multiple Comparison test). 
Darifenacin













































































































































Figure 4.10 Effect of darifenacin (i.c.v.) on pilocarpine-induced saliva secretion. 
  A) Time course. Data are mean ± SEM (n = 7). B) Log-dose response for darifenacin (0.2 – 
98.5 nmol i.c.v., equivalent to 0.1 – 50 µg) on suppression of pilocarpine-induced (3.4 mg/kg 
i.p.) saliva secretion (AUC time course). Data were analysed by a non-linear curve fit; the 
bottom was constrained to the mean of vehicle alone values (black line). ID50 > 98.5 nmol; NS 
compared to vehicle-treated animals (One way ANOVA (p=0.3546; F = 1.145; Df = 4, 30)). 
C) Effect of darifenacin on saliva within the first 20 min (AUC negative peaks time course). 
NS (One way ANOVA (p=0.0771; F = 2.346; Df = 4, 30)). 
 
 
4.3.2.4 Muscarinic M4 selective anticholinergics  
The putative, relatively selective M4 antagonist, tropicamide (0.001 – 20 mg/kg) alone 
showed significant effect on suppression of basal salivation at doses 0.01 and 0.6 – 20 
mg/kg within 20 min of administration when compared to vehicle-treated animals (Fig. 
4.11 C).  
In combination with pilocarpine, tropicamide showed a small and significant inhibition 
of pilocarpine-induced saliva secretion in rats when compared to vehicle-treated 
animals (Fig. 4.11 A & B).  The ID50 was 13.6 mg/kg (95 % CI = 8.2 – 22.7 mg/kg). 
Darifenacin i.c.v.










































































































































Central administration of tropicamide (3.5 – 211 nmol i.c.v., equivalent to 1 and 60 
µg) into the lateral ventricle had no effect on basal reduction of salivation (Fig. 4.12 
C).  
Tropicamide had no significant effect on pilocarpine-induced saliva secretion (Fig. 
4.12 A and B). The ID50 could not be determined.   
 
 
Figure 4.11 Effect of tropicamide (i.p.) on pilocarpine-induced saliva secretion.  
A) Time course. Data are mean ± SEM (n = 7). B) Log-dose response for tropicamide (0.001 
– 20 mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) saliva secretion (AUC 
time course). Data were analysed by a non-linear curve fit; the bottom was constrained to the 
mean of vehicle alone values (black line). ID50 = 13.6 mg/kg ± 1.3 mg/kg; (95 % CI = 8.2 – 
22.7 mg/kg; r2 = 0.37, p<0.05); *p<0.05; **p<0.01; ***p<0.001 compared to vehicle-treated 
animals (One way ANOVA (p<0.001; F = 6.744; Df = 9, 60) followed by Dunnett’s Multiple 
Comparison test). C) Effect of tropicamide on saliva within the first 20 min (AUC negative 
peaks time course).  *p<0.05; **p<0.01; ***p<0.001 (One way ANOVA (p<0.001; F = 14.55; 
Df = 9, 60) followed by Dunnett’s Multiple Comparison test). 
Tropicamide




















































































































































Figure 4.12 Effect of tropicamide (i.c.v.) on pilocarpine-induced saliva secretion.  
A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for tropicamide (3.5 – 
211 nmol i.c.v., equivalent to 1 & 60 µg) on suppression of pilocarpine-induced (3.4 mg/kg 
i.p.) saliva secretion (AUC time course). Data were analysed by a non-linear curve fit; the 
bottom was constrained to the mean of vehicle alone values (black line). ID50 > 211 nmol; (r2 
= 0.07, NS); NS compared to vehicle-treated animals (One way ANOVA (p=0.1418; F = 
2.147; Df = 2, 21). C) Effect of tropicamide on saliva within the first 20 min (AUC negative 
peaks time course).  NS (One way ANOVA (p=0.1414; F = 2.151; Df = 2, 21)). 
 
 
The novel M4 selective antagonist NBI-675 (0.1 – 30 mg/kg i.p.) showed no effect on 
basal salivation within 50 min when administered alone (Fig. 4.13 C).  
NBI-675 did not alter pilocarpine-induced saliva secretion at lower doses, however, 
unexpectedly at the highest dose increased pilocarpine-induced salivation was 
observed, which was significantly different when compared to vehicle-treated animals 
(Fig. 4.13 A & B).  
 
Tropicamide i.c.v.







































































































































Figure 4.13 Effect of NBI-675 (i.p.) on pilocarpine-induced saliva secretion.  
A) Time course. Data are mean ± SEM (n = 8). B) Log-dose response for NBI-675 (0.1 – 30 
mg/kg i.p.) on suppression of pilocarpine-induced (3.4 mg/kg i.p.) saliva secretion (AUC time 
course). Data were analysed by a non-linear curve fit; the bottom was constrained to the mean 
of vehicle alone values (black line). ID50 > 30 mg/kg; (data not converged) **p<0.01; 
compared to vehicle-treated animals (One way ANOVA (p<0.01; F = 3.583; Df = 5, 42) 
followed by Dunnett’s Multiple Comparison test). C) Effect of NBI-675 on saliva within the 
first 50 min (AUC negative peaks time course).  NS (One way ANOVA (p=0.2663; F = 1.340; 





































































































































Table 4.1 Summary of the inhibitory effect of anticholinergics on pilocarpine-induced 
saliva secretion.  





Scopolamine i.p. Non-selective +++ 
Methylscopolamine i.p. Non-selective +++ 
Trihexyphenidyl i.p. M1 + 
Trihexyphenidyl i.c.v. M1 ++ 
Benztropine i.p. M1 ++ 
Pirenzepine i.p. M1 +++ 
Pirenzepine i.c.v. M1 - 
AF-DX 116 i.p. M2 + 
Darifenacin i.p. M3 +++ 
Darifenacin i.c.v. M3 + 
Tropicamide i.p. M4 + 
Tropicamide i.c.v. M4 + 
NBI-675 i.p. M4 - 
 
4.3.3 Other effects of anticholinergics treatment  
As described previously in Section 3.3.3, administration of anticholinergics not only 
suppressed pilocarpine-induced salivation, but also reduced other peripheral and 
central effects of pilocarpine, including diarrhoea, urination, piloerection and 
purposeless chewing (Table 3.3), which were observed but not analysed quantitatively.    
Additionally, higher doses of centrally acting anticholinergics, particularly 
pirenzepine and NBI-675, produced CNS effects which were observed in animals and 
were manifested by reduced activity and movement, recumbency, and overall 




4.4. Discussion  
Oral dryness (xerostomia) is a very common and unpleasant side effect of the 
anticholinergics treatment, reported in patients suffering from PD and dystonia, and is 
triggered by suppression of muscarinic receptors localised on salivary glands (Scully, 
2003; Gautam et al., 2004; Ekström et al., 2012). Saliva secretion is regulated by both 
the sympathetic and parasympathetic branches of the autonomic nervous system. 
Adrenergic receptors of the sympathetic branches of the nervous system are 
responsible for content of proteins in saliva, whereas, muscarinic receptors of the 
parasympathetic nervous system responsible for volume of saliva secretion (Grisius, 
2001). 
In light of the results from previous study (Chapter 3) and current knowledge about 
side effect of anticholinergic treatment, it was hypothesised that muscarinic M4 
receptor antagonists will reduce dystonia without induction of unfavourable side 
effects, such as dry mouth. The present study set out to investigate and compare the 
effect of anticholinergics with different selectivity for muscarinic receptor, with a 
special emphasis on the novel M4 selective muscarinic antagonists, NBI-675, on 
pilocarpine-induced saliva secretion in rats as an index of propensity to induce dry 
mouth.  
Pilocarpine has been used in several preclinical and clinical studies in the assessment 
of salivary dysfunction and to confirm the involvement of muscarinic receptor subtype 
in mediation of saliva secretion (Ferguson, 1993; Wiseman & Faulds, 1995; Fox et al., 
2001; Sato et al., 2006). As shown in the current and previous studies peripheral 
administration of pilocarpine produced excessive saliva secretion, which was visible 
within few minutes of administration (Chapter 2) (Gautam et al., 2004; Sato et al., 
2006). Pre-treatment with antagonists and their effect on pilocarpine-induced 
salivation produced differential results and will be discussed below.  
4.4.1 Which muscarinic receptor subtypes are responsible for salivation?   
One of the aims of the study was to confirm muscarinic receptor subtype responsible 
for mediation of salivation and to understand the role of M4 component in this effect.  
Assessment of various anticholinergics on pilocarpine-induced saliva secretion 
confirms involvement of M3 receptors in mediation of salivation, since systemically 
administered darifenacin, a highly selective M3 antagonist, strongly abolished 
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salivation induced by pilocarpine. Previous studies have demonstrated that salivation 
is mediated by muscarinic M3 receptors located in salivary glands, thus these results 
are in agreement with earlier published research (Baum, 1993; Nakamura et al., 2004; 
Langmead et al., 2008). In addition, as the same doses of the compound evoked strong 
inhibition of salivation along with the moderate suppression of purposeless chewing, 
as described in previous chapter, this could suggest that M3 receptors are not ideal 
target for the treatment of dystonia. Interestingly, the selective M1 antagonist, 
pirenzepine, completely suppressed pilocarpine-induced saliva secretion when 
administered systemically. These results concur with the previous proposition that 
activation of both subtypes of receptors contribute to the production of saliva, as M1 
receptor subtypes are also present in glands and are thought to be co-localised with M3 
receptors (Culp et al., 1991; Tobin, 1995; Tobin et al., 2002; Eglen, 2006; Proctor & 
Carpenter, 2007). In addition, since pirenzepine does not cross the BBB, systemic 
administration of the drug resulted in blockade of the peripheral effects of pilocarpine, 
such as defecation, urination, piloerection and lachrymation. However, whilst 
peripheral administration of pirenzepine almost completely abolished pilocarpine-
induced salivation, the relatively M1 selective antagonists, trihexyphenidyl and 
benztropine, produced more variable effect. This differential effect on salivation may 
be the consequence of antagonist selectivity for the different muscarinic receptors.  
Pirenzepine is considered to be highly selective for the M1 receptor, whereas both 
trihexyphenidyl and benztropine, although considered to be M1 selective, in fact bind 
with moderate to high affinity to all muscarinic receptors. Although both 
trihexyphenidyl and benztropine are used clinically in the treatment of dystonia and 
PD (Adam & Jankovic, 2007; Cloud & Jinnah, 2010) dry mouth may be a problem in 
some patients, even though the lack of dose-relationship suggests that this might be 
unpredictable.  
The results obtained for AF-DX 116 indicate that M2 receptors are less likely to be 
involved in salivation, as the compound had no effect on reduction of salivation on its 
own or in combination with pilocarpine.   
On the other hand, tropicamide, a relatively selective M4 antagonist, reduced saliva 
levels within 20 minutes of administration and produced a small suppression of saliva 
secretion induced by pilocarpine.  By contrast, the highly selective M4 antagonist, 
NBI-675 showed no effect on inhibition of salivation on its own, and did not abolish 
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pilocarpine-induced salivation. However, very surprisingly and unexpectedly, the 
highest dose manifested in a notable and significant increase in salivation.  The reason 
for this effect is unclear, but it could be related to the loss of the compound selectivity 
at the highest dose. However, since the lower doses suppressed pilocarpine-induces 
chewing (Chapter 3) but had no effect of salivation, these finding also suggest a 
beneficial effect of targeting M4 receptors in the prevention of dystonia without 
producing dry mouth, although the use of a more selective compound may be required.  
 
It is important to note that studies on muscarinic M1/M3 double-KO mice showed that 
pilocarpine was unable to stimulate saliva secretion when compared to their WT 
controls, whereas the levels of salivary flow was similar in other muscarinic subtypes 
KO mice (M1/M4, M2/M3, M2/M4) when compared to their WT controls.  This 
clearly demonstrates a role for M1 and M3 receptors in mediation of salivation 
(Gautam et al., 2004).   
This was confirmed by Borella et al., (2008) who showed that central administration 
of M1 (pirenzepine), M2/M4 (methoctramine) and M4 (tropicamide) selective 
anticholinergics, had no effect on suppression of pilocarpine-induced salivation 
(Borella et al., 2008).  
Consequently, the results of the current study agree with previously published data 
(Gautam et al., 2004; Borella et al., 2008) and indicate that activation of muscarinic 
M1 and M3 receptors stimulate salivary flow, but that M2 have no effect and M4 could 
have little contribution to the saliva secretion. 
4.4.2 Is pilocarpine-induced salivation mediated via central or peripheral 
muscarinic receptor?  
Both scopolamine and its peripherally acting derivative, methylscopolamine, 
significantly reduced basal salivation levels. In addition, salivation in response to 
pilocarpine stimulation was completely and dose-dependently inhibited by both of the 
compounds. Although, they are classed as non-subtype specific, their in vitro pKi 
(selectivity) values are comparable to all muscarinic subtypes, and they show very 
similar values for both M1 and M3 receptors (Lazareno et al., 1990; Caulfield & 
Birdsall, 1998) (Chapter 1, Table 1.5). A similar strong inhibitory effect of 
scopolamine was seen on purposeless chewing induced by pilocarpine, indicating both 
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central and peripheral properties of scopolamine, while peripheral administration of 
methylscopolamine lacked this central effect, as was unable to suppress pilocarpine-
induced purposeless chewing (Chapter 3).  
In contrast to the antagonistic effect of peripherally applied anticholinergics, none of 
the centrally administered compounds tested were able to inhibit salivation stimulated 
by pilocarpine. Neither i.c.v. administration of the M3 selective antagonist, 
darifenacin, nor the relatively selective M1 antagonist, trihexyphenidyl, were able to 
antagonise pilocarpine-induced salivation, confirming that the muscarinic control of 
salivation is peripherally mediated (Culp et al., 1991; Gautam et al., 2004). Likewise, 
i.c.v. administration of tropicamide and pirenzepine showed no effect on pilocarpine-
induced salivation, confirming the lack of involvement of central M1 receptor in this 
response. Importantly, these results agree with previous work, which has demonstrated 
no inhibitory effect of central administration of pirenzepine and tropicamide on 
pilocarpine-induced salivation (Borella et al., 2008). Although, i.c.v. tropicamide 
showed no effect on pilocarpine-induced salivation and purposeless chewing, this 
could be related to the poor solubility of the compound, which did not allow further 
testing. However, similar doses of pirenzepine dose-relatively supressed pilocarpine-
induced purposeless chewing with a complete inhibition at the highest dose. Thus, the 
likely conclusion is that both tropicamide and pirenzepine were tested at active doses 
and that neither were able to inhibit saliva secretion.  
Despite the fact that the lowest doses of pirenzepine did not alter the increased saliva 
levels induced by pilocarpine, higher doses of the drug produced marked and 
significant increase in salivation. Unexpectedly, this effect was also seen after 
systemic administration of the highest doses of NBI-675. This was perhaps 
unpredicted and surprising considering the fact that salivation is induced by activation 
of muscarinic receptors, rather than inhibition. The reason for this increase is unclear, 
however, since it was only observed at the highest doses of the compounds, it may be 
related to off target effects, loss of selectivity at higher doses, or central side effect of 
the anticholinergics treatment, such as confusion, drowsiness or sedation (Cloud & 
Jinnah, 2010; Wawruch et al., 2012; Lampela et al., 2015) which could have triggered 
behavioural changes observed during the assessment. Animals receiving high doses of 
these drugs not only exhibited the reduction in pilocarpine-induced purposeless 
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chewing, but also appeared to be somnolent, with overall reduced movement and 
mostly recumbent, which could possibly be due to the suppression of CNS activity. 
This could have reduced swallowing and built up of saliva in the mouth between the 
measurements, without actually increasing saliva secretion. Further studies 
investigation salivation with other sedative agents are required to confirm this 
supposition. 
In many cases during the study pilocarpine-induced saliva secretion tended to be 
inhibited within the first assessment points, and then showing a peak at about 90 min 
after pilocarpine administration. The reason of this discrepancy is unclear, but the 
possibilities could include the duration of drug action, study design or different 
methods of measure the salivation. In previous studies saliva levels were measured in 
anaesthetised animals by placing cotton balls into their mouth (Renzi et al., 2002; 
Borella et al., 2008) or by collecting saliva into the sample tubes (Tobin et al., 2002; 
Nakamura et al., 2004; Sato et al., 2006), whereas the current study was designed to 
obtain a salivation dose response of the effect of the drug in non-anaesthetised animals.  
In addition, normal physiological activities of animals, such as chewing, swallowing, 
grooming, could have had an impact on variability of obtained results.  Although these 
could have not been prevented in this study, it was assumed that they were the same 
in all animals.  
 
In summary, the present study indicate that peripherally located muscarinic receptors, 
in particular M1 and M3 are responsible for pilocarpine-induced salivation and indeed 
these results agree with previous work (Tobin et al., 2002; Gautam et al., 2004; Borella 
et al., 2008). Importantly, the results confirm previous suggestion that muscarinic M4 
receptors do not play a major role in mediation of saliva secretion, as highly selective 




The current study aimed to compare the ability of various anticholinergics to inhibit 
pilocarpine-induced saliva secretion in rats and confirm the receptor subtype 
responsible for mediation of this process. Results confirm previous findings that 
muscarinic M1 and M3 receptors are responsible for promoting salivation (Tobin et 
al., 2002; Gautam et al., 2004; Borella et al., 2008). Importantly, this investigation 
also shows that muscarinic M4 receptors do not play a major role in mediation of 
salivation, since the selective antagonist NBI-675 failed to suppress pilocarpine-
induced saliva secretion in rats at doses that were at the lower end of the DRC that 
inhibited chewing. As a consequence, the hypothesis of this study that selective 
antagonism of muscarinic M4 receptors which reduce dystonia will not induce 
unfavourable oral dryness can be accepted. Importantly, studies in the previous and 
current chapter show that selective antagonism of muscarinic M4 receptors suppressed 
involuntary movements without induction of unfavourable peripheral side effects, 
such as dry mouth, therefore muscarinic M4 receptors could be a target for treatment 
of dystonia. However, it would be important to test drug effects in other models of 
dystonia. One of the well-established model to investigate drug-induced involuntary 
movements is a non-human primate model, the MPTP-treated marmosets, primed to 
express permanent ‘on-drug’ dystonia and chorea (dyskinesia) following chronic L-
DOPA treatment. Therefore, the investigation described in subsequent chapter will 
focus on examination of the effect of anticholinergics of different selectivity in the 
MPTP-treated marmosets model of Parkinson’s disease to assess whether selective 














Chapter 5 The effect of anticholinergics on parkinsonian 




5.1. Introduction  
In the previous chapters, it was reported that selective antagonism of central 
muscarinic M4 receptors can suppress involuntary movements with reduced 
unfavourable peripheral side effects seen with non-selective antagonism in rats. From 
this it was concluded that directly targeting muscarinic M4 receptors may show 
promise for the treatment of dystonia where non-selective antagonists are effective, 
but compliance is poor. Anticholinergics are also used to treat other diseases, including 
the motor symptoms of Parkinson’s disease (PD), and this raises the question as to 
whether M4 antagonists may have a similar beneficial effect in this disease.  However, 
the studies described in Chapters 3 and 4 used a pharmacological model of dystonia, 
they do not fully interrogate the potential use of selective muscarinic antagonists in the 
modulation of motor dysfunction in PD, where striatal cholinergic function is altered 
due to the loss of afferent neuronal control of cholinergic interneurons (section 
1.2.1.2).  
As described earlier (section 1.1.2) PD is the most common hypokinetic movement 
disorder where the loss of DA input into the striatum triggers underactivity of the 
thalamocortical pathway, and reduction in movement, mediated by overactivity in the 
indirect and underactivity in the direct striatal output pathways in the basal ganglia 
(section 1.2.1.1). This imbalance between the two basal ganglia circuits results in 
motor dysfunction, including bradykinesia, rigidity, tremor and postural instability, the 
cardinal symptoms of PD (Bonsi et al., 2011; Benarroch, 2012). The reduced 
dopaminergic activity in the striatum results in increased release of acetylcholine from 
striatal interneurons, explaining the beneficial use of anticholinergics in the treatment 
of PD (Duvoisin, 1967; Schapira, 2005). Originally this increase in ACh was thought 
to be related solely to the disinhibition of D2 receptor activation on ChI (Maurice et 
al., 2004). However, it is now understood that muscarinic receptors play an important 
role in the control of striatal dopaminergic afferents and GABAergic efferents. In 
particular, M4 receptors are expressed postsynaptically on D1 MSN and may play a 
vital inhibitory role in the activity of the direct pathway (Gomeza et al., 1999a; Onali 
& Olianas, 2002; Pisani et al., 2007), thus contributing to the DA-ACh balance in the 
activity of D1 MSN (Onali & Olianas, 2002). 
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A number of preclinical studies have investigated the effect of targeting muscarinic 
receptors, in particular M4 subtype, in the treatment of PD. Rodent studies have shown 
that tropicamide, which is only relatively selective for M4 receptors, can reverse 
parkinsonian symptoms induced by administration of systemic non-selective 
muscarinic agonist pilocarpine (Betz et al., 2007), a model similar to that described in 
Chapter 3 of this thesis.  The authors suggestion that one would expect fewer side 
effects due to the high expression of the M4 receptors within the striatum and lower 
abundance in the periphery compared to other subtypes of muscarinic receptors (Betz 
et al., 2007; Langmead et al., 2008) was confirmed in the studies described in this 
thesis (Chapter 4) with the highly selective M4 antagonist, NBI-675.  
Moreover, Karasawa et al., (2003) reported that haloperidol-induced catalepsy was 
inhibited by scopolamine in wild-type mice, whereas this anticholinergic was 
unsuccessful in blocking cataleptic responses in M4 knockout (KO) mice, indicating 
involvement of M4 receptor in motor control (Karasawa et al., 2003).  
Nevertheless, MPTP-treated primate model is by far the best model of PD to study 
motor symptoms seen in man. The MPTP-treated common marmosets display 
dopaminergic loss in the substantia nigra and loss of striatal dopaminergic terminals 
accounting for 90 – 95% (Jenner et al., 1984). This model mimics mid to late stage 
PD, and as such provides an effective tool to study novel treatment of the motor 
symptoms of the disease. Measures of motor function, including locomotor activity 
and motor disability are used to provide the insights into the drug treatment. In 
addition, chronic dopaminergic treatment results in the expression of dyskinesia which 
mimic those seen after long-term treatment in PD (Kuoppamaki et al., 2007).  
Although anticholinergics are effective in the treatment of PD, as with the treatment 
of dystonia, patients experience similar unpleasant peripheral side effects. There is a 
limited number of studies investigating the effects of anticholinergics in models of PD.  
However, in MPTP-treated primates it has been reported that non-selective centrally 
acting anticholinergics dose-dependently reversed motor disability and reduced 
akinesia (Jackson et al., 2014), but this was accompanied by side effects, including 
mydriasis, incoordination and difficulty in eating (Close et al., 1990).  
Overall, these observations indicate the muscarinic involvement in motor control and 
suggest that muscarinic antagonists, and particularly those selective for the M4 
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receptor, are candidates in the relieving the motor symptoms of PD.  However, no 
studies to date have investigated the effect of the selective M4 antagonists in the 
MPTP-treated primates due to the lack of the appropriate compounds. As reported in 
the previous chapter, the selective M4 antagonist, NBI-674, showed central 
anticholinergic activity, blocking pilocarpine-induced perioral movements with 
reduced peripheral side effects compared to less selective muscarinic receptor 
antagonists, allowing the investigation of the effects of selective M4 antagonists in the 
treatment of the motor symptoms of PD for the first time.    
5.1.1. Hypothesis 
It is hypothesised that selective antagonism of muscarinic M4 receptors with NBI-675 
will relieve motor symptoms of the MPTP-treated marmoset model of Parkinson’s 
disease, when given alone and will enhance the antiparkinsonian effects of L-DOPA, 
when given in combination.  
5.1.2. Aims 
In order to test this hypothesis these studies aimed to compare the effect of selective 
inhibition of M4 receptors with other non-selective or non-M4-selective 
antimuscarinics, when given alone and in combination with L-DOPA, on the reversal 
of motor deficits in the MPTP primate model of Parkinson’s disease.  The specific 
aims of this study were to: 
1) Confirm that L-DOPA reverses motor symptoms in MPTP-treated common 
marmosets.  
2) Determine the role of anticholinergics of different selectivity to muscarinic 
receptors on the reversal of motor symptoms in MPTP-treated common 
marmosets.  
3) Determine whether anticholinergics alter L-DOPA-induced reversal of motor 
disability. 
4) Determine whether the anticholinergic NBI-675 alters the pharmacokinetics of 




5.2 Materials and Methods 
In order to address these aims the following studies were performed: 
1) The effect of L-DOPA on locomotor activity and reversal of motor disability was 
investigated by treating MPTP-treated common marmosets by L-DOPA or vehicle. 
Drug effect was determined by changes in locomotor activity and motor disability.  
2) The role of clinically used anticholinergics alone and their effect on L-DOPA 
increase of locomotor activity and reversal of motor disability was investigated by 
treating MPTP-treated common marmosets with peripheral and central acting 
anticholinergics 1 hr prior to L-DOPA or vehicle. Changes in locomotor activity 
and motor disability were assessed to determine drug effect.  
3)  The role of the M4 muscarinic receptor in L-DOPA increase of locomotor activity 
and reversal of motor disability was investigated using the novel selective M4 
antagonist NBI-675 administered to MPTP-treated common marmosets 1 hr prior 
to L-DOPA or vehicle. Changes in locomotor activity and motor disability were 
assessed to determine drug effect.  
4) The effect of NBI-675 on L-DOPA pharmacokinetics was determined by 
measuring the levels of L-DOPA and its metabolite 3-OMD in blood plasma up to 
3 hr after administration of L-DOPA. Plasma levels of L-DOPA and metabolites 
were measured by HPLC with electrochemical detector.   
An overview of the methods used is described below with detailed methodology found 
in Chapter 2.     
5.2.1 Animals 
Adult common marmosets (Callithrix Jacchus) (Harlan, UK, 350 – 500 g, n = 6-8 per 
group) of either sex were used in this study. Animals were previously treated with 
MPTP and primed with L-DOPA and were not drug naïve prior to the study. For details 
please refer to Chapter 2 section 2.2.3.1. All experiments were carried out in 
accordance with Home Office regulations under the Animas (Scientific Procedures) 




5.2.2 Behavioural assessment  
As described in Chapter 2, all behavioural assessments were carried out between the 
hours 7.00 am and 3.00 pm. The assessment was performed for 1 hr before (baseline 
score) and 6 hr after anticholinergics/vehicle administration, as described in section 
2.2.3.3 In brief, locomotor activity was measured by infrared beam interruptions. 
Animals were observed through one-way mirror by experienced observers blinded to 
the drug treatment through one-way mirror and scored for motor disability reversal 
(Chapter 2, Fig. 2.5) during the last 10 min of each consecutive 30 min intervals. Full 
description of assessment criteria are provided in sections 2.2.3.3.  
Locomotor activity, motor disability and dyskinesia with dystonia and chorea, were 
assessed during one experiment on the same animals, however, for the clarity, 
behavioural outcomes were split into two chapters to assess the effects of 
anticholinergics on motor function (Chapter 5) and on L-DOPA-induced dyskinesia 
(Chapter 6).   
5.2.3 Drug treatment 
Full details of drug preparation and treatment are described in Chapter 2, section 
2.2.3.4. Briefly, on test days animals were placed into the testing units and were given 
60 min acclimatization in the test cages prior to drug treatment. Following the 60 min 
acclimatisation period which provided baseline activity data, animals were dosed with 
appropriate anticholinergic or vehicle (s.c. or p.o.) followed by L-DOPA (8 mg/kg 
p.o.) + benserazide (10 mg/kg p.o.) or vehicle 60 min later. Doses of anticholinergics 
are presented in Table 5.1. Behavioural assessment was then carried out as described 
in Chapter 2 section 2.2.3.3. A repeated crossover design was used, so each marmoset 
was treated with all doses of a single drug or vehicle with at least 72 hr washout 
between the tests. A typical modified Latin square was used to randomise drug 








Table 5.1 Typical example of a latin square with a crossover designed treatment for 
administration of different doses of anticholinergics prior L-DOPA. 
 
 
Locomotor activity was recorded throughout the study. Motor disability was scored 
immediately before each drug treatment and then every 30 minutes for 10 minute 
periods throughout the study for up to 5 hours, as shown in Chapter 2 Figure 2.7. Full 
description of assessment criteria are provided in sections 2.2.3.3.  
One animal was taken out of the study due to seizures caused by the highest dose of 
NBI-675 on the last day of study.  







1 2 3 4 5 6
1 A B C D E F
2 D A E B F C
3 C F A E D B
4 B D F A C E
5 E C B F A D
6 D B E C F A
7 A E C D B F
8 F A D E C B
1) A = vehicle anticholinergic + L-DOPA
2) B = dose 1 anticholinergic + vehicle L-DOPA
3) C = dose 1 anticholinergic + L-DOPA
4) D = dose 2 anticholinergic + vehicle L-DOPA
5) E = dose 2 anticholinergic + L-DOPA
6) F = vehicle anticholinergic + vehicle L-DOPA
Drug Dose Route
Benztropine 0.25 & 0.5 mg/kg s.c.
Scopolamine 0.1 & 0.3 mg/kg s.c.
Methylscopolamine 0.1 & 0.3 mg/kg s.c.
Trihexyphenidyl 0.5 & 1 mg/kg p.o.
NBI-675 1, 5 & 7.5 mg/kg p.o.
L-DOPA + benserazide 8 mg/kg p.o.+ 10 mg/kg p.o.
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5.2.4 Plasma exposure – blood sampling  
To determine whether the NBI-675 alters the pharmacokinetics of L-DOPA, the levels 
of L-DOPA and its metabolite 3-OMD in blood plasma were assessed using HPLC 
with electrochemical detector.  
Animals were placed in the automated activity (test) cages. They were allowed 60 min 
of acclimatization, and were dosed with NBI-675 (5 mg/kg p.o.) followed by L-DOPA 
(4 mg/kg p.o.) + benserazide (10 mg/kg p.o.) 1 hour later. No behavioural assessments 
were performed. At the hour 1 and 3 after L-DOPA treatment, animals were removed 
from the cage (one at the time), hand restrained, the inner side of the thigh was 
disinfected with hibiscrub diluted in water (1:10 hibiscrub to water), 0.4 ml of blood 
was withdrawn from the femoral vein using 25G needle. The blood sample was 
collected into the heparin tubes and kept on ice.  A gauze with adequate finger pressure 
was applied immediately to the site until bleeding stopped. Animals received a reward, 
a marshmallow, and were returned into their cages. The alternate legs were used to 
obtain blood samples. After all samples were collected, they were centrifuged at 4˚C 
at 5000 rpm for 10 min. Supernatant (blood plasma) was collected into the Eppendorf 
tubes and frozen at -70˚C until further use.  
5.2.5 HPLC-ECD detection of L-DOPA and its metabolites  
Concentrations of L-DOPA and 3-O-methyldopa (3-OMD) were analysed in blood 
plasma samples of common marmosets by high pressure liquid chromatography with 
an electrochemical detector (HPLC-ECD). 
5.2.5.1 Sample preparation  
The methods of sample preparation were performed according to a modification of 
methods by Rose et al., (1988). To determine plasma concentration of L-DOPA and 
its metabolite, 3-OMD, blood plasma samples were thawed at 4˚C on ice and mixed 
(9:1 volume/volume ratio) in 0.4 M perchloric acid (PCA) solution containing 1 mM 
EDTA disodium and 0.01% sodium metabisulphate (referred to as PCA solution). The 
PCA solution also contained 3,4-dihydroxybenzylamine hydrobromide (DHBA) as an 
internal standard at a final concentration of 1.0 µg/ml. To further acidify the samples 
30% (volume/volume) of 70% (weight/volume) PCA solution was added. Plasma 
samples were then sonicated using a Microson ultrasonic tissue disruptor to progress 
142 
 
acidification of proteins. The samples were then centrifuged at 4˚C at 13000 rpm for 
10 min and the supernatant was collected and analysed by HPLC-ECD.  
 
5.2.5.2 HPLC-ECD 
Standard solutions of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 5-
hydroxytryptamine (5-HT), 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic 
acid (HVA) were prepared in the PCA solution at a concentration of 1 mg/ml 
individually and stored at -70ºC. DHBA (1 mg/ml in PCA) was also prepared 
separately and stored at -70ºC. Stock solutions of L-DOPA (1 mg/ml) and 3-OMD (1 
mg/ml) in PCA solution were prepared on the day of experiment. A range of standard 
concentrations (200 ng/ml – 5 µg/ml for L-DOPA; 10 µg/ml – 250 µg/ml for 3-OMD) 
containing DHBA (1 µg/ml) was prepared for calibration. Dopamine, DOPAC, 5-HT, 
5-HIAA and HVA were added into the standard to clearly differentiate L-DOPA and 
3-OMD peaks although their concentrations were not determined in the blood plasma 
samples.  
The UltiMate 3000 HPLC system consisted of a LPG-3400A pump, a WPS-3000TSL 
autosampler, a Spherisorb ODS (2) 3 m particle size HPLC column (SpheriClone 
0.46 cm x 10 cm; Phenomenex, UK) and a temperature regulated column compartment 
(all from Dionex, UK). They were coupled to INTRO Electrochemical detector (Antec, 
UK) incorporating a VT-03 flow cell with a spacer of 50 m thickness and KCl 
reference electrode (Aquilant Scientific (Presearch), UK) through the UCI-50 
Universal Chromatography Interface (Dionex, UK). The mobile phase was made of 
0.1 M sodium dihydrogen orthophosphate buffer containing 12% HPLC grade 
methanol, 1 mM disodium EDTA and 56 mM octane-1 sulfonic acid in 18M water 
and adjusted pH with 3 M orthophosphoric acid to pH 3.2. The mobile phase was 
filtered through polyamide membrane filters (0.2 µm pore size; Sartorius Stedim Ltd., 
UK) and degassed during the analysis. Isocratic elution was made at a flow rate of 0.8 
ml/min. The column was maintained at 30ºC in the column compartment, and samples 
and standards were stored at 9ºC in the autosampler. A potential of 0.72 V was 
maintained across the glassy carbon working electrode. The system was calibrated 
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using 1 µg/ml standard every three samples.  All HPLC settings employed in this study 
are listed in Table 5.3. 




5.2.5.3 Determination of L-DOPA and 3-OMD concentrations  
Peak height of the analytes and internal standards were measured by Chromeleon 6.8 
Chromatography Data System (Dionex, UK). Concentrations of the samples were 
determined by the comparison of peak height ratio (PHR) between the internal 
standard peak and analytes using the following equation: 
amount in = PH (sample L-DOPA) x [STD]  x PH (STD DHBA) 
sample   PH (sample DHBA)  x    PH (STD L-DOPA) 
 
where: PH = peak height and  STD = Standard. 
 
Calibration curves were calculated using the peak height to DHBA ratio (PHR) (Fig. 
5.1). Data were expressed as ng/ml. Typical chromatographs for standards, blood 
plasma containing DHBA alone and blood plasma at 1 hr after L-DOPA administration 
are presented in Figure 5.2. Standard mixture solution at the concentration of 1.0 µg/ml 
was repeatedly injected into the system ten times and stability of peak height ratio for 
Column temp 30 C
Samples temp 9 C
Voltage 0.72V
Flow rate 0.8 ml/min (isocratic)
Filter 0.5 s
Range 5-20 nA/V
Injection volume 10 µl
Run per sample 15 min
Standard volume 1 µg/ml for L-DOPA




0.56mM octane-1-sulfonic acid sodium salt (4% w/v)
12% methanol (HPLC grade)
pH 3.2 with 3M phosphoric acid
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L-DOPA and 3-OMD was calculated as an intra assay coefficient of variance. Intra 
assay coefficient of variance was 0.43% and 0.31% for L-DOPA and 3-OMD, 
respectively (Fig. 5.3). The recovery rates were 105  1.18% and 103  0.43% for L-
DOPA and 3-OMD, respectively.  
 
 
Figure 5.1 Representative calibration curves for L-DOPA and 3-OMD using the peak 
height ratio to DHBA in blood plasma.  
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Figure 5.2 Representative chromatographs obtained by HPLC-ECD from common 
marmoset blood plasma.  
 A) standard; B) blood plasma containing DHBA alone and C) blood plasma at one hour after 
L-DOPA treatment. 














































































































Figure 5.3  Typical intra assay stability of L-DOPA and 3-OMD over the repeated 
analysis for common marmoset blood plasma sample.  
Stability of peak height ratio of L-DOPA and 3-OMD to DHBA was assessed as an intra assay 
coefficient of variation following repeated injections of standard solution (1.0 µg/ml). Intra 
assay coefficient of variation of the standards was 0.43% for L-DOPA and 0.31% for 3-OMD.  
 
5.2.6 Statistical analysis  
Data and statistical analysis were performed using GraphPad Prism 5.02 (San Diego, 
CA, USA) as described in Section 2.2.3.5, Chapter 2.  
The statistical analysis for locomotor activity and motor disability data was performed 
as follows: 
4) No statistical analysis was performed on time course data; 
5) Totals (AUC-1-0h) and (AUC0-5h) and Peak for motor disability data were 
transformed by square root (Y=√Y). 
6) Totals (AUC-1-0h) and (AUC0-5h), Peak, On-time, On-time > 2 were analysed 
by Two-way ANOVA (variables: L-DOPA and anticholinergic) and repeated 
measures ANOVA followed by post hoc Newman-Keuls multiple comparisons 
test. 
Concentration of L-DOPA and 3-OMD in MPTP-treated common marmoset plasma 
following L-DOPA administration after 1 and 3 hours were determined using HPLC-
ECD. Data are presented as mean ± SEM (n = 6) and were analysed by Two-way 
ANOVA (variables: time and treatment), if an effect was found then analysis was 
performed by Friedman’s test followed by post hoc Dunn’s test.  





































































In all studies vehicle-A-vehicle-B administration had no effect on locomotor activity 
or reversal of motor disability over time in MPTP-treated common marmosets (Fig. 
5.4 – 5.13).  
Following the acclimatisation time, and in the absence of L-DOPA, animals appeared 
akinetic and hunched, either sitting on the cage floor or on the perches. They were 
often staring in one direction, and at times looked sleepy, however, occasional 
alertness with head checking and overall slow movements were also present.   Their 
locomotor activity scores were low with little variability (with a median t=-1-0 LMA 
score of 150.5, range 0 – 3428) reflecting the akinesia, and their motor disability scores 
were high (with a median t=-1-0 motor disability score of 11, range 2 – 14), as expected 
for a parkinsonian marmoset.   
Administration of L-DOPA alone resulted in an increase in locomotor activity with a 
total duration of about 3.5 hrs and a peak effect between 30 min to 1 hr after 
administration before gradually returning to the baseline. This resulted in a significant 
increase in locomotor activity as measured by total counts (AUC0-5h) (Fig.  5.6 B, 5.8 
B & 5.10 B), on-time (Fig. 5.6 C, 5.8 C & 5.10 C) and peak activity (Fig. 5.4 D, 5.6 
D, 5.8 D, 5.10 D & 5.12 D) when compared to vehicle-A-vehicle-B-treated animals.   
Similarly, L-DOPA alone reversed motor disability with a total duration of around 3.5 
hrs and a peak effect observed between 1 and 2.5 hrs after administration, before 
gradually returning towards baseline. This resulted in a significant increase in total 
motor disability score (AUC0-5h) (Fig. 5.5 B, 5.7 B, 5.11 B & 5.3 B), increase in on-
time (Fig. 5.5 C, 5.7 C, 5.9, 5.11 & 5.13 C) and reduction in peak score (Fig. 5.5 D, 
5.7 D, 5.9 D & 5.11 D) when compared to vehicle-A-vehicle-B-treated animals. 
Combination of L-DOPA and anticholinergics is described below for every compound 
separately, however, generally centrally acting anticholinergics appeared to extend the 
duration of L-DOPA effect.   
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5.3.1 The effect of non-selective anticholinergics  
5.3.1.1 Centrally acting scopolamine 
5.3.1.1.1 Locomotor activity 
Scopolamine alone (0.1 & 0.3 mg/kg) produced an immediate increase in locomotor 
activity, which lasted for about 2 hrs and was not dose-dependent, resulting in a 
significant increase in locomotor activity counts over the first hour (AUC-1-0h) prior to 
L-DOPA administration compared to vehicle-A (Fig. 5.4 E).  
Pre-treatment with scopolamine (0.1 & 0.3 mg/kg) had no significant effect on L-
DOPA-induced rise in locomotor activity, as measured by total counts (AUC0-5h), on-
time or peak activity when compared to L-DOPA alone (Fig. 5.4 B – D).  When 
compared to scopolamine alone, the combination treatment remained significantly 
increased as measured by total counts (AUC0-5h), on-time and peak activity (Fig. 5.4 




Figure 5.4 Effect of scopolamine on L-DOPA-induced locomotor activity in MPTP-
treated common marmosets 
Scopolamine (0.1 & 0.3 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=8)                    
A) Locomotor activity time course and B) Total locomotor activity (AUC0-5h), C) On-time and 
D) Peak activity after L-DOPA/vehicle-B administration; E) Total counts in the first hour after 
scopolamine/vehicle-A (AUC-1-0h). Data are expressed as time course with mean values with 
error bars omitted for clarity (A) and median with individual counts (B – E). A) No statistical 
analysis performed; B – D) Data analysed by Two way ANOVA and B – E) repeated measures 
ANOVA; (B) F=6.806; Df (5,47); p=0.0002; C) F=8.310; Df (5,47); p<0.0001; D) F=10.23; 
Df (5,47); p<0.0001; E) F=5.284; Df (2,23); p=0.0195) followed by Newman-Keuls Multiple 
Comparison post hoc test *p<0.05; **p<0.01; ***p<0.001.  
 
Locomotor Activity Scopolamine









vehicle A + L-DOPA
0.1 mg/kg + vehicle B 0.1 mg/kg + L-DOPA



































































































































































































































5.3.1.1.2 Motor disability  
Scopolamine alone (0.1 & 0.3 mg/kg) produced an immediate reversal of motor 
disability with a peak effect at 30 min (Fig. 5.5 A). This effect was significantly greater 
than vehicle-A over the first hour (AUC-1-0h) (Fig. 5.5 E) and resulted in a significant 
improvement in motor disability over the 5 hours after vehicle-B administration as 
measured by on-time and peak scores when compared to vehicle-A/B-treated animals 
(Fig. 5.5 C & D), although there was no effect of scopolamine on total scores (AUC0-
5h) when compared to vehicle-A/B-treated animals (Fig. 5.5 B).  
There was no significant effect of scopolamine (0.1 & 0.3 mg/kg) on L-DOPA-induced 
reversal of motor disability as measured by total (AUC0-5h) and peak scores and on-
time when compared to L-DOPA alone (Fig. 5.5 B – D), although on-time tended to 
be increased.  
Reversal of the motor disability by the L-DOPA/scopolamine combination was not 






Figure 5.5 Effect of scopolamine on L-DOPA-induced reversal of motor disability in 
MPTP-treated common marmosets 
 Scopolamine (0.1 & 0.3 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=8)                    
A) Motor disability time course and B) Total motor disability reversal (AUC0-5h) C) On-time 
and D) Peak motor disability after L-DOPA/vehicle-B administration; E) Total motor 
disability reversal in the first hour after scopolamine/vehicle-A (AUC-1-0h). Data are expressed 
as time course with median values with error bars omitted for clarity (A) and median with 
individual counts (B – E). A) No statistical analysis performed; B – D) Data analysed by Two 
way ANOVA and B – E) repeated measures ANOVA; For B, D & E data were transformed 
y=√y; (B) F=4.064; Df (5,47); p=0.0052; C) F=7.522; Df (5,47); p<0.0001; D) F=9.258; Df 
(5,47); p<0.0001; E) F=30.59; Df (2, 23); p<0.0001) followed by Newman-Keuls post hoc test 
*p<0.05; ***p<0.001.  
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5.3.1.2 Peripherally acting methylscopolamine  
5.3.1.2.1 Locomotor activity 
Methylscopolamine had no significant effect on locomotor activity as measured by 
total counts (AUC-1-0h) and (AUC0-5h), peak activity and on-time when compared to 
the vehicle-A/B treatments (Fig. 5.10 B – E).  
Pre-treatment with methylscopolamine (0.1 & 0.3 mg/kg) had no effect on L-DOPA-
induced locomotor activity when compared to L-DOPA alone (Fig. 5.6 B – D). When 
compared to methylscopolamine alone, the combination treatment L-
DOPA/methylscopolamine remained significantly improved as measured by on-time 
only (0.3 mg/kg), while there was no increase in locomotor activity when measured by 










Figure 5.6 Effect of methylscopolamine on L-DOPA-induced locomotor activity in 
MPTP-treated common marmosets  
Methylscopolamine (0.1 & 0.3 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) 
(n=8) A) Locomotor activity time course and B) Total locomotor activity (AUC0-5h), C) On-
time and D) Peak activity after L-DOPA/vehicle-B administration; E) Total counts in the first 
hour after methylscopolamine/vehicle-A (AUC-1-0h). Data are expressed as time course with 
mean values with error bars omitted for clarity (A) and median with individual counts (B – E). 
A) No statistical analysis performed; B – D) Data analysed by Two way ANOVA and B – E) 
repeated measures ANOVA; (B) F=3.824; Df (5,47); p=0.0073; C) F=6.904; Df (5,47); 
p=0.0001; D) F=3.817; Df (5,47); p=0.0073; E) F=1.206; Df (2,23); p=0.3288) followed by 
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5.3.1.2.2 Motor disability  
Methylscopolamine alone produced a very small but significant reversal of motor 
disability at the higher dose (0.3 mg/kg) when compared to vehicle-A treatment over 
the first hour (AUC-1-0h) (Fig. 5.7 E), although the animals were not considered “on” 
as determined by a motor disability scores < 8. There was no overall effect of 
methylscopolamine after L-DOPA/vehicle-B administration when compared to 
vehicle-A/B (Fig. 5.7 B – D).  
Pre-treatment with methylscopolamine significantly decreased L-DOPA-induced 
reversal of motor disability as measured by total (AUC0-5h) scores (Fig. 5.7 B) and 
tended to reduce the duration of reversal of motor deficits as measured by on time 
when compared to L-DOPA alone (Fig. 5.7 C), although this was not significant. When 
compared to methylscopolamine alone (0.1 & 0.3 mg/kg) the combination of treatment 
produced a significant reversal of motor deficits as measured by peak scores (Fig. 5.7 







Figure 5.7 Effect of methylscopolamine on L-DOPA-induced motor disability in MPTP-
treated common marmosets  
Methylscopolamine (0.1 & 0.3 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) 
(n=8) A) Motor disability time course and B) Total motor disability reversal (AUC0-5h) C) On-
time and D) Peak motor disability after L-DOPA/vehicle-B administration; E) Total motor 
disability reversal in the first hour after methylscopolamine/vehicle-A (AUC-1-0h). Data are 
expressed as time course with median values with error bars omitted for clarity (A) and median 
with individual counts (B – E). A) No statistical analysis performed; B – D) Data analysed by 
Two way ANOVA and B – E) repeated measures ANOVA; For B, D & E data were 
transformed y=√y; (B) F=16.81; Df (5,47); p<0.0001; C) F=5.616; Df (5,47); p=0.0007; D) 
F=8.896; Df (5,47); p<0.0001; E) F=4.483; Df (2,23); p=0.0313) followed by Newman-Keuls 
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5.3.2 Clinically used selective M1 anticholinergics  
5.3.2.1 Trihexyphenidyl  
5.3.2.1.1 Locomotor activity 
Trihexyphenidyl alone (0.5 & 1 mg/kg) had no significant effect on locomotor activity 
as measured by total counts over the first hour (AUC-1-0h) prior to L-DOPA 
administration compared to vehicle-A (Fig. 5.8 E). However, during the subsequent 5 
hours trihexyphenidyl produced a significant increase in locomotor activity as 
measured by on time (1 mg/kg) when compared to vehicle-A/B-treated animals (Fig. 
5.8 C).  
Pre-treatment with trihexyphenidyl had no significant effect on L-DOPA-induced rise 
in locomotor activity as measured by total counts (AUC0-5h) and peak activity (Fig. 5.8 
B & D) but the highest dose of trihexyphenidyl (1 mg/kg) significantly increased 
duration of L-DOPA (Fig. 5.8 C) when compared to L-DOPA alone.  
Combination treatment L-DOPA/trihexyphenidyl remained significantly improved as 
measured by total counts (AUC0-5h), on-time and peak activity (Fig. 5.8 B – D) when 
compared to trihexyphenidyl alone.  







Figure 5.8 Effect of trihexyphenidyl on L-DOPA-induced locomotor activity in MPTP-
treated common marmosets  
Trihexyphenidyl (0.5 & 1 mg/kg p.o.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=7) 
A) Locomotor activity time course and B) Total locomotor activity (AUC0-5h), C) On-time and 
D) Peak locomotor activity after L-DOPA/vehicle-B administration; E) Total activity in the 
first hour after methylscopolamine/vehicle-A (AUC-1-0h). Data are expressed as time course 
with mean values with error bars omitted for clarity (A) and median with individual counts (B 
– E). A) No statistical analysis performed; B – D) Data analysed by Two way ANOVA and B 
– E) repeated measures ANOVA; (B) F=7.578; Df (5,41); p=0.0001; C) F=15.72; (5,41); 
p<0.0001; D) F=11.00 (5,41); p<0.0001; E) F=1.788; (2,20); p=0.2091) followed by Newman-
Keuls post hoc test *p<0.05; **p<0.01; ***p<0.001.  
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 5.3.2.1.2 Motor disability 
Trihexyphenidyl alone (0.5 & 1 mg/kg) had no effect on reversal of motor disability 
over the first hour as measured by totals (AUC-1-0h) when compared to vehicle-A (Fig. 
5.9 E), however, the highest dose of trihexyphenidyl (1 mg/kg) produced a significant 
improvement in motor disability over the 5 hours after the vehicle-B administration as 
measured by on-time and peak activity when compared to vehicle-A/B-treated animals 
(Fig. 5.9 C & D).  
Pre-treatment with trihexyphenidyl (0.5 & 1 mg/kg) had no significant effect of on L-
DOPA-induced reversal of motor disability as measured by totals scores (AUC0-5h), 
however, the highest dose (1 mg/kg) produced a significant effect on duration and peak 
scores (Fig. 5.9 C & D) when compared to L-DOPA alone. 
Reversal of motor deficits by L-DOPA/trihexyphenidyl combination remained 
significantly different to trihexyphenidyl alone as measured by on-time (Fig.  5.9 C) 






Figure 5.9 Effect of trihexyphenidyl on L-DOPA-motor disability in MPTP-treated 
common marmosets  
Trihexyphenidyl (0.5 & 1 mg/kg p.o.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=7) 
A) Motor disability time course and B) Total motor disability (AUC0-5h), C) On-time and D) 
Peak motor disability after L-DOPA/vehicle-B administration; E) Total motor disability in the 
first hour after trihexyphenidyl/vehicle-A (AUC-1-0h). Data are expressed as time course with 
median values with error bars omitted for clarity (A) and median with individual counts (B – 
E). A) No statistical analysis performed; B – D) Data analysed by Two way ANOVA and B – 
E) repeated measures ANOVA; For B, D & E data were transformed y=√y; (B) F=1.702; Df 
(5,41); p=0.1646; C) F=21.31; Df (5,41); p<0.0001; D) F=8.424; Df (5,41); p<0.0001; E) 
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5.3.2.2.1 Locomotor activity 
Benztropine alone (0.25 & 0.5 mg/kg) produced an immediate increase in locomotor 
activity, which lasted for about 2.5 hrs, resulting in a significant increase in locomotor 
activity counts over the first hour (AUC-1-0h) prior to L-DOPA/vehicle-B 
administration compared to vehicle-A (Fig. 5.10 E).  
Pre-treatment with benztropine (0.25 & 0.5 mg/kg) had no effect on improvement in 
locomotor activity as measured by total counts (AUC0-5h), on-time or peak activity 
when compared to L-DOPA alone (Fig. 5.10 B & D).  
When compared to benztropine alone, the combination treatment L-
DOPA/benztropine remained significant increased as measured total counts (AUC0-5h) 







Figure 5.10 Effect of benztropine on L-DOPA-induced locomotor activity in MPTP-
treated common marmosets 
Benztropine (0.25 & 0.5 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=7) 
A) Locomotor activity time course and B) Total locomotor activity (AUC0-5h), C) On-time and 
D) Peak locomotor activity after L-DOPA/vehicle-B administration; E) Total locomotor 
activity in the first hour after benztropine/vehicle-A (AUC-1-0h). Data are expressed as time 
course with mean values with error bars omitted for clarity (A) and median with individual 
counts (B – E). A) No statistical analysis performed; B – D) Data analysed by Two way 
ANOVA and B – E) repeated measures ANOVA; (B) F=6.180; (5,41); p=0.0005; C) F=10.68; 
(5,41); p<0.0001; D) F=3.082; (5,41); p=0.0204; E) F=10.08; (2,20); p=0.0027) followed by 
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5.3.2.2.2 Motor disability 
Benztropine alone (0.25 & 0.5 mg/kg) immediately and significantly reversed motor 
disability as measured by total scores over the first hour (AUC-1-0h) prior to L-DOPA 
administration when compared to vehicle-A treatment (Fig. 5.11 E). This resulted in a 
significant improvement in motor disability over the 5 hrs after vehicle-B 
administration as measured by total (AUC0-5h) scores, on-time and peak scores 
compared to vehicle-A/B treatment (Fig. 5.11 B – D).   
There was no significant effect of benztropine (0.25 & 0.5 mg/kg) on L-DOPA-
induced reversal of motor disability as measured by total (AUC0-5h) and peak scores 
and on-time when compared to L-DOPA alone  
Reversal of the motor disability by the L-DOPA/benztropine combination had no 
effect on total score (AUC0-5h), on-time and peak score when compared to benztropine 






Figure 5.11 Effect of benztropine on L-DOPA-induced motor disability in MPTP-treated 
common marmosets  
Benztropine (0.25 & 0.5 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=7) 
A) Motor disability time course and B) Total motor disability (AUC0-5h), C) On-time and D) 
Peak motor disability after L-DOPA/vehicle-B administration; E) Total motor disability in the 
first hour after benztropine/vehicle-A (AUC-1-0h). Data are expressed as time course with 
median values with error bars omitted for clarity (n=7) (A) and median with individual counts 
(B – E). A) No statistical analysis performed; B – D) Data analysed by Two way ANOVA and 
B – E) repeated measures ANOVA; For B, D & E data were transformed y=√y; (B) F=15.523; 
Df (5,41); p=0.0010; C) F=6.339; Df (5,41); p=0.0004; D) F=5.411; Df (5,41); p=0.0012; E) 
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5.3.3 Selective M4 antagonist - NBI-675 
5.3.3.1 Locomotor activity 
NBI-675 (1 – 7.5 mg/kg) alone has not significantly improved locomotor activity as 
measured by totals (AUC-1-0h) and (AUC0-5.5h), on-time and peak activity when 
compared to vehicle-A/B (Fig. 5.12 B – E).  
Pre-treatment with NBI-675 (1 – 7.5 mg/kg) had no effect on increase of locomotor 
activity when compared to L-DOPA-alone-treated animals (Fig. 5.12 B – E), although, 
the highest dose of NBI-675 (7.5 mg/kg) in combination with L-DOPA tended to 
produce a decrease in locomotor activity as measured by totals (AUC0-5.5h) when 
compared to L-DOPA alone (Fig. 5.12 B).  
When compared to NBI-675 alone, the combination treatment remained significantly 
increased as measured by total counts (AUC0-5h) and peak activity at the lower doses 
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Figure 5.12 Effect of NBI-675 on L-DOPA-induced locomotor activity in MPTP-treated 
common marmosets 
NBI-675 (1 – 7.5 mg/kg p.o.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=6)                 
A) Locomotor activity time course and B) Total locomotor activity (AUC0-5h), C) On-time and 
D) Peak locomotor activity after L-DOPA/vehicle-B administration; E) Total locomotor 
activity in the first hour after NBI-675/vehicle-A (AUC-1-0h). Data are expressed as time course 
with mean values with error bars omitted for clarity (n=6) (A) and median with individual 
counts (B – E). A) No statistical analysis performed; B – D) Data analysed by Two way 
ANOVA and B – E) repeated measures ANOVA; (B) F=6.309; Df (7,47); p<0.0001; C) 
F=4.029; Df (7,47); p=0.0025; D) F=7.316; Df (7,47); p<0.0001; E) F=0.9252; Df (3,23) 
p=0.4526) followed by Newman-Keuls post hoc test *p<0.05; **p<0.01.  
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5.3.3.2 Motor disability 
NBI-675 alone (1 – 7.5 mg/kg) had no significant effect on reversal of motor disability 
totals (AUC-1-0h) and (AUC0-5.5h), on-time and peak activity when compared to vehicle-
A treatment (Fig. 5.13 B – E).  
Similarly, NBI-675 had no significant effect on L-DOPA-induced reversal of motor 
disability when compared to L-DOPA alone (Fig. 5.13 B – D). The combination 
treatment NBI-675/L-DOPA showed significant reduction on reversal of motor 
deficits when measured by peak at the highest dose (7.5 mg/kg), while on time tended 
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Figure 5.13 Effect of NBI-675 on L-DOPA-induced motor disability in MPTP-treated 
common marmosets 
 NBI-675 (1 – 7.5 mg/kg p.o.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=6)               
A) Motor disability time course and B) Total motor disability (AUC0-5h), C) On-time and D) 
Peak motor disability after L-DOPA/vehicle-B administration; E) Total motor disability in the 
first hour after NBI-675/vehicle-A (AUC-1-0h). Data are expressed as time course with median 
values with error bars omitted for clarity (n=6) (A) and median with individual counts (B – E). 
A) No statistical analysis performed; B – D) Data analysed by Two way ANOVA and B – E) 
repeated measures ANOVA; For B, D & E data were transformed y=√y; (B) F=2.773; Df 
(7,47); p=0.0211; C) F=4.055; Df (7,47); p=0.0024; D) F=4.132; Df (7,47); p=0.0021; E) 
F=3.431; Df (3,23); p=0.0444) followed by Newman-Keuls post hoc test *p<0.05.  
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5.3.4 The effect of NBI-675 on L-DOPA and its metabolite  
Analysis of blood plasma showed no effect of NBI-675 (5 mg/kg p.o.) on 
concentration of L-DOPA (Fig. 5.14 A) and its metabolite 3-OMD (Fig. 5.14 B) at 1 
hr and 3 hr after L-DOPA administration, however, the concentration of L-DOPA was 
significantly lower at 3 hr time point when compared to 1 hr, whereas concentration 




Figure 5.14 Effect of NBI-675 administration on A) L-DOPA and B) 3-OMD levels in 
common marmoset blood plasma following 1 and 3 hours after L-DOPA administration  
Concentrations of L-DOPA and 3-OMD in blood plasma were determined using HPLC-ECD. 
Data are presented as mean ± SEM (n=6); A) **p<0.01 L-DOPA alone (4 mg/kg + benserazide 
10 mg/kg p.o.) B) *p<0.05 L-DOPA (4 mg/kg + benserazide 10 mg/kg p.o.) + NBI-675 (5 
mg/kg p.o.) (Two-way ANOVA and Friedman’s test followed by post hoc Dunn’s test (A) FS 
= 12.60; p=0.0015; B) FS = 10.80; p=0.0061).  
 
5.4.4 Other effects of anticholinergics  
The primary aim of the study was to investigate the effects of anticholinergics on motor 
function in MPTP-treated common marmosets, therefore other central and peripheral 
effects of anticholinergics were not assessed quantitatively. However, based on the 
observation of animals through a one-way mirror during a scoring period, animals 
administered with high doses of anticholinergics appeared to be disorientated at times 
with reduced activity and movement, recumbent and somnolent, with occasional 
tracking particularly within the first hour of drugs administration. These effects are 
similar to those reported in the rodent (Chapter 3 & 4) and are a typical CNS effects 
L-DOPA




































































of anticholinergic treatment, which are important dose limiting considerations in 
clinical use. Additionally, high doses of NBI-675 produced nausea and vomiting in 
some animals within the first hour of administration.  In addition, one animal had 
seizure on the highest dose of the compound, thus had to be taken out of the study.    
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5.4 Discussion  
The studies described in this chapter explored the effect of centrally acting 
anticholinergics in PD with and without L-DOPA in the MPTP-treated marmosets, 
with the particular emphasis on selective inhibition of M4 muscarinic receptors. It was 
hypothesised that selective antagonism of muscarinic M4 receptors with NBI-675 will 
relieve motor symptoms of Parkinson's disease when given alone and in combination 
with L-DOPA.  
L-DOPA has remained the gold standard treatment for PD (Rascol  et al., 2000) and 
so as expected these studies confirmed that L-DOPA alone almost immediately 
attenuated bradykinesia produced by MPTP-treatment increasing locomotor activity 
and reversing motor symptoms observed in MPTP-treated marmosets.  
Centrally acting non-selective scopolamine and M1 selective trihexyphenidyl and 
benztropine tended to improve locomotion and reverse motor deficits in MPTP-treated 
marmosets when administrated alone and in combination with L-DOPA. Interestingly, 
peripherally acting methylscopolamine produced immediate and very short-lasting 
reversal of motor deficits, but overall unexpectedly it showed a tendency to antagonize 
L-DOPA reversal of motor disability. Selective M4 antagonist, NBI-675, had no 
beneficial effect on improvement of locomotion or motor disability either alone or 
when combined with L-DOPA. All anticholinergics appeared to reduce maximal L-
DOPA activity while extending its duration, which might be clinically useful. This 
could also indicate, that they may delay absorption of L-DOPA, nevertheless, 
undertaken pharmacokinetic analysis did not confirm this postulation. 
5.4.1 The effect of anticholinergics on motor symptoms in MPTP-treated 
marmosets 
Although the use of anticholinergics in the symptomatic treatment of PD have been 
supplanted by more efficacious dopamine agonists and L-DOPA, anticholinergics are 
still frequently prescribed, mainly in the early stages of the disease, where tremor is 
predominant and in PD-related dystonia (Brocks, 1999; Fox et al., 2011). Despite this, 
the occurrence of often unpleasant and severe side effects limits their use, as the 
currently used compounds are non-selective for the specific subtype of muscarinic 
receptor. The imbalance between the striatal DA and ACh systems has long been 
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implicated in the regulation of movement disorders (Pisani et al., 2007; Aosaki et al., 
2010; Lester et al., 2010) and preclinical animal studies, including those described in 
this thesis and in previous publications, have indicated involvement of striatal 
muscarinic M4 receptors in the regulation of motor control (Mayorga et al., 1999; 
Karasawa et al., 2003; Betz et al., 2007). For this reason initially the effects of centrally 
acting anticholinergics were investigated on the improvement of motor symptoms 
when administered alone, without L-DOPA, in MPTP-treated marmosets with a view 
to establishing if indeed the M4 receptor is a viable target. The antimuscarinics used 
in the current study are used clinically and included the non-selective antagonist 
(scopolamine), and the M1 selective (trihexyphenidyl and benztropine). Generally, the 
results demonstrate that these antimuscarinics scopolamine, trihexyphenidyl and 
benztropine improved locomotion and reduced motor disability seen in animals treated 
with the MPTP, which is in agreement with previously published studies (Close et al., 
1990; Jackson et al., 2014), and with respect to the latter, reflect their clinical use. The 
findings from previous rodent studies indicate that in general anticholinergic drugs 
increase locomotor activity (Crofton et al., 1991; Sipos et al., 1999). Scopolamine 
reversed motor disability, whereas methylscopolamine failed to show any effect on 
parkinsonian symptoms, indicating the central involvement in this process as shown 
previously in the rodent studies (Chapter 3). This is also in agreement with previously 
conducted studies in our lab (Jackson et al., 2014). Despite all the positive effect of 
centrally acting drugs described above, the M4 selective NBI-675 antimuscarinic 
failed to ameliorate parkinsonian symptoms. The reasons for the lack of effect of 
selective muscarinic M4 antagonist in modulation of motor dysfunction in PD is not 
clear. Inhibitory M4 receptors are predominantly expressed postsynaptically on D1-
MSN where they show inhibitory control on D1-mediated locomotor stimulation 
(Gomeza et al., 1999a; Santiago & Potter, 2001; Pisani et al., 2007). However, M4 are 
also located presynaptically, together with M2 receptors on ChI terminals, and they 
function as autoreceptors inhibiting ACh release (Kreitzer, 2009). It has been reported 
that rather than causing an increase of ACh release by loss of D2 inhibition, the loss 
in striatal dopamine reduces M4 autoreceptor signalling in the ChI following 
attenuation of M4 muscarinic autoreceptor coupling to Cav2 Ca2+ channels (and K+ 
channels) regulating acetylcholine release and spiking (Ding et al., 2006). Therefore, 
the antagonism of M4 autoreceptors could result in proparkinsonian rather than 
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antiparkinsonian effect in the case of striatal DA denervation. However, in the present 
study this pro-parkinsonian effect was not observed suggesting that other M4 mediated 
pathways are affected. In the parkinsonian state, the direct pathway is hypoactive due 
to loss of D1 activation, whereas the indirect pathway is hyperactive due to the loss of 
D2 inhibition. It has been previously shown by using selective M1 antagonists, that 
inhibition of excitatory M1 receptors located on both the direct and indirect MSN, can 
inhibit activity of both output pathways (Ding et al., 2011; Erosa-Rivero et al., 2014) 
thus opposing the loss of DA on the direct pathway, but enhancing its effect on the 
indirect pathway. While non-M4 selective compound improved locomotion and 
parkinsonian symptoms in this study using MPTP-treated marmoset model, therefore 
perhaps M1 receptors are the subtypes of receptors as antiparkinsonian drug targets. 
However, targeting the M1 receptors, may result in severe side effect, due to their 
location in the CNS and periphery, as described in Chapter 1.  
5.4.2 The effect of anticholinergics on L-DOPA-induced motor symptoms in 
MPTP-treated marmosets 
The effect of pre-treatment with anticholinergics on L-DOPA-induced improvement 
of parkinsonian symptoms was also investigated to assess whether they would alter 
the L-DOPA response. All clinically used centrally and peripherally acting 
anticholinergics reduced the peak effect of L-DOPA resulting in a decrease of maximal 
activity while increase in locomotor activity was extended, which agrees with previous 
observations (Jackson et al., 2014). These results are in agreement with the limited 
number of clinical studies where the overall improvement in tremor, bradykinesia and 
rigidity on the comparison of anticholinergic and dopaminergic therapy was reported 
(Parkes et al., 1974; Koller, 1986). In addition, centrally acting anticholinergics in 
combination with L-DOPA improved parkinsonian disability, whereas peripherally 
acting methylscopolamine appeared to block the L-DOPA improvement of motor 
deficits. This effect is unexpected to be seen since the brain penetration of 
methylscopolamine is rather poor (Crofton et al., 1991), although studies on squirrel 
monkey have shown that methylscopolamine can cross the BBB, but at the dose about 
10 times higher to that of scopolamine (Pakarinen & Moerschbaecher, 1993), so 
unlikely to be of importance in this study. Moreover, Crofton and colleagues (1991) 
compared studies from various laboratories utilizing different devices to monitor 
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motor activity and the effect of numerous drugs on motor functions in rats. Among 
many, they found that in majority of the tests, methylscopolamine showed either no 
effect on motor activity or small non-dose dependent decrease (Crofton et al., 1991). 
The possible explanation to the effect seen in these studies could involve the strong 
inhibitory effect of methylscopolamine on peripherally located muscarinic receptors.  
The selective M4 antagonist NBI-675 did not improve the L-DOPA-induced 
antiparkinsonian effect nor reversal of motor deficits in MPTP-treated marmosets, 
indeed, the highest dose of the NBI-675 tended to suppress the L-DOPA activity. The 
reason for this is unclear, but could be a consequence of its effect on the CNS. It has 
been reported and it is well known that anticholinergics cause many central side 
effects, including drowsiness or confusion (Wawruch et al., 2012), making animals 
less able to conduct motor movement. Additionally, higher doses of the compound 
might have led to loss of receptor selectivity. As it was observed in rat studies in this 
thesis (Chapter 3 and 4) higher doses of anticholinergics, including NBI-675, produced 
somnolence, recumbency and overall reduced motion. Cognitive side effects, 
including sedation and memory impairments, are important dose limiting issues in 
human use. There is a number of assessments which could be used to test learning and 
memory in animals, and these include Morris water maze or Y-maze (T-maze), used 
mainly in rodents, while Wisconsin General Test Apparatus (WGTA) was mainly 
designed to be used in non-human primates. 
The failure of the improvement of parkinsonian disability in the current study could 
perhaps be related to the in vitro affinity constant of the compound as the selectivity 
in vivo could have changed and could be different in living cells and isolated 
membranes (Saunders et al., 1996). However, if this would be the case, the compound 
would have not been effective in blocking the pilocarpine-induced chewing 
movements in Chapter 3. 
With the overall improvement of motor function evoked by anticholinergic drugs, the 
duration of the L-DOPA effect was prolonged, and we proposed that was caused by 
decrease in L-DOPA absorption due to a delay in gastric emptying of L-DOPA in 
plasma. The results correlate closely to that seen in man and reported previously in 
both preclinical and clinical studies which have indicated that combination of 
anticholinergics with L-DOPA could alter the plasma concentration of L-DOPA 
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(Algeri et al., 1976; Contin et al., 1991; Djaldetti et al., 1996; Roberts et al., 1996). 
As seen with the clinically used anticholinergics, NBI-675 also delayed the decrease 
in peak effect of L-DOPA and prolonged duration of activity, the PK study of blood 
plasma resulted in no significant effect of the NBI-675 on L-DOPA concentration, 
indicating that the antimuscarinic has no effect on L-DOPA concentration in the blood 
plasma. Perhaps this could be caused by small sample size, or not sufficient time points 
of blood samples.  
5.5 Conclusion  
In conclusion, this study showed that cholinergic system plays a role in mediation of 
motor control, however, the mechanism is not entirely clear. Contrary to the results 
obtained in the Chapter 3 on the effect of the selective M4 antagonist in reduction of 
involuntary movements, the hypothesis of this chapter is rejected, since the selective 
muscarinic M4 antagonist NBI-675 has shown no effect in the improvement of 
parkinsonian disability produced by MPTP treatment in the common marmoset. 
However, since the NBI-675 suppressed involuntary movements in rats, as shown in 
Chapter 3, therefore it is important to test whether this inhibitory effect would be 
replicated in higher species, where dyskinesia, and particularly dystonia, is a 
debilitating symptom of L-DOPA therapy. Therefore, the subsequent study will 
explore, whether administration of NBI-675 to MPTP-treated common marmoset will 

















Chapter 6 The effect of anticholinergic therapy on L-





6.1. Introduction  
In the preceding chapter it was reported that selective inhibition of muscarinic M4 
receptors was ineffective in improvement of motor symptoms in MPTP-treated 
marmoset when administered alone or in combination with L-DOPA. However, since 
the results from Chapter 3 indicate that muscarinic M4 receptors are involved in the 
mediation of involuntary movements in rats, and substantial evidence from the 
literature that cholinergic system plays a role in dyskinesia (Bezard et al., 2001), it is 
important to test whether selective muscarinic M4 inhibition would alter L-DOPA-
induced dyskinesia in the MPTP-treated marmoset.  
As previously described (Chapter 2) MPTP-treated primate model is highly 
reproducible and reflects symptoms and neurophysiological changes observed in man 
(Fox et al., 2011). Chronic L-DOPA treatment results in the onset of L-DOPA-induced 
dyskinesia (LID), including chorea, dystonia and athetosis, closely resembling 
dyskinesia seen in idiopathic PD (Burns et al., 1983; Jenner, 2003a), thus this model 
closely mimics these characteristics of drug treatment that appears in man. LID have 
high prevalence, being observed in approximately 40% of patients within 5 years of 
initiation of L-DOPA, rising to approximately 90% after 10 years (Ahlskog & 
Muenter, 2001; Fabbrini et al., 2007). In some cases, LID can be more debilitating 
than the disease itself and in many patients significantly may affect quality of life.  For 
this reason, it is essential to find alternative treatment strategies that could reduce the 
expression of dyskinesia.  
Pathological alterations in the striatal ACh signalling are associated with the 
expression of dyskinesia (Ding et al., 2006; Ding et al., 2011). Currently, 
anticholinergics are used in PD primarily for the treatment of tremor and dystonia in 
PD (Fox et al., 2011), although the dystonia differs to the idiopathic type previously 
discussed (Chapter 3).  It can be divided into “off” and “on” dystonia.  “Off” dystonia 
usually manifests either in the early morning or during the “wearing off” of L-DOPA 
(Poewe et al., 1988). “On” dystonia is seen as a part of L-DOPA-induced dyskinesia 
and correlates with antiparkinsonian effect once the patient is primed.  
Previous studies have demonstrated beneficial effect of anticholinergics in the 
treatment of dystonia in PD (Pourcher et al., 1989), however, there has been a number 
of reports in PD patients showing that anticholinergic treatment can trigger dyskinesia, 
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mainly oro-buccal dystonia (Hauser & Olanow, 1993) as well as choreic movements 
(Linazasoro, 1994) and abnormal movements of limbs (Birket‐Smith, 1974). 
The role of anticholinergics in LID in animal models of PD is equivocal as there is 
limited number of studies looking at the effects of anticholinergics and LID. It has 
been reported that muscarinic antagonist dicyclomine reduced expression of 
dyskinesia in a mouse model of LID (Ding et al., 2011). By contrast, studies in non-
human primates show that non-selective antimuscarinics had no effect on overall 
expression of LID in MPTP-treated primates, although the drugs altered the nature of 
dyskinesia from dystonia to chorea (Gomez-Mancilla & Bedard, 1993; Jackson et al., 
2014). Despite the mixed reports, these findings support the idea of an involvement of 
cholinergic transmission in mediation of expression of LID. However, there was no 
attempt to interrogate the subclass of muscarinic receptor involved, as the 
antimuscarinics used in these studies were non-selective.  The finding that the M4 
antagonist NBI-675 reduced the expression of pilocarpine-induced perioral 
movements suggests a role in reducing dystonia expression in PD.  For this reason, for 
the first time, the effect of selective antagonism of the M4 muscarinic receptor on the 
expression of L-DOPA-induced dyskinesia (dystonia/chorea) has been investigated in 
MPTP-treated marmoset previously primed to L-DOPA. 
6.1.1. Hypothesis 
It is hypothesised that selective antagonism of muscarinic M4 receptors will reduce 
the expression of L-DOPA-induced dyskinesia and dystonia. 
6.1.2. Aims 
Specific aims of this study were to: 
1) Confirm that L-DOPA induces dyskinesia, including dystonia and chorea, in 
MPTP-treated common marmosets.  
2) Determine the role of anticholinergics of different selectivity to muscarinic 
receptor on expression of L-DOPA-induced dyskinesia, including dystonia and 
chorea, and specifically the role of selective M4 muscarinic receptors 




6.2 Materials and Methods 
In order to address these aims the following studies were performed: 
1) The effect of L-DOPA on the expression of dyskinesia was determined in MPTP-treated 
common marmosets previously primed to exhibit dyskinesia by chronic L-DOPA therapy. 
2) The role of clinically used anticholinergics alone and their effect on L-DOPA-
induced expression of dyskinesia (dystonia and chorea) was investigated by treating 
MPTP-treated common marmosets with peripheral and central acting 
anticholinergics 1 hr prior to L-DOPA or vehicle. Changes in expression of 
dyskinesia (dystonia and chorea) were assessed to determine drug effect.  
3) The role of the M4 muscarinic receptor in L-DOPA-induced expression of 
dyskinesia (dystonia and chorea) was investigated using the novel selective M4 
antagonist NBI-675 administered to MPTP-treated common marmosets 1 hr prior 
to L-DOPA or vehicle. Changes in expression of dyskinesia (dystonia and chorea) 
were assessed to determine drug effect.  
An overview is described below, but detailed methodology are to be found in Chapter 
2.     
 
6.2.1 Animals 
Adult common marmosets (Callithrix Jacchus) (Harlan, UK, 350 – 500 g, n = 6-8 per 
group) of either sex, previously treated with MPTP as described in Chapter 2 section 
2.2.3.1 were used in this study. Animals were housed singly or in pairs (mixed ♂♀or 
single sex ♀♀) in controlled environment suitable for the species (temperature 25 ± 
1°C with 50% relative humidity on a 12 hour light/dark cycle). All animals had ad 
libitum access to water and Mazuri food pellets and received two meals each day. 
Animals were previously primed with L-DOPA and were not drug naïve prior to the 
study. Full details are described in section 2.2.3.1 Chapter 2.  
All experiments were carried out in accordance with Home Office regulations under 





6.2.2 Behavioural assessment  
As described in Chapter 2, all behavioural assessments were carried out between the 
hours 7.00 am and 3.00 pm. Animals were given 60 min acclimatization in the test 
cages prior to drug treatment. Dyskinesia with dystonia and chorea assessment was 
assessed and scored at the same time as motor disability, and performed for 1 hr before 
(baseline score) and 6 hr after anticholinergics/vehicle administration, by experienced 
observers blinded to the drug treatment through one-way mirror during the last 10 min 
consecutive 30 min intervals. Full description of assessment criteria are provided in 
Chapter 2 section 2.2.3.3. 
Locomotor activity, motor disability and dyskinesia with dystonia and chorea, were 
assessed during one experiment and on the same animals, however, for the clarity, 
behavioural outcomes were split into two chapters to assess the effects of 
anticholinergics on motor function (Chapter 5) and on L-DOPA-induced dyskinesia 
(Chapter 6).   
6.2.3 Drug treatment 
Full details of drug preparation and treatment are described in Chapter 2 section 
2.2.3.4. Briefly, animals were placed into the testing units. Following the 60 min 
acclimatisation period which provided baseline activity data, animals were dosed with 
appropriate anticholinergic or vehicle (s.c. or p.o.) followed by L-DOPA + benserazide 
or vehicle 60 min later. Doses of anticholinergics are presented in Table 6.1. 
Behavioural assessment was then carried out as described in Chapter 2 section 2.2.3.3.  
A repeated crossover design was used, so each marmoset was treated with all doses of 
a single drug or vehicle with at least 72 hr wash-out between the tests. A typical 
modified Latin square was used to randomise drug treatments and is shown in Chapter 
2 Table 2.2.  
Dyskinesia with dystonia and chorea was scored immediately before each drug 
treatment and then every 30 minutes for 10 minute periods throughout the study for up 
to 5 hours, as shown in Chapter 2 Figure 2.7.   









6.2.4 Statistical analysis  
Data and statistical analysis were performed using GraphPad Prism 5.02 (San Diego, 
CA, USA) as described in Section 2.2.3.5, Chapter 2. The statistical analysis for 
dyskinesia, dystonia and chorea data was performed as follows: 
1) No statistical analysis was performed on time course data; 
2) Totals (AUC-1-0h) and (AUC0-5h) and Peak data were transformed by square 
root (Y=√Y). 
3) Totals (AUC-1-0h) and (AUC0-5h), Peak, On-time, On-time > 2 were analysed 




Drug Dose and route
Benztropine 0.25 & 0.5 mg/kg s.c.
Scopolamine 0.1 & 0.3 mg/kg s.c.
Methylscopolamine 0.1 & 0.3 mg/kg s.c.
Trihexyphenidyl 0.5 & 1 mg/kg p.o.
NBI-675 1, 5 & 7.5 mg/kg p.o.





In all studies vehicle-A-vehicle-B administration had no effect on induction of 
dyskinesia, dystonia and chorea over time in MPTP-treated common marmosets (Fig. 
6.1 – 6.15).  
As described in section 5.3, following the acclimatisation time, and in the absence of 
L-DOPA, animals appeared akinetic and hunched, either sitting on the cage floor or 
on the perches. They were often staring in one direction, and at times looked sleepy, 
however, occasional alertness with head checking and overall slow movements were 
also present.   Their locomotor activity scores were low with little variability (as 
described in Section 5.3) reflecting the akinesia, and their motor disability scores were 
high, as expected for a parkinsonian marmoset.  Their dyskinesia (t=-1-0, median 0; 
range 0 – 4), dystonia (t=-1-0, median 0; range 0 – 4) and chorea (t=-1-0, median 0; 
range 0 – 3). 
As expected, administration of L-DOPA alone induced moderate to severe dyskinesia, 
dystonia and chorea. The duration of L-DOPA-induced dyskinesia was between 3 and 
3.5 hrs with a peak effect ranging between 30 min to 2 hrs after L-DOPA 
administration. This resulted in a significant induction of dyskinesia as measured by 
increased total scores (AUC0-5h) (Fig. 6.1 B, 6.4 B, 6.7 B, 6.10 B & 6.13 B), on-time 
(Fig. 6.1 C, 6.4 C, 6.7 C & 6.10 C), and on-time > 2 (Fig. 6.1 D, 6.4 D & 6.7 D) and 
peak (Fig. 6. 1 E, 6.4 E, 6.7 E, 6.10 E & 6.13 E) when compared to vehicle-B-treated 
animals.  
The duration of L-DOPA-induced dystonia was between 2.5 and 3.5 hrs with a peak 
at 1 to 2 hrs after L-DOPA administration. This produced a significant induction of 
dystonia as measured by total scores (AUC0-5h) (Fig. 6.2 B, 6.5 B, 6.8 B & 6.11 B), 
on-time (Fig. 6.2 C, 6.5 C, 6.8 C & 6.11 C), on-time > 2 (Fig. 6.2 D & 6.5 D) and peak 
(Fig. 6.2 E, 6.5 E, 6.8 E & 6.11 E) when compared to vehicle-B treatment.  
Similarly, the duration of L-DOPA-induced chorea was between 2.5 and 3 hrs with a 
peak at 30 min to 1.5 hrs after L-DOPA administration. This resulted in a significant 
induction of chorea as measured by total scores (AUC0-5h) (Fig. 6.3 B, 6.6 B, 6.9 B, 
6.12 B & 6.15 B), on-time (Fig. 6.3 C, 6.6 C, 6.9 C, 6.12 C & 6.15 C), on-time > 2 
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(Fig. 6.3 D & 6.6 D) and peak (Fig. 6.3 E, 6.6 E, 6.9 E, 6.12 E & 6.15 E) when 
compared to vehicle-B treatment.  
6.3.1 The effect of non-selective anticholinergics  
6.3.1.1 Centrally acting scopolamine 
6.3.1.1.1 Dyskinesia 
Scopolamine alone (0.1 & 0.3 mg/kg) produced an immediate and significant 
induction of dyskinesia over the first hour of treatment (AUC-1-0h) (Fig. 6.1 F). This 
resulted overall in a significant increase in totals (AUC0-5h), on-time and peak scores 
after the L-DOPA/vehicle administration when compared to vehicle-A treatment (Fig. 
6.1 B, C & E).  
Pre-treatment with scopolamine significantly increased the duration of L-DOPA-
induced dyskinesia as measured by on-time and on-time > 2 when compared to L-
DOPA alone (Fig. 6.1 C & D), although there was no significant effect of scopolamine 
on L-DOPA-induced total (AUC0-5h) scores and peak (Fig. 6.1 B & E).  
When compared to scopolamine alone, the combination L-DOPA/scopolamine 
remained significantly greater as measured by totals (AUC0-5h), on-time and on-time 










Figure 6.1 Effect of scopolamine on L-DOPA-induced dyskinesia in MPTP-treated 
common marmosets 
Scopolamine (0.1 & 0.3 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=8) 
A) Dyskinesia time course and B) Total dyskinesia (AUC0-5h), C) On-time, D) On-time > 2 
and E) Peak dyskinesia after L-DOPA/vehicle-B administration; F) Total dyskinesia in the 
first hour after scopolamine/vehicle-A (AUC-1-0h). Data are expressed as time course with 
median values with error bars omitted for clarity (A) and median with individual counts (B – 
F). A) No statistical analysis performed; B – F) Data analysed by repeated measures ANOVA; 
For B, E & F data were transformed y=√y; (B) F=14.89; Df (5,47); p<0.0001; C) F=11.12; Df 
(5,47); p<0.0001; D) F=12.66; Df (5,47); p<0.0001; E) F=12.41; Df (5,47); p<0.0001; F) 
F=21.05; Df (2,23); p<0.0001) followed by Newman-Keuls post hoc test. *p<0.05; **p<0.01; 
***p<0.001.  
Dyskinesia Scopolamine
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0.1 mg/kg + vehicle B 0.1 mg/kg + L-DOPA



















































































































































































































































As with dyskinesia, administration of scopolamine alone (0.1 & 0.3 mg/kg) produced 
an immediate and significant induction of dystonia over the first hour of administration 
(AUC-1-0h) when compared to vehicle-A (Fig.6.2 F). This resulted overall in a 
significant increase in total (AUC0-5h), on-time and peak scores when compared to 
vehicle-A/B-treated animals over the 5 hours after the L-DOPA/vehicle-B 
administration (Fig. 6.2 B, C & E).  
Pre-treatment with scopolamine (0.1 & 0.3 mg/kg) potentiated the duration of L-
DOPA-induced dystonia resulting in a significant increase in on-time (0.3 mg/kg) and 
on-time > 2 scores when compared to L-DOPA alone (Fig. 6.2 C & D), although there 
was no effect on total (AUC0-5h) and peak score (Fig. 6.2 B & E).  
Induction of dystonia by the L-DOPA/scopolamine combination remained 
significantly different to scopolamine alone treatment as measured by total (AUC0-5h), 








Figure 6.2 Effect of scopolamine on L-DOPA-induced dystonia in MPTP-treated 
common marmosets  
Scopolamine (0.1 & 0.3 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=8) 
A) Dystonia time course and B) Total dystonia (AUC0-5h), C) On-time, D) On-time > 2 and E) 
Peak dystonia after L-DOPA/vehicle-B administration; F) Total dystonia in the first hour after 
scopolamine/vehicle (AUC-1-0h). Data are expressed as time course with median values with 
error bars omitted for clarity (A) and median with individual counts (B – F). A) No statistical 
analysis performed; B – F) Data analysed by repeated measures ANOVA; For B, E & F data 
were transformed y=√y; (B) F=13.54; Df (5,47); p<0.0001; C) F=9.885; Df (5,47); p<0.0001; 
D) F=11.04; Df (5,47); p<0.0001; E) F=12.26; Df (5,47); p<0.0001; F) F=16.58; Df (2,23); 
p=0.0002) followed by Newman-Keuls post hoc test *p<0.05; **p<0.01; ***p<0.001.  
Dystonia Scopolamine
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Administration of scopolamine alone (0.1 & 0.3 mg/kg) resulted in a significant 
induction of chorea over first hour of administration (AUC-1-0h), when compared to 
vehicle-A treatment (Fig. 6.3 F), and overall producing a significant effect in total 
(AUC0-5h), on-time and peak over 5 hrs after L-DOPA/vehicle-B administration (Fig. 
6.3 B, C & E).  
Pre-treatment with scopolamine (0.1 & 0.3 mg/kg) significantly increased total (AUC0-
5h) and extended duration of L-DOPA-induced chorea as measured by on-time and on-
time > 2 scores when compared to that produced by L-DOPA alone (Fig. 6.3 C & D), 
although there was no significant effect on peak scores (Fig. 6.3 B & F).  
When compared to scopolamine alone (0.1 & 0.3 mg/kg), the combined L-
DOPA/scopolamine treatment resulted in a significant increase in chorea as measured 











Figure 6.3 Effect of scopolamine on L-DOPA-induced chorea in MPTP-treated common 
marmosets  
Scopolamine (0.1 & 0.3 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=8) 
A) Chorea time course and B) Total chorea (AUC0-5h), C) On-time, D) On-time > 2 and E) 
Peak chorea after L-DOPA/vehicle-B administration; F) Total chorea in the first hour after 
scopolamine/vehicle (AUC-1-0h). Data are expressed as time course with median values with 
error bars omitted for clarity (A) and median with individual counts (B – F). A) No statistical 
analysis performed; B – F) Data analysed by repeated measures ANOVA; For B, E & F data 
were transformed y=√y; (B) F=16.12; Df (5,47); p<0.0001; C) F=11.19; Df (5,47); p<0.0001; 
D) F=10.22; Df (5,47); p<0.0001; E) F=11.96; Df (5,47); p<0.0001; F) F=5.471; Df (2,23); 
p=0.0176) followed by Newman-Keuls post hoc test *p<0.05; **p<0.01; ***p<0.001.  
Chorea Scopolamine
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6.3.1.2 Peripherally acting methylscopolamine  
6.3.1.2.1 Dyskinesia 
Methylscopolamine alone (0.1 & 0.3 mg/kg) had no effect on induction of dyskinesia 
within the first hour of administration (AUC-1-0h) or throughout the 5 hours after L-
DOPA/vehicle-B administration when compared to vehicle treatment (Fig. 6.4 B – F).  
Unexpectedly, pre-treatment with methylscopolamine (0.1 & 0.3 mg/kg) significantly 
reduced L-DOPA-induced dyskinesia as measured by total (AUC0-5h), on-time and 
peak scores when compared to L-DOPA alone (Fig. 6.4 B, C, E), although when 
compared to methylscopolamine alone (0.1 & 0.3 mg/kg), dyskinesia following 
combined L-DOPA/methylscopolamine treatment remained significantly increased as 










Figure 6.4 Effect of methylscopolamine on L-DOPA-induced dyskinesia in MPTP-
treated common marmosets  
A) Dyskinesia time course and B) Total dyskinesia (AUC0-5h), C) On-time, D) On-time > 2 
and E) Peak dyskinesia after L-DOPA/vehicle-B administration; F) Total dyskinesia in the 
first hour after methylscopolamine/vehicle-A (AUC-1-0h). Data are expressed as time course 
with median values with error bars omitted for clarity (A) and median with individual counts 
(B – F). A) No statistical analysis performed; B – F) Data analysed by repeated measures 
ANOVA; For B, E & F data were transformed y=√y; (B) F=15.55; Df (5,47); p<0.0001; C) 
F=12.22; Df (5,47); p<0.0001; D) F=5.590; Df (5,47); p=0.0007; E) F=19.34; Df (5,47); 
p<0.0001; F) F=1.000; Df (2,23); p=0.3927) followed by Newman-Keuls post hoc test 
*p<0.05; **p<0.01; ***p<0.001.  
 
Dyskinesia
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Methylscopolamine alone (0.1 & 0.3 mg/kg) had no effect on induction of dystonia 
within the first hour of administration (AUC-1-0h) and throughout the 5 hours after L-
DOPA/vehicle-B administration when compared to vehicle treatment (Fig. 6.5 B – F).  
As seen with dyskinesia, pre-treatment with methylscopolamine significantly reduced 
L-DOPA-induced dystonia as measured by total (AUC0-5h), on-time, on-time > 2 and 
peak (0.1 mg/kg) when compared to L-DOPA alone (Fig. 6.5 B – E), although when 
compared to methylscopolamine alone (0.1 & 0.3 mg/kg) following combined L-
DOPA/methylscopolamine treatment dystonia remained significantly increased as 








Figure 6.5 Effect of methylscopolamine on L-DOPA-induced dystonia in MPTP-treated 
common marmosets  
Methylscopolamine (0.1 & 0.3 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) 
(n=8) A) Dystonia time course and B) Total dystonia (AUC0-5h), C) On-time, D) On-time > 2 
and E) Peak dystonia after L-DOPA/vehicle-B administration; F) Total dystonia in the first 
hour after methylscopolamine/vehicle-A (AUC-1-0h). Data are expressed as time course with 
median values with error bars omitted for clarity (A) and median with individual counts (B – 
F). A) No statistical analysis performed; B – F) Data analysed by repeated measures ANOVA; 
For B, E & F data were transformed y=√y;  (B) F=15.86; Df (5,47); p<0.0001; C) F=12.20; 
Df (5,47); p<0.0001; D) F=5.650; Df (5,47); p=0.0006; E) F=19.03; Df (5,47); p<0.0001; F) 
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Methylscopolamine alone (0.1 & 0.3 mg/kg) had no effect on induction of chorea 
within the first hour of administration (AUC-1-0h) and throughout the 5 hours after L-
DOPA/vehicle-B administration when compared to vehicle treatment (Fig. 6.6 B – F).  
As seen with dyskinesia and dystonia, pre-treatment with methylscopolamine (0.1 & 
0.3 mg/kg) significantly reduced L-DOPA-induced chorea as measured by total 
(AUC0-5h), on-time, on-time > 2 and peak scores when compared to L-DOPA alone 
(Fig. 6.6 B – E).  
When compared to methylscopolamine alone (0.1 & 0.3 mg/kg) the combined L-
DOPA/methylscopolamine treatment remained significantly increased as measured by 









Figure 6.6 Effect of methylscopolamine on L-DOPA-induced chorea in MPTP-treated 
common marmosets  
Methylscopolamine (0.1 & 0.3 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) 
(n=8) A) Chorea time course and B) Total chorea (AUC0-5h), C) On-time, D) On-time > 2 and 
E) Peak chorea after L-DOPA/vehicle-B administration; F) Total chorea in the first hour after 
methylscopolamine/vehicle-A (AUC-1-0h). Data are expressed as time course with median 
values with error bars omitted for clarity (A) and median with individual counts (B – F). A) 
No statistical analysis performed; B – F) Data analysed by repeated measures ANOVA; For 
B, E & F data were transformed y=√y; (B) F=16.40; Df (5,47); p<0.0001; C) F=10.65; Df 
(5,47); p<0.0001; D) F=5.056; Df (5,47); p=0.0014; E) F=18.84; Df (5,47); p<0.0001; F) 
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6.3.2 Clinically used selective M1 anticholinergics  
6.3.2.1 Trihexyphenidyl  
6.3.2.1.1 Dyskinesia 
Trihexyphenidyl alone (0.5 & 1 mg/kg) produced an immediate and significant 
induction of dyskinesia over the first hour of treatment (AUC-1-0h) when compared to 
vehicle-A (Fig. 6.7 F). This resulted overall in a significant increase in total (AUC0-
5h), on-time and peak scores after L-DOPA/vehicle-B administration when compared 
to vehicle-A/B treatment (Fig. 6.7 B, C & E). 
Pre-treatment with trihexyphenidyl (0.5 & 1 mg/kg) significantly increased the 
duration of L-DOPA-induced dyskinesia as measured by total (AUC0-5h), on-time and 
on-time > 2 (1 mg/kg) when compared to L-DOPA alone (Fig. 6.7 B, C & D), although 
there was no significant effect of trihexyphenidyl on peak scores (Fig. 6.1 E). When 
compared to trihexyphenidyl alone (0.5 & 1 mg/kg) the combination L-
DOPA/trihexyphenidyl remained significantly greater as measured by totals (AUC0-







Figure 6.7 Effect of trihexyphenidyl on L-DOPA-induced dyskinesia in MPTP-treated 
common marmosets  
Trihexyphenidyl (0.5 & 1 mg/kg p.o.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=7) 
A) Dyskinesia time course and B) Total dyskinesia (AUC0-5h), C) On-time, D) On-time > 2 
and E) Peak dyskinesia after L-DOPA/vehicle-B administration; F) Total dyskinesia in the 
first hour after trihexyphenidyl/vehicle-A (AUC-1-0h). Data are expressed as time course with 
median values with error bars omitted for clarity (A) and median with individual counts (B – 
F). A) No statistical analysis performed; B – F) Data analysed by repeated measures ANOVA; 
For B, E & F data were transformed y=√y; (B) F=17.69; Df (5,41); p<0.0001; C) F=27.03; Df 
(5,41); p<0.0001; D) F=9.915; Df (5,41); p<0.0001; E) F=9.882; Df (5,41); p<0.0001; F) 
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Administration of trihexyphenidyl alone (0.5 & 1 mg/kg) produced an immediate and 
significant induction of dystonia over the first hour of administration (AUC-1-0h) when 
compared to vehicle-A-treated animals (Fig. 6.8 F). This resulted in an increase in total 
(AUC0-5h) scores and extended duration of dystonia as measured by on-time, which 
was significantly different to vehicle-A/B treatment (Fig. 6.8 B & C).  
Pre-treatment with trihexyphenidyl (0.5 & 1 mg/kg) had no effect on peak scores but 
significantly increased total (AUC0-5h) scores (1 mg/kg) and duration of L-DOPA-
induced dystonia when compared to L-DOPA alone (Fig. 6.8 B, C & E). When 
compared to trihexyphenidyl alone, the combination L-DOPA/trihexyphenidyl 
remained significantly different to trihexyphenidyl alone as measured by total (AUC0-













Figure 6.8 Effect of trihexyphenidyl on L-DOPA-induced dystonia in MPTP-treated 
common marmosets  
Trihexyphenidyl (0.5 & 1 mg/kg p.o.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=7) 
A) Dystonia time course and B) Total dystonia (AUC0-5h), C) On-time, D) On-time > 2 and E) 
Peak dystonia after L-DOPA/vehicle-B administration; F) Total dystonia in the first hour after 
trihexyphenidyl/vehicle-A (AUC-1-0h). Data are expressed as time course with median values 
with error bars omitted for clarity (A) and median with individual counts (B – F). A) No 
statistical analysis performed; B – F) Data analysed by repeated measures ANOVA; For B, E 
& F data were transformed y=√y; (B) F=14.79; Df (5,41); p<0.0001; C) F=16.88; Df (5,41); 
p<0.0001; D) F=5.822; Df (5,41); p=0.0007; E) F=9.524; Df (5,41); p<0.0001; F) F=4.548; 
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Trihexyphenidyl alone (0.5 & 1 mg/kg) had no effect of induction of chorea over the 
first hour of administration (AUC-1-0h) when compared to vehicle-A treatment (Fig. 
6.9 F), however, produced a significant effect in total (AUC0-5h), on-time and peak 
over 5 hrs after L-DOPA/vehicle-B administration when compared to vehicle-A/B 
treatment (Fig. 6.9 B, C & E).  
Pre-treatment with trihexyphenidyl (0.5 & 1 mg/kg) significantly increased totals 
(AUC0-5h), extended duration of L-DOPA-induced chorea as measured by on-time and 
increased the peak (1 mg/kg) when compared to L-DOPA alone (Fig. 6.9 B. C & E).  
When compared to trihexyphenidyl alone (0.5 & 1 mg/kg), the combined L-
DOPA/trihexyphenidyl treatment remained significantly different as measured by total 





Figure 6.9 Effect of trihexyphenidyl on L-DOPA-induced chorea in MPTP-treated 
common marmosets  
Trihexyphenidyl (0.5 & 1 mg/kg p.o.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=7) 
A) Chorea time course and B) Total chorea (AUC0-5h), C) On-time, D) On-time > 2 and E) 
Peak chorea after L-DOPA/vehicle-B administration; F) Total chorea in the first hour after 
trihexyphenidyl/vehicle-A (AUC-1-0h). Data are expressed as time course with median values 
with error bars omitted for clarity (A) and median with individual counts (B – F). A) No 
statistical analysis performed; B – F) Data analysed by repeated measures ANOVA; For B, E 
& F data were transformed y=√y; (B) F=23.88; Df (5,41); p<0.0001; C) F=34.20; Df (5,41); 
p<0.0001; D) F=6.534; Df (5,41); p=0.0003; E) F=12.20; Df (5,41); p<0.0001; F) F=2.967; 
Df (5,41); p=0.0897) followed by Newman-Keuls post hoc test *p<0.05; **p<0.01; 
***p<0.001.  
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Benztropine alone (0.25 & 0.5 mg/kg) immediately and significantly induced 
dyskinesia over the first hour of administration (AUC-1-0h) when compared to vehicle-
A treatment (Fig. 6.10 F). This resulted overall in a significant increase in total (AUC0-
5h), on-time and peak over the 5 hours after L-DOPA/vehicle-B administration when 
compared to vehicle-A/B treatment (Fig. 6.10 C & E).  
Pre-treatment with benztropine (0.25 & 0.5 mg/kg) had no effect on L-DOPA-induced 
dyskinesia when compared to L-DOPA alone (Fig. 6.10 B – E), however, when 
compared to benztropine alone, the combination L-DOPA/benztropine treatment 
resulted in a significant increase in total (AUC0-5h) scores and on-time at the lower 








Figure 6.10 Effect of benztropine on L-DOPA-dyskinesia in MPTP-treated common 
marmosets  
Benztropine (0.25 & 0.5 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=7) 
A) Dyskinesia time course and B) Total dyskinesia (AUC0-5h), C) On-time, D) On-time > 2 
and E) Peak dyskinesia after L-DOPA/vehicle-B administration; F) Total dyskinesia in the 
first hour after benztropine/ vehicle-A (AUC-1-0h). Data are expressed as time course with 
median values with error bars omitted for clarity (A) and median with individual counts (B – 
F). A) No statistical analysis performed; B – F) Data analysed by repeated measures ANOVA; 
For B, E & F data were transformed y=√y; (B) F=10.81; Df (5,41); p<0.0001; C) F=11.13; Df 
(5,41); p<0.0001; D) F=3.845 Df (5,41); p=0.0082; E) F=10.10; Df (5,41); p<0.0001; F) 
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Administration of benztropine alone (0.25 & 0.5 mg/kg) produced an immediate and 
significant induction of dystonia over the first hour (AUC-1-0h) when compared to 
vehicle-A-treated animals (Fig. 6.11 F). This resulted in an extended duration of 
dystonia as measured by on-time and peak at the higher dose (0.5 mg/kg) over the 5 
hrs, which was significantly different to vehicle-A/B treatment (Fig. 6.11 C & E).  
Pre-treatment with benztropine (0.25 & 0.5 mg/kg) had no effect on L-DOPA-induced 
dystonia when compared to L-DOPA treatment (Fig. 6.11 B – E). There was no effect 
of the combination L-DOPA/benztropine treatment when compared to benztropine 
alone as measured by total (AUC0-5h), scores on-time, on-time > 2 or peak (Fig. 6.11 







Figure 6.11 Effect of benztropine on L-DOPA-induced dystonia in MPTP-treated 
common marmosets  
Benztropine (0.25 & 0.5 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=7)   
A) Dystonia time course and B) Total dystonia (AUC0-5h), C) On-time, D) On-time > 2 and E) 
Peak dystonia after L-DOPA/vehicle-B administration; F) Total dystonia in the first hour after 
benztropine/vehicle-A (AUC-1-0h). Data are expressed as time course with median values with 
error bars omitted for clarity (A) and median with individual counts (B – F). A) No statistical 
analysis performed; B – F) Data analysed by repeated measures ANOVA; For B, E & F data 
were transformed y=√y; (B) F=7.542; Df (5,41); p=0.0001; C) F=6.237; Df (5,41); p=0.0004; 
D) F=3.913; Df (5,41); p=0.0075; E) F=9.390; Df (5,41)p<0.0001; F) F=6.681; Df (5,41); 
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Benztropine alone (0.25 & 0.5 mg/kg) produced immediate and significant induction 
of chorea over the first hour (AUC-1-0h) when compared to vehicle-A-treated animals 
(Fig. 6.12 F). This produced a significant effect in total (AUC0-5h) and peak scores, and 
on-time over the 5 hrs when compared to vehicle-A/B treatment (Fig. 6.12 B, C & F).  
Pre-treatment with benztropine (0.25 & 0.5 mg/kg) significantly extended the duration 
of L-DOPA-induced chorea when compared to L-DOPA alone (Fig. 6.12 C). When 
compared to benztropine alone (0.25 & 0.5 mg/kg), the combined L-
DOPA/benztropine treatment remained significantly different as measured by total 






Figure 6.12 Effect of benztropine on L-DOPA-induced chorea in MPTP-treated common 
marmosets  
Benztropine (0.25 & 0.5 mg/kg s.c.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=7) 
A) Chorea time course and B) Total chorea (AUC0-5h), C) On-time, D) On-time > 2 and E) 
Peak chorea after L-DOPA/vehicle-B administration; F) Total chorea in the first hour after 
benztropine/vehicle-A (AUC-1-0h). Data are expressed as time course with median values with 
error bars omitted for clarity (A) and median with individual counts (B – F). A) No statistical 
analysis performed; B – F) Data analysed by repeated measures ANOVA; For B, E & F data 
were transformed y=√y; (B) F=11.36; Df (5,41); p<0.0001; C) F=11.72; Df (5,41); p<0.0001; 
D) F=1.063; Df (5,41); p=0.4003; E) F=8.756; Df (5,41); p<0.0001; F) F=8.670; Df (5,41); 
p=0.0047) followed by Newman-Keuls post hoc test *p<0.05; **p<0.01; ***p<0.001.  
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6.3.3 Selective M4 antagonist - NBI-675  
6.3.3.1 Dyskinesia 
NBI-675 alone (1 – 7.5 mg/kg) had no effect on induction of dyskinesia over the first 
hour (AUC-1-0h) and over the 5 hours (AUC0-5.5h) after the L-DOPA/vehicle-B 
administration when compared to vehicle-A/B treatment (Fig. 6.13 B – F).  
Pre-treatment with NBI-675 (1 – 7.5 mg/kg) had no effect on L-DOPA-induced 
dyskinesia when compared to L-DOPA alone (Fig. 6.13 B – E), however, when 
compared to NBI-675 alone, the combination L-DOPA/NBI-675 treatment remained 
significantly different as measured by total scores (AUC0-5.5h) (1 & 5 mg/kg), on-time 
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Figure 6.13 Effect of NBI-675 on L-DOPA-induced dyskinesia in MPTP-treated common 
marmosets  
NBI-675 (1 – 7.5 mg/kg p.o.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=6)                 
A) Dyskinesia time course and B) Total dyskinesia (AUC0-5.5h); C) On-time, D) On-time > 2 
and E) Peak dyskinesia after L-DOPA/vehicle-B administration; F) Total dyskinesia in the 
first hour after NBI-675/vehicle-A (AUC-1-0h). Data are expressed as time course with median 
values with error bars omitted for clarity (A) and median with individual counts (B – F). A) 
No statistical analysis performed; B – F) Data analysed by repeated measures ANOVA; For 
B, E & F data were transformed y=√y; (B) F=6.513; Df (7,47); p<0.0001; C) F=6.183; Df 
(7,47); p<0.0001; D) F=1.546; Df (7,47); p=0.1843; E) F=8.016; Df (7,47); p<0.0001; F) 






NBI-675 alone (1 – 7.5 mg/kg) had no effect on induction of dystonia over the first 
hour (AUC-1-0h) when compared to vehicle-A (Fig. 6.14 F) and no effect over the 5 hrs 
(AUC0-5.5h) after the L-DOPA/vehicle-B administration when compared to vehicle-
A/B treatment (Fig. 6.14 B – E).  
Pre-treatment with NBI-675 (1 – 7.5 mg/kg) had no significant effect on L-DOPA-
induced dystonia (Fig. 6.14 B – E), however, when compared to NBI-675 alone, the 
combination L-DOPA/NBI-675 treatment remained significantly different as 
measured by total (AUC0-5.5h) (5 mg/kg) and on-time at the middle dose (5 mg/kg), 
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Figure 6.14 Effect of NBI-675 on L-DOPA-induced dystonia in MPTP-treated common 
marmosets  
NBI-675 (1 – 7.5 mg/kg p.o.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=6)                 
A) Dystonia time course and B) Total dystonia (AUC0-5.5h), C) On-time, D) On-time > 2 and 
E) Peak dystonia after L-DOPA/vehicle-B administration; F) Total dystonia in the first hour 
after NBI-675/vehicle-A (AUC-1-0h). Data are expressed as time course with median values 
with error bars omitted for clarity (A) and median with individual counts (B – F). A) No 
statistical analysis performed; B – F) Data analysed by repeated measures ANOVA; For B, E 
& F data were transformed y=√y; (B) F=4.604; Df (7,47); p=0.0010; C) F=4.685; Df (7,47); 
p=0.0009; D) F=2.175; Df (7,47); p=0.0608; E) F=5.073; Df (7,47); p=0.0005; F) F=3.143; 




NBI-675 alone (1 – 7.5 mg/kg) produced a significant induction of chorea at the 
highest dose (7.5 mg/kg) over the first hour (AUC-1-0h) when compared to vehicle-A 
treatment (Fig. 6.15 F), however, there was no effect over the 5 hrs (AUC0-5.5h) after 
the L-DOPA/vehicle-B administration, when compared to vehicle-A/B (Fig. 6.15 B – 
E).  
Pre-treatment with NBI-675 had no effect on L-DOPA-induced chorea when 
compared to L-DOPA alone (Fig. 6.15 B – E), however, the combination L-
DOPA/NBI-675 treatment remained significantly different as measured by total 
(AUC0-5.5h) scores (1 & 5 mg/kg) and on-time (5 mg/kg), whereas the peak tended to 















vehicle + vehicle vehicle + L-DOPA
NBI-675 1 mg/kg + vehicle NBI-675 1 mg/kg + L-DOPA
NBI-675 5 mg/kg + vehicle NBI-675 5 mg/kg + L-DOPA






































































































































































































































Figure 6.15 Effect of NBI-675 on L-DOPA-induced chorea in MPTP-treated common 
marmosets  
NBI-675 (1 – 7.5 mg/kg p.o.), L-DOPA (8 mg/kg + benserazide 10 mg/kg p.o.) (n=6)                 
A) Chorea time course and B) Total chorea (AUC0-5.5h), C) On-time, D) On-time > 2 and E) 
Peak chorea after L-DOPA/vehicle-B administration; F) Total chorea in the first hour after 
NBI-675/vehicle-A (AUC-1-0h). Data are expressed as time course with median values with 
error bars omitted for clarity (A) and median with individual counts (B – F). A) No statistical 
analysis performed; B – F) Data analysed by repeated measures ANOVA; For B, E & F data 
were transformed y=√y; (B) F=7.530; Df (7,47); p<0.0001; C) F=5.074; Df (7,47); p=0.0005; 
D) F=1.682; Df (7,47); p=0.1456; E) F=5.067; Df (7,47); p=0.0005; F) F=5.063; Df (3,23); 




6.4 Discussion  
The purpose of these studies was to investigate the effects of antagonism of muscarinic 
receptors with a special emphasis on the muscarinic M4 subtype on the expression of 
LID and particularly dystonia in MPTP-treated marmosets using clinically utilised 
non-selective or non-M4 selective anticholinergics. It was hypothesised that selective 
antagonism of muscarinic M4 receptors with NBI-675 will reduce the expression of 
L-DOPA-induced dyskinesia and dystonia. 
The present study in MPTP-treated marmosets showed that administration of centrally 
acting non-selective (scopolamine) and with preferential selectivity to M1 receptor 
(trihexyphenidyl and benztropine) anticholinergics induce dyskinesia with dystonia 
and chorea. Additionally, these compounds potentiated L-DOPA-induced dyskinesia. 
In contrast, the novel selective M4 antagonist, NBI-675 alone, showed no significant 
effect on induction of dyskinesia and dystonia, however, at the highest dose some 
chorea was expressed. Similarly, there was no effect of NBI-675 on L-DOPA-induced 
dyskinesia, however, the highest dose of the compound tended to reduce the severity 
of the dyskinesia.  Peripherally acting non-selective methylscopolamine had no effect 
on induction of dyskinesia, dystonia or chorea when administered alone, but 
unexpectedly a significant reduction of L-DOPA-induced dyskinesia with dystonia 
and chorea was observed in this study.  
Dyskinesia is the most frequent side effect of long term L-DOPA therapy in PD 
patients. It is also exhibited in the MPTP-treated primates, once the priming process is 
established, every subsequent use of L-DOPA or dopamine agonists induces 
dyskinetic episodes. Therefore, in the current study, initially it was confirmed that 
animals exhibited a reproducible onset of dyskinesia, manifested by dystonia and 
chorea, after the administration of L-DOPA alone. This effect was as expected and as 
previously reported (Pearce et al., 1995; Kuoppamaki et al., 2007). Generally, the 
severity of dyskinesia reflects the degree of disability and akinesia, where the least 
disabled animals display milder dyskinesia and this correlates with the degree of 
nigrostriatal damage (Pearce et al., 1995). This is similar to dyskinesia observed in PD 
patients, where likelihood of dyskinesia developing in more advanced disease is high 
and usually is exhibited on the most severely impaired side, thus the likely prevalence 
and severity of dyskinesia correlates with a degree of striatal denervation (Marconi et 
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al., 1994). Commonly, L-DOPA produces a rapid onset of improvement of motor 
symptoms which is accompanied by onset of dyskinesia, manifested by dystonia and 
chorea (Kuoppamaki et al., 2007). This was also observed in this study. Both dystonia 
and rapid choreic movements were predominantly seen at a peak of L-DOPA duration 
in MPTP-treated marmosets. Often during the peak-dose dyskinesia, animals appeared 
akinetic, and were exhibiting dystonia induced by L-DOPA, which was making them 
less active, and as a result their locomotor activity was lower (Kuoppamaki et al., 
2002).  
6.4.1 The effect of administration of anticholinergics on expression of dyskinesia 
in MPTP-treated marmosets 
Administration of clinically used centrally acting anticholinergics, scopolamine, 
trihexyphenidyl and benztropine alone, resulted in almost immediate induction of 
dyskinesia, consisting of both dystonia and chorea. Previously, it has been reported 
that anticholinergic treatment induced dyskinesia in parkinsonian patients who were 
not being treated previously with L-DOPA (Birket‐Smith, 1974; Hauser & Olanow, 
1993; Linazasoro, 1994). The dyskinesia seen in PD sufferers induced by 
anticholinergics comprised mainly of oro-buccal form, however, it was also 
manifested as generalised choreic movements. Withdrawal of anticholinergics resulted 
in cessation of dyskinesia (Birket‐Smith, 1974; Hauser & Olanow, 1993; Linazasoro, 
1994). In contrast to the above clinical studies, the manifestation of dyskinesia induced 
by anticholinergics in the MPTP-treated marmosets was short-lasting and manifested 
mainly as chorea, with choreic movements of arms and legs, and dystonia, 
predominantly seen in the trunk and hip. Animals returned to their baseline shortly 
after the onset. This dyskinetic effect, however, appears to be centrally mediated since 
peripheral methylscopolamine had no effect on expression of dyskinesia, neither 
dystonia nor chorea, and it is in agreement with previous studies (Jackson et al., 2014). 
Interestingly, in contrast to the effect of centrally acting anticholinergics, the highly 
selective M4 antagonist NBI-675 induced dystonia and chorea only at the highest dose, 




6.4.2 The effect of pre-treatment with anticholinergics on L-DOPA-induced 
dyskinesia in MPTP-treated marmosets  
Pre-treatment with centrally acting scopolamine and M1 selective trihexyphenidyl 
significantly potentiated the effect and extended L-DOPA-induced duration of 
dyskinesia with both manifestation of dystonia and chorea in MPTP-treated 
marmosets, whereas benztropine showed a tendency to potentiate and extend L-DOPA 
effect on induction of dyskinesia and dystonia, while significantly extending the 
duration of L-DOPA-induced chorea. It has been reported in PD patients that the 
combination of L-DOPA with anticholinergics improve parkinsonian symptoms and 
reduce dystonia, while often chorea is more pronounced (Poewe et al., 1988). Previous 
studies in MPTP-treated primates show that “on” dystonia was reduced while “on” 
chorea was unchanged or often became more marked (Gomez-Mancilla & Bedard, 
1993; Jackson et al., 2014). Similarly, in the current study, L-DOPA-induced chorea 
appeared to be exacerbated after administration of the centrally acting non-M4 
selective anticholinergics used in the study. Since the mechanism underlying LID is 
mediated centrally, peripherally acting methylscopolamine had no effect on LID and 
both chorea and dystonia, however, interestingly pre-treatment with this drug tended 
to reduce the L-DOPA effect. This effect is not clear, but since methylscopolamine is 
a quaternary methylated derivative of scopolamine, has a poor central penetration and 
high selectivity for both M1 and M3 receptors, therefore the inhibition of peripheral 
muscarinic receptors might have played a role in this effect, such as the high doses of 
methylscopolamine could have caused number of side effects.   
NBI-675 showed no ability to prevent the expression of L-DOPA-induced dyskinesia, 
dystonia or chorea, however, there was a trend for it to produce an additive effect on 
L-DOPA with a tendency of extending the duration of L-DOPA-induced dyskinesia, 
dystonia and chorea at the lower and mid dose. This tendency of delaying the LID in 
a manner similar to that seen for locomotor activity and motor disability, as discussed 
in Chapter 5, could be a possible result of antimuscarinic action in the GI tract, 
delaying absorption, although this was not confirmed by the PK studies.  
Nonetheless, the highest dose showed a tendency of reduction of the L-DOPA effect 
in some animals. This is unlikely to be an antidyskinetic property, even though all 
scores for dyskinesia, dystonia or chorea tended to be reduced, as the combination of 
L-DOPA and the highest dose of NBI-675 were likely to reduce the anti-PD effect 
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seen with L-DOPA alone (see Chapter 5) on locomotor activity and motor disability, 
the L-DOPA effect tended to be reduced. Previously, it has been shown that expression 
of LID correlates closely with locomotor activity, so usually the onset of motor 
improvement is accompanied by onset of dyskinesia, such that when the same degree 
of reversal of motor disability is attained with L-DOPA, expression of marked 
dyskinesia is observed (Kuoppamaki et al., 2007; Lincoln et al., 2016). Comparing the 
results in Chapter 5, the motor disability correlates with dyskinesia, and the 
measurements indicate that the highest doses of the drug blunted the L-DOPA effects. 
This, however, could indicate that the dose of the compound was too high, which 
possibly could have led to the loss of selectivity and thus reduction of a therapeutic 
effect, causing the loss of efficacy of the NBI-675 at the higher doses. Consequently, 
if the selectivity was lost, then the compound could have been acting at other receptors, 
and this could be the reason for reduced motor activity and inhibited manifestation of 
dyskinesia as observed. In addition, anticholinergics are known to cause numerous 
effect in the CNS (Lieberman, 2004), and this could be the reason that animals 
appeared less active and drowsy, as was speculated in previous chapters (Chapter 3, 4 
& 5).  Administration of the clinically used centrally acting anticholinergics resulted 
in an increase of dyskinesia, dystonia and chorea. The effects of anticholinergics on 
induction of dyskinesia have been previously reported in human studies (Pourcher et 
al., 1989), and primate studies also indicate that LID and particularly chorea was more 
pronounced (Gomez-Mancilla & Bedard, 1993; Jackson et al., 2014), therefore this is 
perhaps not unusual to be seen. 
The reason behind the lack of NBI-675 antidyskinetic/antidystonic effect is not 
entirely clear since it was proposed that muscarinic M4 subtype of receptors, based on 
their striatal location, could be involved in mediation of dyskinesia without inducing 
peripheral side effects (Salamone, 1997; Betz et al., 2007). Indeed, studies in rats 
presented in Chapter 3 showed that NBI-675 reduced involuntary movements in the 
form of purposeless chewing induced by pilocarpine. Although, one would argue that 
the rat model is rather simplistic compared to the more complex MPTP-treated 
marmoset model, where degeneration of nigrostriatal dopaminergic neurons occurs.   
The rat model, where acute muscarinic response was tested, proved that the cholinergic 
system indeed is involved in the mediation of involuntary movement. Moreover, it was 
shown that NBI-675 suppressed the involuntary movements, suggesting a central 
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action, without inducing the dry mouth, one of the side effect of anticholinergic 
treatment. Despite that NBI-675 shows high selectivity to M4 receptors, as described 
in Chapter 1 and 5, it had no effect on LID, and when administered alone, unexpectedly 
induced short acting mild chorea and dystonia.  
Based on this, two different animal models were used in this chapter and Chapter 3. 
Rat model of pilocarpine-induced purposeless chewing gives acute muscarinic 
response without any degeneration, whereas MPTP-treated marmoset is more complex 
giving insights into the human condition PD. The damage to the nigrostriatal tract and 
loss of striatal DA together with chronic L-DOPA treatment results in altered 
biochemistry (Chapter 1). In spite that non-selective scopolamine, and preferential M1 
selective benztropine and trihexyphenidyl show affinity for M1 receptors, they also 
show affinity for M4 receptors (Caulfield, 1993), and thus these compounds produced 
increase in dyskinesia, dystonia and chorea.  This may be an M1 receptor effect 
through the indirect pathway, as it becomes hyperactive due to the loss of D2 
inhibition.  Blockade of M1 receptors located on D2 MSN may worsen this by further 
increasing the activity. On the other hand, M4 receptors show inhibitory control of D1 
receptor-mediated locomotor stimulation (Gomeza et al., 1999a), due to the opposing 
effects of the D1 receptor and M4 receptor on adenylyl cyclase activity (Caulfield, 
1993; Di Chiara et al., 1994; Onali & Olianas, 2002). Thus, in the MPTP-treated 
primate, where the indirect pathway is down-regulated due to the loss of dopamine, 
one would expect that administration of M4 selective compound would further reduce 
the activity of the direct pathway, so perhaps the likelihood of LID could be reduced.  
However, this was not the case, and thus may indicate that a balance between M1 and 
M4 is important for reduction of LID.   
In spite of these finding, the exact mechanism of LID and particularly dystonia induced 
by L-DOPA in PD is still not fully understood. The exact central location of action of 
anticholinergics is not known, and it is a very complex process, since M1 and M4 
receptors are both expressed on striatal projection neurons, and M4 receptors are also 
expressed on ChI (Ding et al., 2006). The evidence and suggestions coming from the 
studies described in this thesis and published in the literature implies the importance 
of both M1 and M4 subtypes of muscarinic receptors (Bonsi et al., 2008; Ding et al., 
2011; Erosa-Rivero et al., 2014) as therapeutic targets, therefore perhaps a 
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development of a mixture of M1/M4 antagonists would be beneficial in the treatment 
of LID.  
Studies described in this and previous chapter are not without limitations. Indeed, the 
sample size was small, one animal was taken out of the study due to seizures caused 
by the highest dose of NBI-675. Moreover, two animal groups were used in the study, 
scopolamine and methylscopolamine was tested in one animal group, and the 
remaining drugs were tested in another group of animals. This could result in a 
variation in response. Dosing of L-DOPA 1 hr after the anticholinergic administration, 
might have made animals anxious or disturbed and they might have appeared to be 
more agitated, as a result of technicians entering the behaviour room in order to 
administer L-DOPA orally, thus resulting in an increase of locomotor activity or 
expression of dyskinesia induced by stress, although this was controlled in the vehicle 
treated groups.  
6.5 Conclusion 
L-DOPA-induced dyskinesia is a serious effect of L-DOPA treatment in PD and 
possibly involves numerous pathways and mechanisms, which still remain unclear. 
The main aim of this study intended to probe the role of the M4 receptor in the 
expression of dyskinesia in PD.  In contrast to the results obtained in Chapter 3 where 
the pilocarpine-induced purposeless chewing oral movements in rats were suppressed 
by the NBI-675, this inhibitory effect was not observed on dyskinesia, dystonia or 
chorea expressed in the MPTP-treated marmoset.  For this reason, the hypothesis of 
this chapter is rejected. However, since the clinically used anticholinergics tested in 
this study do not have absolute selectivity for a particular subtype of muscarinic 
receptor, further studies with more selective compounds or perhaps mixture of 
muscarinic M1/M4 antagonists would need to be undertaken to elucidate whether this 



















7.1 Summary of results  
Anticholinergics are frequently used in the treatment of dystonia and Parkinson’s 
disease either alone or as an adjunct to other forms of therapy. However, their use is 
often limited due to unwanted side effects, including dry mouth, cognitive disturbance, 
confusion, blurred vision or urinary retention (Schapira, 2005). There is a considerable 
evidence that the basal ganglia play a major role in the control of movement, and 
pathways within the basal ganglia are altered, resulting in the motor symptoms of 
dystonia and PD.  The majority of clinically used anticholinergics are relatively non-
selective, and the peripheral side effects are mainly attributable to M1 and M3 
receptors.   Since the highest expression of M4 subtype of muscarinic receptor is in 
the striatum, and there is low expression in peripheral tissues, they could be a target 
for the treatment of the motor dysfunction with minimised side effects profile.  For 
this reason, it was hypothesised that selective antagonists of the muscarinic M4 
receptor would control abnormal involuntary movements and motor deficits in 
dystonia and Parkinson’s disease with reduced side effect profile. In order to test this 
hypothesis, the effect of anticholinergics with differing selectivity for the muscarinic 
receptor subtypes were investigated in two experimental animal models: pilocarpine-
induced chewing rat model of dystonia, and the MPTP-treated common marmoset 
model of PD. In addition, an indication of peripheral side effects was determined by 
measuring antagonism of M1/M3-mediated saliva production. The following results 
were obtained in the individual studies:  
1. Selective antagonism of central muscarinic M4 receptors suppressed 
pilocarpine-induced chewing movements in rats;  
2. Selective antagonism of central muscarinic M4 receptors did not induce 
peripheral side effects, such as oral dryness, in rats; 
3. In MPTP-treated common marmoset, selective antagonism of M4 receptors did 
not show effect in improvement of parkinsonian disability either alone or in 
combination with L-DOPA; 
4. In MPTP-treated common marmoset, selective antagonism of M4 receptors did 
not improve L-DOPA-induced dyskinesia, but rather extended the duration of 
dystonia.   
Overall, these results support the hypothesis that central cholinergic systems play a 
role in modulation of involuntary movements, as it has been shown throughout the 
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studies described in this thesis. Treatment with relatively M4 non-selective 
anticholinergics resulted in suppression of involuntary movements as presented in a 
rat model of dystonia described in Chapter 3, and improved motor control in MPTP-
treated common marmoset model of PD (Chapter 5 & 6) but with a significant effect 
on oral dryness (Chapter 4). Similarly, administration of selective muscarinic M4 
antagonist NBI-675, suppressed purposeless chewing movements in rats but had no 
effect on inhibition of pilocarpine-induced salivation, suggesting that selective 
inhibition of M4 receptors would be useful in the treatment of dystonia but with 
reduced side effects profile. By contrast, these results do not support the hypothesis 
that selective M4 antagonists would be beneficial in any aspect of the treatment of PD 
since the selective NBI-675 showed no improvement of parkinsonian symptoms and 
motor deficits in MPTP-treated marmosets.   
7.2 Specificity of anticholinergics  
The selectivity of the currently used anticholinergics in the treatment of both of the 
disorders plays an enormous role in their efficacy and side effect profile, since the 
clinically utilized compounds show little selectivities for the specific subtypes of 
muscarinic receptors, resulting in undesired side effects, which often appear more 
serious in older patients (Lieberman, 2004). Despite the continuous research, currently 
there is still lack of highly selective compound that could help to understand the 
mechanisms beyond these conditions.  
Availability of selective subtypes of muscarinic antagonists, and particularly M4 
subtypes is limited. In the current study, NBI-675 was chosen as the best available 
compound showing CNS brain penetration, a logP of 4.6, and high affinity towards 
M4 receptors (> 900 more selective for M4 compared to M1 subtype, based on the 
selectivity data provided by Neurocrine Biosciences, Inc.) (Table 1.5). Its rank order 
towards muscarinic receptors based on affinities is M4>M2>M3>M1>M5 (Neurocrine 
Biosciences, Inc). Since the compound is in the pre-clinical stage, the available 
information is very limited. Additionally, there is lack of in vivo studies utilizing 
highly selective muscarinic antagonists in the mediation of motor control. The only 
compound that has been extensively used to study involvement of M4 subtypes in 
motor movement is tropicamide, deemed in the literature as having a “moderate” 
selectivity to M4 receptors (Betz et al., 2007) or called a “purported M4 antagonist” 
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(Erosa-Rivero et al., 2014), but since its relatively low selectivity to M4 receptor 
subtypes when compared to M1 (5-fold higher selectivity over M1), it appears 
incorrect to say that tropicamide is M4 selective.  
Relative selectivity of the muscarinic antagonists used in the studies described in this 
thesis towards particular subtype of muscarinic receptor is mainly based on their pKi 
values from in vivo studies (Section 1.3.2.1), so when tested and used in vivo they often 
may not sufficiently reflect their in vivo and clinical relevance. Therefore, the “highly 
M4 selective” NBI-675 may not be show the same pKi value when tested in the living 
organism.   
Consequently, there is an unmet need for the development of new or improved 
compounds which would alleviate the symptoms of both diseases without producing 
unwanted effects.  
7.3 Advantages and limitations of the animal models  
7.3.1 Pilocarpine-induced purposeless chewing movements in rat  
When considering the importance of these results, the advantages and limitations of 
the techniques used must be considered.  Central stimulation of muscarinic cholinergic 
receptors in rats produces a number of orofacial movements, which has been described 
in the literature as purposeless chewing or vacuous/tremulous jaw movements (Stewart 
et al., 1988; Mayorga et al., 1997; Betz et al., 2007) and it share some characteristics 
of dystonia or PD, and in particular parkinsonian tremor (Stewart et al., 1987; Stewart 
et al., 1988; Mayorga et al., 1997; Betz et al., 2007). Initially, it was suggested that 
this behaviour observed in rats reflects tardive dyskinesia, since it can be induced by 
the administration of DA antagonists or neuroleptics, however, further studies showed 
that the mechanism differs between the tardive dyskinesia and purposeless chewing 
movements. The main difference is that tardive dyskinesia is induced by chronic 
administration of DA antagonists, and they usually worsen it, while it is improved by 
cholinomimetic drugs. On the contrary, purposeless chewing behaviour is induced by 
single, acute administration of cholinomimetic drugs and usually anticholinergics 
improve this effect (Rupniak et al., 1983; Ellison & See, 1989) as was demonstrated 
in Chapter 3. Moreover, studies revealed that purposeless chewing has higher 
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frequency than tardive dyskinesia, therefore the former is more indicative of 
impairment of voluntary movements (Salamone et al., 1998).  
Although the model at first appears rather simplistic, as involves mechanical counting 
of number of chews the rat does, pharmacological studies have shown that this 
behaviour is related to the ventrolateral striatum, a homologue of ventral putamen in 
primates, thus indicating its involvement in motor control systems (Salamone et al., 
1990). The measurement of the number of purposeless chewing movement may appear 
to be inconsistent, and that could provide variabilities in findings, nevertheless it has 
been shown that the measurement can be conducted with a high degree of concordance 
(Mayorga et al., 1997; Trevitt et al., 1997) and this was the case in the present study 
which used a rigorous study design with internal controls. The model has been 
extensively utilised to evaluate the involvement of muscarinic receptors in motor 
function as described earlier (Stewart et al., 1988; Mayorga et al., 1997; Mayorga et 
al., 1999; Betz et al., 2007) and in this thesis (Chapter 3). Research conducted with 
the use of this model have contributed to better understanding of the striatal 
involvement in generation of involuntary movements (Collins et al., 1991; Cousins et 
al., 1997; Finn et al., 1997) and work carried out with the used of cholinomimetic, 
mainly pilocarpine-induced purposeless chewing, have suggested possible 
involvement of muscarinic M4 subtypes (Betz et al., 2007), which has been confirmed 
in the current thesis. The model itself is simple and easy to assess, and has presented 
to meet the validation criteria for using it as a predictive model (Salamone et al., 1998; 
Cenci et al., 2002). Administration of several muscarinic antagonists on pilocarpine-
induced purposeless chewing movement in rats in the current study confirmed 
previous speculations (Salamone et al., 2001; Betz et al., 2007) and hypothesis that 
M4 receptors are involved in generation of these movements in rats without inducing 
unfavourable peripheral side effects. 
Despite its limitations the model has demonstrated the cholinergic component 
involved in involuntary movement, including muscarinic M4 receptors. Whether this 
will be translated to the treatment of dystonia remains to be seen.  
Animal models play an important role in the research into disease states, as they not 
only give insights into the underlying mechanisms, but also help to improve existing 
treatment and contribute to explore different avenues for therapeutic development. 
Many animal models of dystonia have been generated, including genetic rodent 
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models, drug/toxin-induced rodent models and non-humane primate models. Etiologic 
models reflect event known that lead to dystonia in humans, such as gene defect or 
exposure to toxins, whereas phenotypic models reflect a motor syndrome similar to 
human dystonia which can be seen in animals (Jinnah et al., 2005). Genetic models 
include spontaneous mutants, transgenic or knockout models. Many models implicate 
some pathogenic features involved in dystonia, for example involvement of basal 
ganglia or cerebellum. Transgenic mouse model overexpressing of human mutated 
torsinA protein is used in the study of DYT1 form of dystonia (Grundmann et al., 
2007; Tassone et al., 2011). These transgenic mice usually show impairment in motor 
learning indicating changes in synaptic plasticity (Martella et al., 2009) and also 
implicate dopaminergic neurotransmission (Grundmann et al., 2007). The dystonic dtsz 
hamster, reflects inherited model of paroxysmal dystonia (Jinnah et al., 2008). 
Dystonic attacks are triggered by stress or sudden movement and can last hours 
(Loscher et al., 1989). It has been reported that there is altered GABAergic 
transmission in this model and studies show that dystonic symptoms improve after 
administration of GABA agonists such as benzodiazepines (Loscher et al., 1989), 
however, administration of anticholinergics (trihexyphenidyl) did not have effect on 
severity of dystonia, but delayed onset of attacks (Loscher & Fredow, 1992). This 
somewhat challenges the validity of the models. 
There are also toxin-induced models of dystonia in both rodents and primates. Non-
human primate models are used to study focal types of dystonia, e.g. hand dystonia 
(Byl et al., 1996) or cervical forms induced by GABA agonists and antagonists 
administration into the GPi or SNr (Burbaud et al., 1998; Klier et al., 2002). They 
often involve torticollis or abnormal limb postures (Guehl et al., 2009). Administration 
of 3-nitropropionic acid to both rodents and primates produces lesions of the striatum 
and manifestations in hindlimbs, trunk, bradykinesia and impaired posture (Fu et al., 
1995; Palfi et al., 2000). Since dystonia is considered as a neuronal disorder, there are 
also models looking at the role of cerebellum in the formation of dystonic movements. 
Studies have demonstrated that administration of kainic acid, AMPA-glutamate 
receptor agonist, into the cerebellar vermis in rodents trigger dystonic movement 
involving limbs and trunk, and are involved in dysfunction of cerebellum (Pizoli et al., 
2002; Alvarez-Fischer et al., 2012).  
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Dystonia has many different aetiologies and is very heterogeneous disorder, therefore 
generating animal model which would mimic all aspects of the disease is rather 
unrealistic, nevertheless the most important goal is to use these models to better 
understand pathophysiology and discover novel therapeutics.  
7.3.2 MPTP-treated common marmoset  
The non-human primate model is useful in preclinical research as it closely resembles 
the clinical condition. Systemic administration of MPTP results in degeneration of 
dopaminergic cells in substantia nigra and closely replicates the motor behaviour seen 
in man, such as bradykinesia and akinesia, tremor and postural instability, however, 
the resting tremor is not commonly observed (Jenner, 2009). The major difference 
between the model and PD is the onset of the neurodegeneration, as in the MPTP-
treated primates cell death take place faster than in humans and there is a lack of Lewy 
bodies (Forno et al., 1988). The neurodegeneration usually closely mimics the later 
stages of the disease where there is substantial loss of dopaminergic cells, the process 
is static and non-progressive. Additionally, the disease can be mimicked in relatively 
young animals, whereas PD in humans is age-dependent (Jenner, 2003b). Similarly, as 
in PD patients, administration of L-DOPA reverses the parkinsonian symptoms and 
treatment over period of time results in an expression of dyskinesia that closely 
resembles seen in man, and includes dystonia, chorea and akathisia (Jenner, 2009). 
Nevertheless, induction of LID in MPTP-treated animals occurs faster than in humans 
and as such may involve different biochemical changes (Smith et al., 2003; 
Kuoppamaki et al., 2007). In spite of these differences, the model has been extensively 
used in order to find antiparkinsonian treatments.  Additionally, many other 
dopaminergic treatments used in PD are proven to be effective in MPTP-treated 
marmoset (Close et al., 1990; Jenner, 2008). Despite these benefits, the model has 
produced failures in translation. Monoamine reuptake inhibitors showed to be effective 
in reversing motor deficits in MPTP-treated marmosets (Pearce et al., 2002; Hansard 
et al., 2004), whereas when taken into clinics, they showed no effect in improving 
parkinsonian disability (Hauser et al., 2007; Rascol et al., 2008). 
Currently, there is no ideal non-human primate model for dystonia. However, the 
MPTP-treated primate model exhibit dystonia as an accompanying feature of PD, as 
part of LID. It closely resembles the outcome seen in late stage of PD in patients where 
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dyskinesia develops after commencement of dopaminergic therapy (Jenner, 2008). 
Similarly, as in the clinics, these involuntary movements can be easily assessed using 
a semi quantitative rating scales (Langston et al., 2000).  
There are several other animal models used to mimic the disease. They involve lesion 
models, such as 6-OHDA rodent model of motor complications related to the PD 
treatment. This model results in degeneration of dopaminergic neurons and expresses 
locomotive, axial, limb and orolingual dyskinesia (Lundblad et al., 2002; Cenci, 2007). 
Usually extensive neurodegeneration is needed so the animals could develop 
involuntary movements (Cenci, 2007). The model resembles late-stage disease and 
does not express “on” and “off” and “end of dose deterioration”, as seen in man and 
MPTP-primates, but only L-DOPA-induced peak dose dyskinesia (Cenci, 2007). 
Although, the toxin-induced models of PD have some validity, they show no 
progression and exhibit rapid-onset of motor complications, most likely because the 
pathology is mainly restricted to dopaminergic neurons (Cenci, 2007). The process of 
cell death is thought to reflect those seen in PD, however, poor translation of the 
potential neuroprotective strategies suggests the need for the better models.   
The genetic component underlying PD have led to the development of transgenic 
models of PD. Despite the attempts to produce some of the models with genetic 
variations, including mutations of α-synuclein, LRRK, parkin, PINK1, DJ-1 showing 
some behavioural deficits, many of them failed to produce substantial loss of 
dopaminergic nigral cells (Duty & Jenner, 2011). Thus, these models also fail to reflect 
the disease state. In addition, they also represent small proportion of patients making 
predictions in ‘idiopathic’ disease difficult.  
Despite variability of all models available, it is hard to generate an ideal model, which 
would mimic all aspects of the diseases. Selection of an appropriate model is often 
complex, as there are many considerations that should be taken into account, including 
the convenience, transferability of information, appropriateness, genetic uniformity of 
organisms, background knowledge, adaptability to experimental manipulation or 
ethical issues (Tassone et al., 2011).  
Two different animal models and two different species were used in the studies 
described in this thesis. Generally, marmosets brain is bigger than rats, and studies 
show the differences in the distribution, proportion and size of various neurons in 
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different structures of BG, indicating fewer and smaller neurons in rats when compared 
to primates (Hardman et al., 2002). Therefore the differences in relation to BG 
anatomy and neurochemistry might have had impact on the results.  
No model to date has shown to be 100% predictive of effects in man (Blandini & 
Armentero, 2012). Additionally, there is a lack of models that could be utilised to 
investigate the cholinergic component that is involved in PD and dystonia, 
nevertheless the use of cholinergic agonists has been reported to induce involuntary 
oral movements in rats, resembling chewing, thus this model together with the MPTP-
treated primate model provides useful and excellent tool in the assessment of novel 
treatments with potential antiparkinsonian and antidystonic properties.  
Since in vivo work gives a better indication of what is happening in the whole system, 
the caveat of behavioural studies is that the generated data generally show a high 
degree of variability, and this has also been demonstrated in the current thesis 
(Chapters 3 – 6) in rats and primate studies. Although, this closely resemble the clinical 
outcome, where often large variations occur in drug response between patients, it can 
also indicate necessity of using much larger number of animals in order to achieve 
significant or desired effect. Many animal models, including non-human primates, are 
often technically challenging to develop and maintain, as they breed slowly and in a 
few numbers, and require special animal facilities, therefore it is often not possible to 
employ bigger sample size, due to the practicality, costs and more importantly, ethical 
concerns. Nevertheless, the numbers of animals used in the studies in this thesis are 
comparable to the frequently reported in the literature, where the number of rats was 
usually 6 – 8 (Mayorga et al., 1999; Betz et al., 2007) and MPTP-treated primates 5 – 
8 (Pearce et al., 1998; Kuoppamaki et al., 2002; Kuoppamaki et al., 2007; Jackson et 
al., 2014).  
7.4 Is there a role of muscarinic M4 receptors in control of involuntary 
movements?  
From the behavioural studies utilizing rats and MPTP-treated marmosets reported in 
this thesis, it was shown that selective muscarinic M4 antagonist NBI-675 suppressed 
involuntary movement in the form of purposeless chewing movement induced by 
pilocarpine without induction of peripheral unwanted effects in the form of oral 
dryness in rats. By contrast, in the marmoset treated with MPTP, as a model of PD and 
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LID, this compound failed to show antiparkinsonian effect nor improvement of LID. 
Despite that, both models support the notion that cholinergic system and muscarinic 
receptors are important targets for the treatment of both dystonia and PD, as other, 
especially M1 selective anticholinergics showed beneficial effect.  
In spite of recent emerging preclinical evidence suggesting M4 involvement in 
dystonia and Parkinson’s disease, the results reported here suggest that the 
involvement of selective M4 antagonism would be beneficial in control of involuntary 
movements only in dystonia. NBI-675, as well as M1 (M1/M4) selective pirenzepine 
resulted in a suppression of involuntary movements induced by pilocarpine in rat 
studies. However, in the MPTP-treated parkinsonian model, non-selective 
anticholinergics improved the locomotor symptoms, whereas the selective M4 did not. 
This suggests the clear difference in the neurochemistry behind dystonia and PD, such 
that the M4 antagonism may be a suitable pharmacotherapy for the former but not the 
latter. Indeed, it may be that M1 receptors are better targets for reversal of motor 
symptoms in PD. Muscarinic M1 subtypes are found on MSN of direct and indirect 
pathways (Hersch et al., 1994). Since these receptors are excitatory, in a PD state it 
would indicate that the inhibition of M1 receptors on overactive indirect pathway (loss 
of D2 inhibition) would oppose the action of lost dopamine and decrease the 
hyperactivity, triggering stimulation of underactive direct pathway, and this potentially 
be beneficial.   
Inhibitory M4 receptors, are predominantly expressed postsynaptically on direct 
pathway MSN where they show inhibitory control on D1-mediated locomotor 
stimulation (Bernard et al., 1992; Gomeza et al., 1999b). Since the direct pathway in 
PD is underactive, one would expect that inhibition of M4 receptors should improve 
motor function, however, this was not seen.  
Recently, there have been an increasing number of studies investigating the 
involvement of muscarinic receptor subtypes, and particularly M1 and M4, in 
locomotion and involuntary movements.  For example, a recent study indicated that 
haloperidol-induced catalepsy was inhibited by an M1 antagonist pirenzepine. 
However, the difference in affinity of pirenzepine for both M1 and M4 receptors is 
small (about 5-fold; Table 1.5), therefore authors speculate that this effect could be 
contributed to a blockade of M1/M4 muscarinic receptors (Erosa-Rivero et al., 2014). 
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Previously it has been shown that D1-M4-KO mutant mice exhibited reduction in 
haloperidol-induced catalepsy, indicating involvement of M4 subtypes in mediation of 
motor control (Jeon et al., 2010).  
Moreover, a recent study by Ztaou et al., (2016) demonstrated that muscarinic M1 and 
M4 receptors are both involved in regulation of motor function. In this study, the 6-
OHDA mice model of PD was utilised together with the photoinhibition of ChI, mutant 
mice lacking M4 receptors and preferential blockade of M1 and M4 receptors. Despite 
the fact that telenzepine and tropicamide are not highly selective for muscarinic M1 
and M4 receptors, respectively, the study suggested that both of these compounds were 
able to relieve the motor deficits produced by 6-OHDA. Most likely, this effect was 
due to the inhibition of the postsynaptic M1 receptors located on MSN indirect 
pathway by telenzepine, while antiparkinsonian effect of tropicamide was eliminated 
in lesioned mutant mice suggesting involvement of postsynaptic M4 receptors located 
on MSN direct pathway (Ztaou et al., 2016). These studies support the notion that both 
of these receptors may play a role in motor control, and perhaps in mediation of 
involuntary movements.  
In another study, muscarinic M4 receptor deficient mice demonstrated increase in 
basal locomotor activity. Administration of D1 centrally acting agonist, SKF38393, 
resulted in an increase of enhancement of locomotor activity (Gomeza et al., 1999b), 
which supports the idea that M4 receptors located on the direct pathway MSN show 
inhibitory effect on D1 receptor-stimulated locomotor activity. This could perhaps 
indicate that multiple receptor subtypes play a role in motor control.  
In the current study in this thesis, administration of non-M4-highly-selective 
anticholinergics, including trihexyphenidyl, benztropine and scopolamine (Table 1.5), 
evoked better response as such the improvement of parkinsonian symptoms and 
increase in locomotion, than that seen with NBI-675, suggesting that M1 or a mixture 
of M1/M4 receptor could be a potential target for symptomatic treatment of PD.   
Growing evidence coming from animal studies suggests involvement of M1 receptors 
in DYT1 form of dystonia. The electrophysiological studies using knock-in of torsinA 
gene mouse model of DYT1 dystonia show changes in MSN, corticostriatal synaptic 
plasticity and irregular reaction of ChI resulted from activation of D2 receptors 
(Martella et al., 2014). The high-frequency stimulation of MSN did not cause long-
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term depression (LTD) but enhancement of long-term potentiation (LTP). 
Additionally, blockade of M1 receptors by pirenzepine and trihexyphenidyl on the 
corticostriatal slices resulted in a restoration of LTD (Martella et al., 2014). 
Interestingly, a recent series of experiments conducted by Shen et al., (2015) showed 
that M4 positive allosteric modulator (PAM) administered with L-DOPA, reduced 
dyskinesia in a mouse unilateral model of 6-OHDA and non-human primate MPTP 
model of PD and the effect of reduction of LID was similar to that seen by amantadine. 
It was demonstrated that increase in M4 signalling by PAM blunts D1 receptor-
mediated LTP in models of LID, by lessening induction of LTP and allowing 
depotentiation (Shen et al., 2015). This suggests that both subtypes of muscarinic 
receptors may be involved in the plastic changes in basal ganglia that might result in 
abnormal movement, however, more studies need to be conducted to clarify these 
findings. 
Taken together data presented in this thesis, particularly rat studies (Chapter 3), where 
both M1 and M4 antagonists showed high efficacy in suppression of pilocarpine-
induced purposeless chewing movements, suggest that a development of mixed 
M1/M4 antagonist would provide aid with reduced side effect profile. Additional 
benefit would bring compounds that alleviate the LID without reducing L-DOPA 
therapeutic efficacy, as this is a major challenge, since many drugs reduce dyskinesia 
but do not improve parkinsonian symptoms. Nonetheless, a major limitation of this 
approach are adverse effects related to muscarinic M1 receptor, both central and 
peripheral, such as cognitive impairment and dementia, sedation, confusion or dry 
mouth and eyes (Lampela et al., 2015). Despite that, further studies with more 
appropriate compounds need to be conducted to clarify these issues.  
7.5 Other possible treatments 
7.5.1 Nicotinic acetylcholine receptors   
Acetylcholine exerts also its effect through nicotinic receptors and perhaps these 
receptors could also be a target for the treatment (Wess et al., 2007). As described 
earlier (Chapter section 1.3.1), nicotinic receptors are expressed in the striatum at 
glutamatergic terminals and when activated, they release glutamate from 
corticostriatal terminals (Marchi et al., 2002; Marchi & Grilli, 2010). However, there 
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is less indication for a role of the nicotinic receptors.  Historically nicotine has been 
used to treat writer’s cramp and spastic dystonia though local or transdermal 
application (Vaughan et al., 1997; Murase et al., 2000). More recently it has been 
shown that mutations in α4 or β2 nicotinic receptor subunits can contribute to a 
dystonic arousal state (Teper et al., 2007), however, to date there is little evidence for 
a role of nicotinic antagonists in the treatment of dystonia. 
By contrast, in PD there is an historic link to therapy related to the nicotinic receptor.  
It has been demonstrated that smokers have reduced risk of PD, which is associated 
with the duration and strength of smoking (Thacker et al., 2007), although this may be 
a disease modifying effect.  Interestingly, reduced motor complications have been 
linked to striatal α7 nACh receptors, suggesting the potential of this receptor to manage 
motor complications in PD (Morissette et al., 2016).  Using ACh knock out mice, Quik 
et al., (2013) have suggested a role for α6β2*, α4β2* and α7 nAChRs in L-DOPA-
induced AIMs, thus proposing future targets for reducing LID in Parkinson's disease 
(Quik et al., 2013).  Indeed, α7 nicotinic receptor agonists ABT-126 and ABT-107 
reduce LID in a non-human primate model of PD (Zhang et al., 2014; Zhang et al., 
2015), although the α7 nicotinic agonist AQW051 failed to show benefit on PD 
symptoms or LID (Trenkwalder et al., 2016). Further work is needed to fully elucidate 
the role of the nicotinic receptors in motor function. 
7.5.2 Glutamate receptors  
Another approach could be to target other neurotransmitters in the basal ganglia. 
Glutamate is one of the major neurotransmitters in the BG, and plays an important role 
in the control of movement, thus is a target for modification in the control of motor 
function.   
In the DYT1 mouse models of torsion dystonia there is evidence of altered 
glutamatergic activity in the cerebellum but not in the striatum (Vanni et al., 2015), 
however, functional alterations in the basal ganglia circuits have been reported in both 
DYT1 dystonia patients and rodent models (Yokoi et al., 2015), but no reported 
changes in levels of striatal ionotropic glutamate receptor subunits or, interestingly the 
muscarinic M4 receptor and adenosine A2a receptor.  However, the story may be more 
complicated as Sciamanna et al., (2014) showed that negative modulation of mGlu5 
receptors with dipraglurant may counteract abnormal D2 receptor responses, 
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normalizing cholinergic cell excitability in the Tor1a(+/ΔGAG) mice and transgenic 
mice overexpressing human torsinA (hMT1) (Sciamanna et al., 2014). Clearly 
considerably more work needs to be done to fully understand the role of glutamate in 
dystonia. 
There is considerably more understanding of the role of glutamate in PD.  The 
alterations in direct and indirect pathway involve glutamatergic hyperactivity, causing 
the motor symptoms of PD and contributing to the pathophysiology of dyskinesia.  
Amantadine, a weak NMDA receptor antagonist, is the only clinically used drug to 
treat dyskinesia (Hallett et al., 2006). However, its non-selective pharmacology makes 
it intolerable for some patients.  There have been a number of attempt to find better 
treatments, and recently a new formulation of amantadine, ADS-5102 has shown to 
reduce LID when compared to placebo-treated patients in phase III study. Moreover, 
it has been reported that “on” time was increased by >2 hrs and “off” time was reduced 
by 0.9 hrs compared to placebo.  A number of patients still experienced side effects, 
including hallucinations, peripheral oedema, dizziness, dry mouth, constipation, falls, 
anxiety, confusion, livedo reticularis, abnormal dreams, depression and headaches 
(Pahwa et al., 2015). 
Of particular interest in the treatment of PD are metabotropic glutamate receptors. 
They are G-protein coupled receptors (GPCRs) and classified into three groups I, II 
and III. The group III are presynaptically located and coupled to Go/i G proteins 
(Johnson et al., 2009) and mGlus 4, 7 and 8, which belong to this group, are expressed 
in the BG where play a role in control of motor function (Niswender et al., 2008). 
Activation of these receptors decreases GABA transmission in the striato-pallidal 
synapse (Conn et al., 2009).  
In MPTP-treated macaque model of LID, the mGlu5 NAM, dipraglurant, reduced 
dyskinesia, including dystonia and chorea, but had no effect on L-DOPA efficacy 
(Bezard et al., 2014), the latter often being seen with drugs that reduce the severity of 
dyskinesia.  
Studies on 6-OHDA-lesioned rats show that group III mGlu agonists reversed akinesia 
when injected bilaterally into the globus pallidus and reduced haloperidol-induced 
catalepsy in the rat model of PD (Lopez et al., 2007). Another mGlu4 agonist, L-AP4 
showed antiparkinsonian properties in both haloperidol-induced catalepsy and 
reserpine-model of PD, and studies in mGluR4 knock out mice demonstrated reduction 
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of striato-pallido synapse transmission, as it is believed that antiparkinsonian effects 
are thought to be a result of suppression of the increased activity in the indirect 
pathway (Valenti et al., 2003). Since highly conserved orthosteric side of the receptor 
make it difficult to develop highly selective compounds, development of positive 
allosteric modulators appears to be attractive (Niswender et al., 2008).  
In in vitro studies it is suggested that GluR Group III agonists control nigral glutamate 
release. This antiparkinsonian potential is extended to in vivo studies where direct 
injection into the SN reversed reserpine-induced akinesia (Austin et al., 2010). Lu 
AF21934, a selective mGlu4 PAM, showed positive antiparkinsonian effect by 
alleviating haloperidol-induced catalepsy, and, when combined with L-DOPA 
following 6-OHDA lesions, decreased incidence of LID indicating antiparkinsonian 
and antidyskinetic properties (Bennouar et al., 2013).  
Dipraglurant the mGluR5 NAM reduces LID in non-human primates, and in clinical 
studies was found to reduce peak dose dyskinesia and increase “on” time (Bezard et 
al., 2014; Tison et al., 2016). Similarly, mGluR5 antagonists also showed to have 
antidyskinetic properties in PD patients with moderate to severe LID. Clinical study 
has shown that mavoglurant (AFQ056) reduced severity of dyskinesia (Berg et al., 
2011).  
Clearly there has been a lot of interest in targeting glutamate receptors, and in PD at 
least there has been some positive translation to clinic. 
7.5.3 Serotonergic system  
A number of studies performed in rodents implicate changes to the serotonin system 
in the pathology of the dystonia (Ledoux et al., 1994) but as yet no preclinical studies 
have suggested a pharmacological target.  
Clinical studies have investigated the effect of serotonin in dystonia, but most of these 
have been based on individual case reports.  For instance, aripiprazole, an atypical 
antipsychotic with partial agonist activity at the D2 and 5-HT1A receptors and an 
antagonist at 5-HT2A receptors may be more likely to cause movement disorders than 
other atypical antipsychotics, suggesting a role for 5-HT receptors.  Recently Smit et 
al., (2016) performed a systematic review of the literature and suggested that there was 
an association between dystonia and the serotonergic system (Smit et al., 2016).  
However, there was no suggestion of any particular serotonin receptor target.   
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Serotonergic system plays an important role in pathogenesis of LID as release of 
dopamine from serotonergic neurons can contribute to pulsatile stimulation of DA 
receptors triggering appearance of dyskinesia. Indeed, studies on 6-OHDA-lesioned 
rats primed with L-DOPA have demonstrated that 5-HT1A receptor agonist 8-OH-
DPAT attenuates L-DOPA-induced dyskinesia (Dupre et al., 2008; Bishop et al., 
2009). This antidyskinetic effect of various 5-HT1A receptor agonists was also seen in 
MPTP-treated monkeys (Bibbiani et al., 2001; Grégoire et al., 2009). The mixed 5-
HT1A/1B receptor agonist, eltoprazine, showed antidyskinetic effect in 6-OHDA-
lesioned rats and MPTP-treated macaques, however, reduction of L-DOPA 
antiparkinsonian effect was also observed (Bezard et al., 2013). Similarly, clinical 
study demonstrated that a single dose of eltoprazine reduces L-DOPA-induced 
dyskinesia and did not alter antiparkinsonian effects of L-DOPA (Svenningsson et al., 
2015). Other clinical studies also reported antidyskinetic effect of 5-HT1A agonists on 
LID (Bara‐Jimenez et al., 2005; Politis et al., 2014) indicating that selective serotonin 
5-HT1A agonists show promise in alleviating L-DOPA-induced dyskinesia.   
7.6 Final conclusion 
Overall the work described in this thesis supports the continued examination of the 
involvement of muscarinic receptors subtypes in the formation of involuntary 
movements. Although, these studies do not represent ways of defining the causal 
factors underlying the changes that appear in BG circuits that contribute to dystonia, 
nor the neural degeneration seen in PD, they focused on the observational responses 
of drug treatment in predictive animal models of PD and dystonia to measure specific 
outcomes of drug-induced behaviour, such as motor disability and involuntary 
movements (dystonia). This is the first time that studies with the use of selective 
muscarinic M4 antagonist have been carried out in the MPTP-treated marmoset model 
of PD and LID. While the results reported in this work have partly failed to support 
the hypothesis of this thesis, due to the rather unexpected results from MPTP-treated 
marmoset studies, the findings nevertheless emphasise the importance of the 
cholinergic system and selective inhibition of M1/M4 subtypes of muscarinic 
receptors and their implication in both disorders. The exact mechanisms underlying 
both idiopathic and levodopa-induced dystonia as well as dyskinesia are still not fully 
understood despite the ongoing research, but with our expanding knowledge, further 
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treatment strategies with the use of different models or other targets may provide 
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